Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Inguinal hernia								
White	2	(0.1)	2	0.13	1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rectal polyp								
White	2	(0.1)	2	0.13	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatic failure								
White	2	(0.1)	2	0.24	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anal fissure								
White	2	(0.1)	2	0.19	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Impaired gastric emptying								
White	2	(0.1)	3	0.32	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Enterocolitis								
White	2	(0.1)	3	0.19	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Hiatus hernia								
White	2	(0.1)	2	0.16	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Abdominal pain lower								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	2	(0.1)	2	0.20	1	(0.1)	1	0.06
Black or African American	1	(1.5)	1	1.59	0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Pancreatitis chronic								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Abdominal wall disorder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colitis microscopic								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic gastropathy								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eosinophilic oesophagitis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eructation								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric ulcer								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Gastrointestinal haemorrhage								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemorrhoidal haemorrhage								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoaesthesia oral								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	2	(0.4)	4	1.39	0			
Other	0				0			
Missing	0				0			
Intestinal dilatation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lip swelling								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Umbilical hernia								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Noninfective gingivitis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vomiting projectile								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colitis								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry mouth								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	1		1		0			
Missing	0				0			
Frequent bowel movements								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haematochezia								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Loose tooth								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatitis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tooth disorder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Abdominal discomfort								
White	1	(0.1)	1	0.13	3	(0.2)	3	0.26
Black or African American	0				0			
Asian	3	(0.6)	3	0.78	3	(0.6)	4	1.26
Other	0				0			
Missing	0				0			
Irritable bowel syndrome								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diverticulum								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				1		1	
Gastrointestinal angiodysplasia								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gingival bleeding								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperaesthesia teeth								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Intra-abdominal haematoma								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acid peptic disease								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.39
Other	0				0			
Missing	0				0			
Anal pruritus								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Colitis ischaemic								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Crohn's disease								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Duodenitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Enteritis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Epigastric discomfort								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Faeces pale								
White	0				1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Faeces soft								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Gastric dilatation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Gastric disorder								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric dysplasia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Gastric mucosal hypertrophy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Gastric polyps								
White	0				0			
Black or African American	0				0			
Asian	2	(0.4)	2	0.59	4	(0.7)	4	1.17
Other	0				0			
Missing	0				0			
Gastritis erosive								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Gastrointestinal disorder								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastrointestinal inflammation								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastrointestinal sounds abnormal								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gingival disorder								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gingival recession								
White	0				1	(0.1)	2	0.27
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperchlorhydria								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Ileus								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Lumbar hernia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Melaena								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Mesenteric panniculitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Odynophagia								
White	0				2	(0.1)	2	0.25
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oesophageal pain								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oesophagitis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral discomfort								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Oral pain								
White	0				0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	1		1		0			
Pancreatic duct dilatation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Pancreatic pseudocyst								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatitis acute								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peptic ulcer								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Periodontal disease								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	2	(0.4)	2	0.67
Other	0				0			
Missing	0				0			
Periodontal inflammation								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pneumatosis intestinalis								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Proctalgia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Rectal prolapse								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Small intestinal obstruction								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Stomatitis								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.39
Other	0				0			
Missing	0				0			
Tongue rough								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Tooth impacted								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Ulcerative gastritis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Upper gastrointestinal haemorrhage								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Musculoskeletal and connective tissue disorders								
All								
White	196	(12.5)	295	24.46	196	(12.9)	290	26.72
Black or African American	13	(17.1)	15	27.50	14	(17.7)	21	33.80
Asian	55	(11.8)	72	21.58	68	(13.0)	84	23.66
Other	7		15		4		4	
Missing	2		3		2		2	
Back pain								
White	49	(3.1)	53	4.40	50	(3.3)	66	7.07
Black or African American	1	(1.1)	1	1.82	8	(9.6)	9	13.82
Asian	15	(3.2)	15	4.11	13	(2.6)	13	3.62
Other	0				1		1	
Missing	0				0			
Arthralgia								
White	35	(2.2)	42	3.83	40	(2.7)	46	4.22
Black or African American	3	(4.4)	3	5.34	2	(2.4)	2	3.34
Asian	12	(2.6)	12	2.90	14	(2.6)	14	4.18
Other	1		2		1		1	
Missing	0				0			
Pain in extremity								
White	26	(1.7)	28	2.24	24	(1.6)	29	2.76
Black or African American	2	(2.3)	2	2.99	2	(2.1)	2	2.10
Asian	7	(1.5)	7	1.93	10	(1.9)	11	3.47
Other	2		2		1		1	
Missing	0				0			
Osteoarthritis								
White	20	(1.3)	21	1.78	25	(1.6)	28	2.39
Black or African American	1	(1.1)	1	1.82	0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.36
Other	2		3		0			
Missing	0				0			
Muscle spasms								
White	18	(1.1)	18	1.51	4	(0.3)	4	0.31
Black or African American	1	(1.5)	1	2.48	0			
Asian	4	(0.9)	6	2.30	5	(1.0)	5	1.29
Other	1		1		0			
Missing	1		1		0			
Myalgia								
White	13	(0.8)	13	1.20	6	(0.4)	6	0.68

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				3	(4.7)	3	7.08
Asian	2	(0.5)	2	0.86	7	(1.2)	8	2.53
Other	1		1		0			
Missing	0				0			
Neck pain								
White	11	(0.7)	11	0.96	6	(0.4)	6	0.45
Black or African American	2	(3.3)	2	4.40	0			
Asian	2	(0.4)	2	0.57	2	(0.4)	2	0.54
Other	1		1		0			
Missing	0				0			
Tendonitis								
White	8	(0.5)	10	0.78	5	(0.3)	5	0.49
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Trigger finger								
White	5	(0.3)	5	0.49	5	(0.3)	5	0.45
Black or African American	1	(0.5)	1	1.07	0			
Asian	3	(0.6)	3	1.09	1	(0.2)	3	0.58
Other	0				0			
Missing	0				0			
Intervertebral disc protrusion								
White	5	(0.3)	9	0.57	2	(0.1)	3	0.20
Black or African American	0				1	(1.1)	1	1.05
Asian	2	(0.4)	2	0.57	2	(0.4)	2	0.69
Other	1		1		1		1	
Missing	0				0			
Arthritis								
White	5	(0.3)	5	0.35	5	(0.3)	5	0.53
Black or African American	0				0			
Asian	2	(0.4)	2	0.84	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Spinal osteoarthritis								
White	4	(0.3)	4	0.25	3	(0.2)	4	0.25
Black or African American	1	(1.1)	1	1.82	0			
Asian	1	(0.2)	1	0.35	2	(0.5)	2	0.47
Other	0				0			
Missing	0				0			
Periarthritis								
White	4	(0.3)	4	0.31	4	(0.3)	4	0.41
Black or African American	0				1	(1.3)	1	1.37
Asian	4	(0.9)	4	1.04	4	(0.8)	4	1.08
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Bursitis								
White	4	(0.3)	4	0.29	4	(0.3)	4	0.34
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Foot deformity								
White	3	(0.2)	5	0.37	2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Exostosis								
White	3	(0.2)	3	0.19	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Tendon disorder								
White	3	(0.2)	3	0.28	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rotator cuff syndrome								
White	3	(0.2)	3	0.24	4	(0.3)	4	0.25
Black or African American	0				0			
Asian	2	(0.4)	2	0.61	0			
Other	0				0			
Missing	0				0			
Musculoskeletal chest pain								
White	3	(0.2)	3	0.19	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Musculoskeletal stiffness								
White	3	(0.2)	3	0.30	0			
Black or African American	0				0			
Asian	2	(0.4)	2	0.61	2	(0.4)	2	0.53
Other	0				0			
Missing	0				0			
Intervertebral disc disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	3	(0.2)	3	0.23	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Osteochondrosis								
White	2	(0.1)	2	0.18	4	(0.3)	4	0.35
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Back disorder								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Coccydynia								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chondropathy								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Polyarthritis								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Musculoskeletal pain								
White	2	(0.1)	2	0.17	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscular weakness								
White	2	(0.1)	2	0.24	2	(0.1)	2	0.18
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.16	1	(0.2)	1	0.34

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Fibromyalgia								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Plantar fasciitis								
White	2	(0.1)	3	0.19	2	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	2		2		0			
Missing	0				0			
Acquired claw toe								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diastasis recti abdominis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facet joint syndrome								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Joint effusion								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	1		2		0			
Meniscopathy								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Psoriatic arthropathy								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sacroiliitis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle contracture								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Torticollis								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Costochondritis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fistula								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Groin pain								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.20
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myositis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Osteopenia								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal pain								
White	1	(0.1)	1	0.06	4	(0.3)	4	0.31
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Synovial cyst								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	0			
Other	0				0			
Missing	0				0			
Limb discomfort								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tenosynovitis								
White	1	(0.1)	1	0.13	3	(0.2)	3	0.19
Black or African American	0				1	(1.4)	1	2.29
Asian	0				5	(1.0)	6	1.33
Other	1		1		0			
Missing	0				0			
Axillary mass								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Flank pain								
White	1	(0.1)	1	0.10	3	(0.2)	4	0.35
Black or African American	0				0			
Asian	0				3	(0.6)	3	0.73
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Osteoporosis								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Soft tissue swelling								
White	1	(0.1)	3	0.30	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal stenosis								
White	1	(0.1)	2	0.20	2	(0.1)	2	0.13
Black or African American	1	(1.8)	1	1.92	0			
Asian	2	(0.4)	3	1.00	0			
Other	0				0			
Missing	0				0			
Arthropathy								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Bone cyst								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Bone pain								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervical spinal stenosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chondromalacia								
White	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dupuytren's contracture								
White	0				2	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemarthrosis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intervertebral disc degeneration								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Intervertebral disc space narrowing								
White	0				1	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Jaw disorder								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Joint swelling								
White	0				3	(0.2)	3	0.29
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Limb deformity								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Limb mass								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lumbar spinal stenosis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Mastication disorder								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle twitching								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Neuropathic arthropathy								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nodal osteoarthritis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Osteochondritis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pain in jaw								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Periostitis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Polymyalgia rheumatica								
White	0				1	(0.1)	3	0.36
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Rheumatoid arthritis								
White	0				2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				2	(0.3)	2	0.64
Other	0				0			
Missing	0				0			
Scoliosis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal retrolisthesis								
White	0				1	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tenosynovitis stenosans								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vertebral osteophyte								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Nervous system disorders								
All								
White	154	(9.8)	216	18.85	139	(9.2)	179	16.44
Black or African American	11	(15.0)	17	34.05	9	(12.2)	16	30.69
Asian	42	(9.0)	65	22.20	56	(10.7)	128	38.29
Other	0				3		3	
Missing	0				0			
Headache								
White	50	(3.2)	66	6.44	38	(2.5)	43	4.06
Black or African American	6	(7.2)	9	18.22	4	(6.4)	6	18.26
Asian	14	(3.0)	17	5.08	21	(3.9)	30	7.67
Other	0				1		1	
Missing	0				0			
Dizziness								
White	30	(1.9)	38	3.08	22	(1.5)	29	2.73
Black or African American	1	(1.5)	2	4.96	1	(1.3)	1	1.37
Asian	9	(1.9)	11	3.68	16	(3.1)	17	4.73
Other	0				0			
Missing	0				0			
Carpal tunnel syndrome								
White	10	(0.6)	10	0.78	8	(0.5)	8	0.78
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Sciatica								
White	9	(0.6)	9	0.74	10	(0.7)	10	0.86
Black or African American	0				2	(2.4)	3	3.47
Asian	4	(0.8)	4	1.30	0			
Other	0				0			
Missing	0				0			
Paraesthesia								
White	8	(0.5)	9	0.62	8	(0.5)	8	0.70
Black or African American	0				1	(1.1)	1	1.05
Asian	0				3	(0.6)	3	1.06
Other	0				0			
Missing	0				0			
Tremor								
White	7	(0.5)	8	0.55	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	5	(1.0)	5	1.42	7	(1.3)	58	19.59

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Syncope								
White	7	(0.4)	7	0.55	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Migraine								
White	6	(0.4)	7	0.68	5	(0.3)	5	0.56
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Diabetic neuropathy								
White	5	(0.3)	5	0.47	8	(0.5)	8	0.70
Black or African American	0				1	(1.1)	1	1.05
Asian	1	(0.2)	1	0.47	3	(0.6)	3	0.89
Other	0				0			
Missing	0				0			
Neuropathy peripheral								
White	5	(0.3)	5	0.41	9	(0.6)	9	0.75
Black or African American	0				0			
Asian	1	(0.2)	2	0.74	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Hypoaesthesia								
White	5	(0.3)	7	0.54	5	(0.3)	6	0.54
Black or African American	1	(1.8)	1	1.92	1	(1.3)	1	1.37
Asian	3	(0.6)	4	1.32	4	(0.7)	4	1.07
Other	0				0			
Missing	0				0			
Carotid artery stenosis								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Amnesia								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cerebrovascular disorder								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Memory impairment								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dysgeusia								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Transient ischaemic attack								
White	2	(0.1)	2	0.17	3	(0.2)	3	0.25
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Burning sensation								
White	2	(0.1)	2	0.19	2	(0.1)	2	0.18
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Post herpetic neuralgia								
White	2	(0.1)	2	0.16	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Autonomic nervous system imbalance								
White	2	(0.1)	2	0.23	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervicobrachial syndrome								
White	2	(0.1)	2	0.23	1	(0.1)	1	0.06
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Somnolence								
White	2	(0.1)	2	0.23	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Cerebral arteriosclerosis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vascular encephalopathy								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral atrophy								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cluster headache								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cognitive disorder								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Disturbance in attention								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	1	(0.2)	9	4.27	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Intracranial pressure increased								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vascular headache								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Balance disorder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral haemorrhage								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervical radiculopathy								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dizziness postural								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Lumbar radiculopathy								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.14
Black or African American	0				1	(1.3)	2	2.75
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Presyncope								
White	1	(0.1)	1	0.06	4	(0.3)	4	0.26

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Trigeminal neuralgia								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemorrhage intracranial								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus headache								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Speech disorder								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Carotid artery aneurysm								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neuralgia								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.07
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Piriformis syndrome								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Tension headache								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	2	(0.4)	3	0.65	0			
Other	0				0			
Missing	0				0			
Thalamic infarction								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ageusia								
White	0				0			
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anosmia								
White	0				1	(0.1)	1	0.11
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Basilar migraine								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Brain injury								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Carotid arteriosclerosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral artery embolism								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral infarction								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebrovascular accident								
White	0				2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dementia Alzheimer's type								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Encephalopathy								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Essential tremor								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facial nerve disorder								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facial paralysis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Hemiparesis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoglycaemic coma								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoglycaemic seizure								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Hypoglycaemic unconsciousness								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyporeflexia								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypotonia								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ischaemic stroke								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lethargy								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Loss of consciousness								
White	0				2	(0.1)	2	0.20
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Mental impairment								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Meralgia paraesthetica								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Morton's neuralgia								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Myelopathy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Neuroglycopenia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	3	0.58
Other	0				0			
Missing	0				0			
Ophthalmic migraine								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Orthostatic tremor								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Parkinsonian gait								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Peripheral paralysis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Radiculopathy								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Restless legs syndrome								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sleep deficit								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Thrombotic stroke								
White	0				2	(0.1)	2	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vertebral artery occlusion								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
White matter lesion								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
General disorders and administration site conditions								
All								
White	153	(9.7)	217	19.93	120	(7.9)	172	14.96
Black or African American	13	(17.9)	25	46.70	9	(13.2)	13	31.78
Asian	65	(14.0)	104	33.35	78	(14.9)	158	44.75
Other	7		11		1		1	
Missing	2		6		0			
Fatigue								
White	25	(1.6)	28	2.44	13	(0.9)	13	1.01
Black or African American	4	(5.4)	5	9.87	1	(1.8)	1	3.24
Asian	2	(0.4)	2	0.57	2	(0.4)	2	0.50
Other	1		1		0			
Missing	0				0			
Pyrexia								
White	18	(1.1)	19	1.81	15	(1.0)	15	1.52
Black or African American	2	(2.6)	2	4.30	0			
Asian	19	(4.2)	20	6.25	28	(5.3)	30	7.43
Other	2		2		0			
Missing	0				0			
Oedema peripheral								
White	11	(0.7)	11	1.03	9	(0.6)	10	0.83
Black or African American	2	(3.3)	2	3.52	1	(1.3)	1	1.37
Asian	4	(0.9)	4	1.41	0			
Other	2		2		0			
Missing	0				0			
Chest pain								
White	10	(0.6)	10	0.74	5	(0.3)	5	0.46
Black or African American	1	(1.5)	1	1.59	0			
Asian	3	(0.6)	3	1.11	2	(0.4)	2	0.43
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Injection site reaction								
White	9	(0.6)	22	2.35	3	(0.2)	3	0.29
Black or African American	0				1	(1.7)	1	3.31
Asian	5	(1.0)	5	1.62	2	(0.4)	4	0.90
Other	0				0			
Missing	1		2		0			
Pain								
White	8	(0.5)	8	0.80	8	(0.5)	9	0.73
Black or African American	4	(5.4)	5	9.87	1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.39	4	(0.8)	4	1.08
Other	0				1		1	
Missing	0				0			
Medical device site bruise								
White	7	(0.4)	9	0.78	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Asthenia								
White	6	(0.4)	6	0.52	6	(0.4)	6	0.57
Black or African American	0				1	(2.3)	1	4.66
Asian	3	(0.6)	3	0.78	3	(0.6)	3	0.75
Other	0				0			
Missing	1		1		0			
Malaise								
White	6	(0.4)	6	0.55	5	(0.3)	7	0.57
Black or African American	1	(1.5)	1	1.59	0			
Asian	8	(1.7)	9	2.65	10	(1.8)	53	16.98
Other	1		2		0			
Missing	0				0			
Influenza like illness								
White	6	(0.4)	7	0.70	4	(0.3)	4	0.33
Black or African American	1	(0.5)	1	1.07	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site reaction								
White	6	(0.4)	8	0.79	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Medical device site dermatitis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	4	(0.2)	7	0.55	2	(0.1)	2	0.20
Black or African American	0				1	(1.1)	1	1.05
Asian	3	(0.7)	3	1.30	8	(1.5)	15	3.33
Other	0				0			
Missing	0				0			
Medical device site pruritus								
White	4	(0.2)	4	0.36	2	(0.1)	2	0.27
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				2	(0.4)	2	0.53
Other	0				0			
Missing	0				0			
Peripheral swelling								
White	3	(0.2)	3	0.19	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	2	(0.4)	3	0.95	2	(0.4)	2	0.72
Other	0				0			
Missing	0				0			
Injection site bruising								
White	3	(0.2)	3	0.28	5	(0.3)	5	0.37
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chest discomfort								
White	3	(0.2)	3	0.24	2	(0.1)	2	0.18
Black or African American	2	(3.3)	2	4.40	0			
Asian	2	(0.4)	2	0.59	0			
Other	1		1		0			
Missing	0				0			
Drug intolerance								
White	3	(0.2)	3	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gait disturbance								
White	3	(0.2)	3	0.19	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site erythema								
White	3	(0.2)	5	0.50	3	(0.2)	3	0.20
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Chills								
White	3	(0.2)	3	0.23	0			
Black or African American	0				1	(1.1)	1	1.05
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Feeling abnormal								
White	2	(0.1)	2	0.23	0			
Black or African American	0				0			
Asian	1	(0.2)	3	0.65	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Thirst								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Injection site mass								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Swelling face								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Injection site haematoma								
White	2	(0.1)	6	0.66	3	(0.2)	8	0.89
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site haemorrhage								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	2	(0.4)	2	0.44	2	(0.4)	2	0.39
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Medical device site rash								
White	2	(0.1)	2	0.26	3	(0.2)	3	0.41
Black or African American	1	(0.5)	1	1.07	1	(1.4)	1	2.29
Asian	3	(0.7)	3	1.42	4	(0.7)	4	1.34
Other	0				0			
Missing	0				0			
Injection site swelling								
White	2	(0.1)	2	0.21	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hunger								
White	2	(0.1)	3	0.23	0			
Black or African American	0				0			
Asian	5	(1.1)	5	1.34	3	(0.5)	4	1.17
Other	0				0			
Missing	0				0			
Vaccination site pain								
White	2	(0.1)	3	0.23	4	(0.3)	4	0.34
Black or African American	0				0			
Asian	8	(1.7)	9	2.87	5	(0.9)	5	1.65
Other	0				0			
Missing	0				0			
Medical device site erythema								
White	2	(0.1)	2	0.20	4	(0.3)	4	0.45
Black or African American	0				1	(2.3)	2	9.32
Asian	0				0			
Other	0				0			
Missing	0				0			
Multiple organ dysfunction syndrome								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oedema								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.07
Black or African American	0				1	(1.3)	1	1.37
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Xerosis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Early satiety								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Localised oedema								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Application site pruritus								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site haemorrhage								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Injection site pain								
White	1	(0.1)	1	0.11	10	(0.7)	28	2.05
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	3	(0.6)	3	0.88
Other	0				0			
Missing	1		1		0			
Injection site rash								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Discomfort								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	8	2.88
Other	0				0			
Missing	1		1		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Feeling hot								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Implant site pruritus								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site hypersensitivity								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Medical device site eczema								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Swelling								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Inflammation								
White	1	(0.1)	1	0.13	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Injection site urticaria								
White	1	(0.1)	2	0.26	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site haematoma								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.07

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site irritation								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site pain								
White	1	(0.1)	1	0.13	3	(0.2)	3	0.31
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Application site bruise								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Axillary pain								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Condition aggravated								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Cyst								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Death								
White	0				3	(0.2)	3	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Facial pain								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hernia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperthermia								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site dermatitis								
White	0				0			
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site hypertrophy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Injection site induration								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Injection site oedema								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site pruritus								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				0			
Black or African American	0				0			
Asian	4	(0.7)	19	6.58	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Medical device site hypersensitivity								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Medical device site inflammation								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Non-cardiac chest pain								
White	0				3	(0.2)	5	0.31
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Oedema due to renal disease								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Procedural failure								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Systemic inflammatory response syndrome								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaccination site erythema								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Vaccination site inflammation								
White	0				0			
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaccination site pruritus								
White	0				0			
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaccination site reaction								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Vessel puncture site bruise								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Injury, poisoning and procedural complications								
All								
White	145	(9.2)	180	16.21	126	(8.3)	146	14.37
Black or African American	8	(11.0)	12	26.35	4	(6.0)	7	15.41
Asian	36	(7.7)	43	12.54	46	(8.8)	60	16.78
Other	4		4		2		2	
Missing	1		2		2		2	
Fall								
White	16	(1.0)	16	1.28	8	(0.5)	9	0.80
Black or African American	1	(1.8)	1	1.92	1	(1.3)	1	1.37
Asian	3	(0.6)	3	0.77	2	(0.4)	2	0.60
Other	0				0			
Missing	0				0			
Accidental overdose								
White	14	(0.9)	15	1.68	2	(0.1)	3	0.36
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				1		1	
Missing	0				1		1	
Vaccination complication								
White	13	(0.8)	13	1.28	15	(1.0)	19	1.87
Black or African American	1	(1.5)	4	9.92	0			
Asian	6	(1.3)	7	1.87	14	(2.6)	19	4.91
Other	0				0			
Missing	0				0			
Contusion								
White	9	(0.6)	10	0.72	3	(0.2)	3	0.26
Black or African American	0				0			
Asian	6	(1.3)	6	2.00	6	(1.1)	6	1.47
Other	0				0			
Missing	0				0			
Ligament sprain								
White	9	(0.6)	9	0.90	5	(0.3)	5	0.47
Black or African American	0				0			
Asian	3	(0.7)	3	0.98	3	(0.6)	3	0.90
Other	0				0			
Missing	0				0			
Hand fracture								
White	6	(0.4)	6	0.58	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Incorrect dose administered								
White	5	(0.3)	5	0.62	4	(0.3)	5	0.51
Black or African American	1	(1.1)	1	1.82	1	(1.7)	2	6.62
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin abrasion								
White	5	(0.3)	8	0.72	3	(0.2)	3	0.32
Black or African American	0				0			
Asian	4	(0.9)	4	1.17	2	(0.4)	2	0.72
Other	0				0			
Missing	0				0			
Prescribed overdose								
White	5	(0.3)	5	0.65	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin laceration								
White	5	(0.3)	5	0.36	1	(0.1)	1	0.14
Black or African American	1	(1.1)	1	1.82	0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Ankle fracture								
White	4	(0.3)	4	0.25	2	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Procedural pain								
White	4	(0.3)	4	0.41	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Road traffic accident								
White	4	(0.3)	5	0.49	0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Limb injury								
White	4	(0.3)	4	0.37	6	(0.4)	7	0.70
Black or African American	0				0			
Asian	2	(0.4)	2	0.59	0			
Other	0				0			
Missing	0				0			
Joint injury								
White	4	(0.3)	4	0.39	5	(0.3)	5	0.45
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Foot fracture								
White	3	(0.2)	3	0.29	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.50
Other	0				0			
Missing	0				0			
Tooth fracture								
White	3	(0.2)	3	0.24	2	(0.1)	2	0.20

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Arthropod bite								
White	3	(0.2)	3	0.33	4	(0.3)	4	0.43
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rib fracture								
White	3	(0.2)	3	0.23	3	(0.2)	3	0.19
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.69
Other	0				0			
Missing	1		1		0			
Arthropod sting								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Back injury								
White	2	(0.1)	2	0.13	2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Upper limb fracture								
White	2	(0.1)	2	0.13	0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tendon rupture								
White	2	(0.1)	2	0.17	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Radius fracture								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Medication error								
White	2	(0.1)	2	0.22	2	(0.1)	2	0.25
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Thermal burn								
White	2	(0.1)	2	0.17	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Wound								
White	2	(0.1)	2	0.13	3	(0.2)	3	0.32
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	2	(0.4)	2	0.65
Other	0				0			
Missing	0				1		1	
Accidental underdose								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Extra dose administered								
White	1	(0.1)	1	0.11	0			
Black or African American	0				1	(1.7)	1	3.31
Asian	0				0			
Other	0				0			
Missing	0				0			
Subdural haematoma								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Animal bite								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.55
Other	0				0			
Missing	0				0			
Bone contusion								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Femoral neck fracture								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hip fracture								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Inflammation of wound								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injury of conjunctiva								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Multiple injuries								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle injury								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.23
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neck injury								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Penile contusion								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural complication								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural inflammation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Radiation skin injury								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal compression fracture								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Gun shot wound								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ligament rupture								
White	1	(0.1)	2	0.22	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Procedural complication								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervical vertebral fracture								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye injury								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fibula fracture								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Injury								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Meniscus injury								
White	1	(0.1)	1	0.06	5	(0.3)	5	0.36
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Overdose								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.29
Black or African American	2	(3.0)	2	4.96	0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Post procedural fistula								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural haemorrhage								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural hypothyroidism								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Traumatic haematoma								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Epicondylitis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Product administration error								
White	1	(0.1)	1	0.13	2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Product dispensing error								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Craniocerebral injury								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Face injury								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Facial bones fracture								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Subcutaneous haematoma								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Wrist fracture								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anaemia postoperative								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Animal scratch								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Burn oral cavity								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Burns first degree								
White	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Chillblains								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Clavicle fracture								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Concussion								
White	0				2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Corneal abrasion								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Crush injury								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Deafness traumatic								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Endotracheal intubation complication								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Exposure to SARS-CoV-2								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Head injury								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Heat illness								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	3	(0.6)	4	0.89
Other	0				0			
Missing	0				0			
Heat stroke								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Humerus fracture								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intentional overdose								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intentional product use issue								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Lower limb fracture								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle contusion								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Muscle strain								
White	0				5	(0.3)	5	0.49
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Nerve injury								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Periprocedural myocardial infarction								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural haematuria								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Post procedural stroke								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural swelling								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Post-traumatic neck syndrome								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Scar								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Scratch								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Seroma								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Soft tissue injury								
White	0				2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal column injury								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Stab wound								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Sunburn								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tendon injury								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tibia fracture								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Underdose								
White	0				5	(0.3)	5	0.54
Black or African American	1	(1.5)	1	2.48	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Wound dehiscence								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Wrong dose								
White	0				2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Wrong product administered								
White	0				5	(0.3)	5	0.65
Black or African American	0				0			
Asian	1	(0.2)	2	0.70	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			

Eye disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
White	113	(7.2)	147	13.36	110	(7.2)	137	13.15
Black or African American	12	(15.0)	14	26.05	9	(13.7)	14	34.25
Asian	47	(10.1)	59	19.86	60	(11.6)	83	24.90
Other	3		4		1		2	
Missing	1		1		0			
Diabetic retinopathy								
White	37	(2.4)	39	3.79	45	(3.0)	48	4.81
Black or African American	2	(2.6)	2	3.42	2	(3.1)	2	4.61
Asian	24	(5.2)	27	9.89	25	(4.7)	26	7.97
Other	1		2		0			
Missing	0				0			
Cataract								
White	18	(1.2)	22	1.73	13	(0.8)	14	1.00
Black or African American	1	(0.5)	1	1.07	3	(4.0)	3	5.04
Asian	8	(1.7)	9	2.55	10	(1.9)	11	3.31
Other	0				1		2	
Missing	1		1		0			
Macular oedema								
White	10	(0.6)	11	1.18	5	(0.3)	5	0.43
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Retinopathy hypertensive								
White	8	(0.5)	9	0.90	5	(0.3)	5	0.51
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry eye								
White	5	(0.3)	5	0.38	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	2	(0.4)	2	0.61	6	(1.2)	6	1.31
Other	0				0			
Missing	0				0			
Diabetic retinal oedema								
White	5	(0.3)	5	0.57	5	(0.3)	6	0.60
Black or African American	0				1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.35	4	(0.8)	4	1.21
Other	0				0			
Missing	0				0			
Vision blurred								
White	4	(0.3)	4	0.37	2	(0.1)	2	0.13
Black or African American	1	(1.1)	1	1.91	2	(3.1)	2	5.53

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	1	(0.2)	1	0.47	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Retinal haemorrhage								
White	3	(0.2)	3	0.29	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Eye pain								
White	3	(0.2)	3	0.19	2	(0.1)	2	0.18
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Glaucoma								
White	3	(0.2)	3	0.26	2	(0.1)	2	0.20
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	4	(0.8)	4	1.22
Other	0				0			
Missing	0				0			
Non-proliferative retinopathy								
White	3	(0.2)	4	0.48	4	(0.3)	4	0.50
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Age-related macular degeneration								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blepharitis								
White	2	(0.1)	2	0.17	0			
Black or African American	1	(1.8)	1	1.92	0			
Asian	2	(0.4)	2	0.44	0			
Other	0				0			
Missing	0				0			
Astigmatism								
White	2	(0.1)	3	0.19	3	(0.2)	3	0.29
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.57
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vitreous detachment								
White	2	(0.1)	2	0.13	0			
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				2	(0.3)	2	0.67
Other	0				0			
Missing	0				0			
Arteriosclerotic retinopathy								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye inflammation								
White	2	(0.1)	2	0.17	2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ocular hypertension								
White	2	(0.1)	2	0.16	2	(0.1)	3	0.34
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Presbyopia								
White	1	(0.1)	1	0.11	2	(0.1)	2	0.24
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Retinal deposits								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal scar								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Amaurosis fugax								
White	1	(0.1)	1	0.06	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Angle closure glaucoma								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival hyperaemia								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival suffusion								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Maculopathy								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vitreous opacities								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival erosion								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival haemorrhage								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.86	0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Diplopia								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Optic disc vascular disorder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post thrombotic retinopathy								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal aneurysm								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal tear								
White	1	(0.1)	1	0.06	0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Posterior capsule opacification								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Retinal vascular disorder								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry age-related macular degeneration								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Epiretinal membrane								
White	1	(0.1)	1	0.10	3	(0.2)	3	0.31
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Eye irritation								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lacrimation increased								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Myopia								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.57
Other	0				0			
Missing	0				0			
Ocular hyperaemia								
White	1	(0.1)	1	0.10	1	(0.1)	2	0.22
Black or African American	1	(1.1)	2	3.81	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acquired epiblepharon								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Asthenopia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Cataract nuclear								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	1		1		0			
Missing	0				0			
Chorioretinal atrophy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Conjunctivitis allergic								
White	0				0			
Black or African American	0				0			
Asian	2	(0.4)	3	0.80	0			
Other	0				0			
Missing	0				0			
Corneal bleeding								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Corneal erosion								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Cystoid macular oedema								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dacryoadenitis acquired								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eye discharge								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Eye pruritus								
White	0				1	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eyelid oedema								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypermetropia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Macular degeneration								
White	0				2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Macular hole								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Meibomianitis								
White	0				0			
Black or African American	0				1	(1.8)	1	3.24
Asian	0				0			
Other	0				0			
Missing	0				0			
Normal tension glaucoma								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Ocular ischaemic syndrome								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Open angle glaucoma								
White	0				0			
Black or African American	0				1	(1.8)	2	6.48
Asian	0				0			
Other	0				0			
Missing	0				0			
Ophthalmic vein thrombosis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Optic disc haemorrhage								
White	0				0			
Black or African American	0				1	(1.7)	1	3.31
Asian	0				0			
Other	0				0			
Missing	0				0			
Photophobia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Photopsia								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pterygium								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Retinal artery occlusion								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Retinal degeneration								
White	0				0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Retinal detachment								
White	0				2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal drusen								
White	0				1	(0.1)	1	0.11
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal exudates								
White	0				1	(0.1)	1	0.11
Black or African American	1	(1.5)	1	2.48	0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Retinal vein occlusion								
White	0				1	(0.1)	1	0.07
Black or African American	1	(1.5)	1	2.48	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinopathy								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Scintillating scotoma								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Uveitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Visual acuity reduced								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Visual impairment								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	1	(0.2)	9	3.24
Other	0				0			
Missing	0				0			
Vitreous degeneration								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vitreous floaters								
White	0				1	(0.1)	1	0.14
Black or African American	0				1	(1.7)	1	3.31
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Vitreous haemorrhage								
White	0				2	(0.1)	2	0.18
Black or African American	0				0			
Asian	2	(0.4)	2	0.74	0			
Other	0				0			
Missing	0				0			
Respiratory, thoracic and mediastinal disorders								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	101	(6.4)	144	12.92	86	(5.7)	106	9.96
Black or African American	9	(11.7)	9	16.78	4	(5.7)	6	17.45
Asian	19	(3.9)	20	5.49	27	(5.3)	32	9.02
Other	3		4		2		6	
Missing	0				3		3	
Cough								
White	18	(1.2)	21	1.94	19	(1.3)	19	1.89
Black or African American	2	(3.3)	2	4.40	3	(4.7)	4	11.74
Asian	5	(1.0)	5	1.33	6	(1.2)	7	1.87
Other	1		1		0			
Missing	0				0			
Oropharyngeal pain								
White	18	(1.1)	19	1.63	12	(0.8)	13	1.31
Black or African American	0				1	(1.1)	1	1.05
Asian	5	(1.0)	6	1.70	5	(1.0)	6	1.61
Other	1		1		1		1	
Missing	0				0			
Rhinorrhoea								
White	11	(0.7)	14	1.24	11	(0.7)	11	1.12
Black or African American	0				1	(2.3)	1	4.66
Asian	1	(0.2)	1	0.39	1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Respiratory disorder								
White	8	(0.5)	8	0.92	7	(0.5)	7	0.70
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal congestion								
White	8	(0.5)	8	0.60	5	(0.3)	5	0.39
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	1		1		0			
Missing	0				0			
Sleep apnoea syndrome								
White	6	(0.4)	6	0.46	0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dyspnoea								
White	5	(0.3)	5	0.46	10	(0.6)	11	0.99
Black or African American	0				0			
Asian	4	(0.7)	4	1.06	3	(0.6)	3	0.62

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Asthma								
White	4	(0.3)	5	0.42	0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Sinus congestion								
White	4	(0.3)	5	0.45	2	(0.1)	2	0.20
Black or African American	2	(2.2)	2	3.73	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Productive cough								
White	4	(0.2)	4	0.33	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				3	(0.5)	3	0.87
Other	0				0			
Missing	0				0			
Epistaxis								
White	4	(0.2)	8	0.85	1	(0.1)	2	0.22
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	1	(0.2)	2	0.39
Other	1		1		0			
Missing	0				0			
Sneezing								
White	3	(0.2)	3	0.29	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic obstructive pulmonary disease								
White	3	(0.2)	3	0.31	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Emphysema								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pulmonary fibrosis								
White	2	(0.1)	3	0.24	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus pain								
White	2	(0.1)	3	0.24	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rhinitis allergic								
White	2	(0.1)	2	0.19	2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				3	(0.6)	3	1.02
Other	0				1		5	
Missing	0				0			
Interstitial lung disease								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Upper-airway cough syndrome								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute respiratory failure								
White	2	(0.1)	2	0.16	1	(0.1)	1	0.07
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal septum deviation								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	1	(1.5)	1	2.48	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pleurisy								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.14
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary hypertension								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Increased viscosity of upper respiratory secretion								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Upper respiratory tract inflammation								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bronchospasm								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acquired diaphragmatic eventration								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bronchiectasis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Laryngeal cyst								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Nasal dryness								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal turbinate hypertrophy								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary embolism								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary mass								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.69
Other	0				0			
Missing	0				0			
Throat irritation								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Bronchial hyperreactivity								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dyspnoea exertional								
White	1	(0.1)	1	0.13	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Hiccups								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal obstruction								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory failure								
White	1	(0.1)	1	0.10	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute pulmonary oedema								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Allergic bronchitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Allergic cough								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Aphonia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bronchitis chronic								
White	0				2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Dry throat								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Dysphonia								
White	0				1	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemoptysis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lung disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Paranasal cyst								
White	0				2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Paranasal sinus discomfort								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pleural disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pleural effusion								
White	0				3	(0.2)	3	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pleuritic pain								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary congestion								
White	0				0			
Black or African American	1	(0.5)	1	1.07	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory tract inflammation								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metabolism and nutrition disorders								
All								
White	89	(5.7)	117	9.57	87	(5.7)	103	8.83
Black or African American	4	(6.0)	5	8.94	6	(8.1)	8	13.44
Asian	32	(6.6)	34	9.60	35	(6.6)	52	13.39
Other	7		7		4		4	
Missing	0				2		2	
Vitamin D deficiency								
White	17	(1.1)	17	1.19	14	(0.9)	14	1.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoglycaemia								
White	13	(0.8)	21	2.28	8	(0.5)	11	0.98
Black or African American	0				1	(1.3)	1	1.37
Asian	5	(1.1)	5	1.48	13	(2.4)	27	6.75
Other	0				0			
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperlipidaemia								
White	11	(0.7)	11	0.78	11	(0.7)	11	0.87
Black or African American	0				1	(1.3)	1	1.37
Asian	3	(0.6)	3	1.10	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Vitamin B12 deficiency								
White	7	(0.5)	7	0.44	1	(0.1)	1	0.06
Black or African American	1	(1.5)	1	1.59	0			
Asian	3	(0.5)	3	0.49	0			
Other	0				0			
Missing	0				0			
Dyslipidaemia								
White	7	(0.4)	7	0.59	12	(0.8)	12	1.16
Black or African American	1	(1.1)	1	1.91	0			
Asian	10	(2.0)	11	3.13	3	(0.6)	3	0.88
Other	3		3		2		2	
Missing	0				0			
Hyperglycaemia								
White	6	(0.4)	7	0.66	7	(0.5)	7	0.70
Black or African American	0				2	(3.1)	2	5.53
Asian	0				4	(0.8)	4	0.94
Other	0				1		1	
Missing	0				0			
Gout								
White	4	(0.3)	5	0.32	6	(0.4)	7	0.45
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Iron deficiency								
White	4	(0.3)	4	0.25	3	(0.2)	3	0.18
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	0			
Other	0				0			
Missing	0				0			
Hypertriglyceridaemia								
White	4	(0.3)	4	0.35	4	(0.3)	4	0.40
Black or African American	0				0			
Asian	5	(1.1)	5	1.22	3	(0.6)	3	0.58
Other	1		1		1		1	
Missing	0				0			
Hyperkalaemia								
White	4	(0.3)	4	0.31	6	(0.4)	6	0.58
Black or African American	1	(1.8)	2	3.85	2	(2.4)	2	2.42

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	3	(0.7)	3	0.98	2	(0.4)	2	0.55
Other	0				0			
Missing	0				0			
Hyponatraemia								
White	3	(0.2)	3	0.36	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Increased appetite								
White	3	(0.2)	3	0.19	6	(0.4)	7	0.69
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperuricaemia								
White	3	(0.2)	3	0.23	2	(0.1)	2	0.12
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Decreased appetite								
White	3	(0.2)	3	0.24	5	(0.3)	5	0.36
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Diabetes mellitus								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Folate deficiency								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fluid retention								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypercholesterolaemia								
White	2	(0.1)	2	0.18	3	(0.2)	3	0.32
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	1		1		0			
Missing	0				0			
Hypokalaemia								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoalbuminaemia								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dehydration								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	2	(0.4)	3	0.87
Other	0				0			
Missing	0				0			
Hypernatraemia								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Magnesium deficiency								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malnutrition								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Vitamin B complex deficiency								
White	1	(0.1)	1	0.06	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Zinc deficiency								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Abnormal weight gain								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Appetite disorder								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	2	0.39
Other	0				0			
Missing	0				0			
Diabetes mellitus inadequate control								
White	0				0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrolyte imbalance								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Food craving								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Hyperammonaemia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Hypercalcaemia								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Insulin resistance								
White	0				2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lactic acidosis								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipomatosis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metabolic acidosis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Metabolic disorder								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Obesity								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.68
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin and subcutaneous tissue disorders								
All								
White	77	(4.9)	82	7.25	76	(5.0)	91	7.94
Black or African American	3	(3.7)	4	7.06	5	(6.0)	5	6.22
Asian	38	(8.2)	40	12.47	45	(8.5)	57	16.16
Other	4		4		1		1	
Missing	1		1		1		1	
Rash								
White	7	(0.4)	7	0.72	9	(0.6)	10	0.69
Black or African American	2	(2.6)	2	3.42	0			
Asian	4	(0.8)	4	1.16	2	(0.4)	2	0.50
Other	1		1		0			
Missing	0				0			
Alopecia								
White	7	(0.4)	7	0.68	2	(0.1)	2	0.14
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Pruritus								
White	6	(0.4)	6	0.42	7	(0.5)	7	0.59
Black or African American	1	(1.1)	1	1.82	1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.37	3	(0.6)	3	1.04
Other	0				1		1	
Missing	0				0			
Eczema								
White	5	(0.3)	5	0.32	3	(0.2)	3	0.31
Black or African American	0				0			
Asian	5	(1.1)	5	1.54	4	(0.8)	4	1.21
Other	0				0			
Missing	0				0			
Urticaria								
White	5	(0.3)	5	0.39	10	(0.7)	10	0.90
Black or African American	0				0			
Asian	2	(0.4)	2	0.74	2	(0.4)	2	0.39
Other	0				0			
Missing	0				0			
Skin ulcer								
White	4	(0.3)	4	0.36	3	(0.2)	3	0.28
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.69
Other	0				0			
Missing	0				0			
Dermatitis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	4	(0.3)	4	0.37	6	(0.4)	7	0.61
Black or African American	0				0			
Asian	3	(0.7)	3	1.42	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Skin irritation								
White	4	(0.3)	5	0.45	3	(0.2)	3	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dermatitis contact								
White	3	(0.2)	3	0.32	7	(0.5)	7	0.65
Black or African American	0				1	(1.1)	1	1.05
Asian	2	(0.4)	3	0.65	6	(1.1)	6	1.90
Other	2		2		0			
Missing	0				0			
Night sweats								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Dermatitis allergic								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Ingrowing nail								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.39
Other	0				0			
Missing	0				0			
Rash erythematous								
White	2	(0.1)	2	0.24	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Psoriasis								
White	2	(0.1)	2	0.13	2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Skin lesion								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Hyperhidrosis								
White	2	(0.1)	2	0.16	4	(0.3)	4	0.36
Black or African American	0				1	(1.3)	1	1.37
Asian	6	(1.2)	6	1.66	0			
Other	0				0			
Missing	0				0			
Blister								
White	2	(0.1)	2	0.23	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Intertrigo								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Umbilical haematoma								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acne								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Diabetic foot								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Erythema								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.32
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Livedo reticularis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nail bed inflammation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Decubitus ulcer								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ecchymosis								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Skin odour abnormal								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry skin								
White	1	(0.1)	1	0.06	4	(0.3)	4	0.30
Black or African American	0				0			
Asian	3	(0.7)	3	0.91	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Granuloma annulare								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperkeratosis								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.25
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Lipodystrophy acquired								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin exfoliation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Dermal cyst								
White	1	(0.1)	1	0.13	2	(0.1)	2	0.19
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.53
Other	0				0			
Missing	0				0			
Hidradenitis								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ingrown hair								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lichen sclerosus								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Macule								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Actinic keratosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Alopecia areata								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Angioedema								
White	0				3	(0.2)	3	0.26
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Asteatosis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Chronic spontaneous urticaria								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cold sweat								
White	0				0			
Black or African American	0				0			
Asian	4	(0.8)	4	1.13	8	(1.4)	12	3.77
Other	0				0			
Missing	0				0			
Cold urticaria								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Dermatitis atopic								
White	0				2	(0.1)	2	0.27
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Drug eruption								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemorrhage subcutaneous								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Lentigo								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Leukoplakia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Lipohypertrophy								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.55
Other	0				0			
Missing	0				0			
Miliaria								
White	0				0			
Black or African American	0				1	(1.1)	1	1.05
Asian	2	(0.5)	2	0.78	3	(0.6)	3	0.58
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Myxoid cyst								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Neurodermatitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Pruritus allergic								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Purpura								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rash maculo-papular								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Rash papular								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Seborrhoea								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin discolouration								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Skin fissures								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Skin reaction								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Telangiectasia								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urticaria contact								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Urticaria thermal								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Xeroderma								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Investigations								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	74	(4.8)	83	7.53	59	(3.9)	62	5.64
Black or African American	5	(5.4)	7	11.40	3	(3.7)	3	3.80
Asian	15	(3.1)	19	5.08	16	(3.0)	22	6.60
Other	0				1		1	
Missing	0				0			
Weight increased								
White	17	(1.1)	17	1.54	14	(0.9)	14	1.25
Black or African American	0				1	(1.3)	1	1.37
Asian	3	(0.6)	3	0.65	3	(0.6)	3	0.58
Other	0				0			
Missing	0				0			
SARS-CoV-2 test positive								
White	6	(0.4)	6	0.56	4	(0.3)	4	0.54
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood pressure increased								
White	5	(0.3)	5	0.50	4	(0.3)	4	0.31
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood creatinine increased								
White	5	(0.3)	5	0.49	0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	2	(0.4)	2	0.76	0			
Other	0				0			
Missing	0				0			
Blood triglycerides increased								
White	4	(0.3)	4	0.37	2	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Blood immunoglobulin E increased								
White	3	(0.2)	3	0.19	3	(0.2)	3	0.18
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood alkaline phosphatase increased								
White	3	(0.2)	3	0.33	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Weight decreased								
White	3	(0.2)	3	0.19	2	(0.1)	2	0.20
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Blood cholesterol increased								
White	3	(0.2)	3	0.26	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Prostatic specific antigen increased								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Occult blood								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram abnormal								
White	2	(0.1)	2	0.19	2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatic enzyme increased								
White	2	(0.1)	2	0.19	2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Alanine aminotransferase increased								
White	2	(0.1)	2	0.21	0			
Black or African American	0				0			
Asian	2	(0.4)	2	0.59	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eosinophil count increased								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				1	(0.2)	2	0.67
Other	0				0			
Missing	0				0			
Liver function test abnormal								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				1	(0.2)	2	0.62
Other	0				0			
Missing	0				0			
Electrocardiogram ST segment abnormal								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram T wave inversion								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Liver function test increased								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	1	(1.1)	1	1.82	0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
QRS axis abnormal								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Thyroid function test abnormal								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arthroscopy								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood glucose fluctuation								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood potassium increased								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Monofilament pressure perception test								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood creatine increased								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Body temperature increased								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
International normalised ratio abnormal								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
International normalised ratio decreased								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
International normalised ratio increased								
White	1	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Transferrin saturation decreased								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Angiogram								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aspartate aminotransferase increased								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Heart rate increased								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Low density lipoprotein increased								
White	1	(0.1)	1	0.13	0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				2	(0.4)	2	0.69
Other	0				0			
Missing	0				0			
Mycobacterium tuberculosis complex test positive								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Occult blood positive								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Amylase increased								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Antinuclear antibody positive								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood creatine phosphokinase increased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Blood glucose decreased								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood glucose increased								
White	0				2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood pressure decreased								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood testosterone decreased								
White	0				0			
Black or African American	1	(0.5)	1	1.07	0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Blood uric acid increased								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Blood urine present								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	3	0.49	0			
Other	0				1		1	
Missing	0				0			
Bone density decreased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	0			
Other	0				0			
Missing	0				0			
Breath sounds abnormal								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Carbohydrate antigen 19-9 increased								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac murmur								
White	0				2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac stress test abnormal								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Catheterisation cardiac								
White	0				0			
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ejection fraction decreased								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram P wave biphasic								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Electrocardiogram repolarisation abnormality								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram ST segment depression								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Free fatty acids increased								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Glomerular filtration rate decreased								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Glycosylated haemoglobin increased								
White	0				2	(0.1)	3	0.18
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Grip strength decreased								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Haematocrit increased								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemoglobin decreased								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.53
Other	0				0			
Missing	0				0			
Haemoglobin increased								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatitis B virus test positive								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Intraocular pressure increased								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipase increased								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lipids abnormal								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipids increased								
White	0				0			
Black or African American	0				1	(1.1)	1	1.05
Asian	0				0			
Other	0				0			
Missing	0				0			
Monocyte count decreased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Platelet count decreased								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.70
Other	0				0			
Missing	0				0			
Red blood cell count decreased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Transaminases increased								
White	0				1	(0.1)	1	0.11
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vitamin D decreased								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
White blood cell count decreased								
White	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac disorders								
All								
White	70	(4.5)	106	7.68	62	(4.0)	92	7.29
Black or African American	5	(7.3)	5	9.17	5	(6.6)	5	6.86
Asian	16	(3.5)	18	6.50	17	(3.3)	18	4.85
Other	3		3		0			
Missing	1		1		0			
Coronary artery disease								
White	12	(0.8)	12	0.85	10	(0.6)	10	0.73
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial fibrillation								
White	12	(0.8)	13	0.87	5	(0.3)	5	0.38
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Cardiac failure								
White	8	(0.5)	8	0.55	3	(0.2)	4	0.42
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute myocardial infarction								
White	7	(0.5)	7	0.50	7	(0.5)	7	0.55
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.39	1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Angina pectoris								
White	7	(0.5)	7	0.56	3	(0.2)	3	0.23
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Ventricular extrasystoles								
White	4	(0.3)	4	0.32	1	(0.1)	2	0.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	1	(1.8)	1	1.92	0			
Asian	3	(0.7)	3	1.17	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Tachycardia								
White	3	(0.2)	3	0.19	4	(0.3)	4	0.30
Black or African American	0				1	(1.3)	1	1.37
Asian	0				2	(0.4)	2	0.69
Other	0				0			
Missing	0				0			
Acute coronary syndrome								
White	3	(0.2)	3	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Palpitations								
White	3	(0.2)	3	0.24	4	(0.3)	4	0.33
Black or African American	1	(1.8)	1	1.92	0			
Asian	2	(0.5)	2	0.69	3	(0.6)	3	0.89
Other	1		1		0			
Missing	0				0			
Cardiac failure congestive								
White	3	(0.2)	3	0.19	2	(0.1)	3	0.33
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Left ventricular hypertrophy								
White	3	(0.2)	3	0.19	2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Angina unstable								
White	3	(0.2)	3	0.19	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Myocardial infarction								
White	3	(0.2)	3	0.23	2	(0.1)	2	0.13
Black or African American	0				1	(1.3)	1	1.37
Asian	2	(0.4)	2	0.70	1	(0.2)	1	0.19
Other	1		1		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Atrioventricular block first degree								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myocardial ischaemia								
White	2	(0.1)	2	0.18	3	(0.2)	3	0.26
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Cardiac failure chronic								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Coronary artery occlusion								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bundle branch block right								
White	2	(0.1)	2	0.19	5	(0.3)	6	0.49
Black or African American	0				1	(1.3)	1	1.37
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Supraventricular tachycardia								
White	2	(0.1)	2	0.16	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic valve sclerosis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arrhythmia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				2	(0.4)	2	0.54
Other	0				0			
Missing	0				0			
Arteriosclerosis coronary artery								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bundle branch block left								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Cardio-respiratory arrest								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Mitral valve stenosis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic valve incompetence								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial flutter								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial thrombosis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Bradycardia								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac ventricular thrombosis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic coronary syndrome								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diastolic dysfunction								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Left atrial dilatation								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Left ventricular dysfunction								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Mitral valve incompetence								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Black or African American	0				0			
Asian	2	(0.4)	2	0.53	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pericardial effusion								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pericarditis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus tachycardia								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tricuspid valve incompetence								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiovascular disorder								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac flutter								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic valve calcification								
White	0				2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial enlargement								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrioventricular block complete								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac arrest								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Cardiac dysfunction								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Cardiac failure acute								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac perfusion defect								
White	0				1	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiomegaly								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Coronary artery stenosis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Left atrial enlargement								
White	0				0			
Black or African American	1	(1.1)	1	1.82	1	(1.3)	1	1.37
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Sinus arrhythmia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus bradycardia								
White	0				3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Subendocardial ischaemia								
White	0				2	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Supraventricular extrasystoles								
White	0				1	(0.1)	1	0.07
Black or African American	0				1	(1.3)	1	1.37
Asian	2	(0.4)	2	0.59	0			
Other	0				0			
Missing	1		1		0			
Ventricular arrhythmia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ventricular tachycardia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

Vascular disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
White	59	(3.8)	67	5.56	56	(3.7)	68	5.65
Black or African American	1	(1.8)	1	1.92	4	(5.3)	6	9.15
Asian	18	(3.8)	19	5.49	18	(3.5)	22	6.47
Other	1		1		1		1	
Missing	0				1		2	
Hypertension								
White	24	(1.5)	24	2.08	23	(1.5)	26	2.19
Black or African American	1	(1.8)	1	1.92	1	(1.4)	1	2.29
Asian	11	(2.4)	11	3.52	13	(2.5)	15	4.21
Other	1		1		1		1	
Missing	0				0			
Hypotension								
White	6	(0.4)	6	0.47	2	(0.1)	2	0.18
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral arterial occlusive disease								
White	4	(0.3)	5	0.41	2	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arteriosclerosis								
White	4	(0.3)	4	0.32	5	(0.3)	5	0.37
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.69
Other	0				0			
Missing	0				0			
Superficial vein thrombosis								
White	3	(0.2)	3	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral artery stenosis								
White	2	(0.1)	5	0.47	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral venous disease								
White	2	(0.1)	2	0.18	2	(0.1)	2	0.13

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Aortic arteriosclerosis								
White	2	(0.1)	2	0.13	3	(0.2)	3	0.29
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Deep vein thrombosis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic vascular disorder								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Haematoma								
White	1	(0.1)	1	0.11	3	(0.2)	3	0.29
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Hypertensive crisis								
White	1	(0.1)	1	0.11	2	(0.1)	4	0.40
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood pressure inadequately controlled								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	0			
Other	0				0			
Missing	0				0			
Hot flush								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Venous stenosis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Varicose ulceration								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic stenosis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Brachiocephalic arteriosclerosis								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Flushing								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypertensive urgency								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				1	(1.3)	2	2.75
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral artery occlusion								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral coldness								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	2	(0.4)	2	0.44	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Peripheral vascular disorder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Orthostatic hypotension								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Aneurysm								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic aneurysm								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic dilatation								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Arterial insufficiency								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Blood pressure fluctuation								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Iliac artery stenosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intermittent claudication								
White	0				2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Macroangiopathy								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neovascularisation								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral artery aneurysm								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Peripheral ischaemia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Phlebitis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Thrombophlebitis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Thrombosis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Varicose vein								
White	0				2	(0.1)	2	0.20
Black or African American	0				1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Renal and urinary disorders								
All								
White	41	(2.6)	52	4.39	34	(2.2)	44	3.44
Black or African American	2	(2.6)	2	4.39	2	(2.6)	2	2.75
Asian	9	(1.9)	9	2.88	17	(3.4)	21	5.65
Other	2		2		0			
Missing	0				1		3	
Nephrolithiasis								
White	5	(0.3)	5	0.32	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				2	(0.4)	3	0.81
Other	0				0			
Missing	0				1		2	
Chronic kidney disease								
White	4	(0.3)	4	0.40	5	(0.3)	5	0.44
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Pollakiuria								
White	4	(0.3)	4	0.39	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	2	(0.4)	2	0.39
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Renal cyst								
White	4	(0.3)	4	0.29	4	(0.3)	4	0.30
Black or African American	0				0			
Asian	3	(0.6)	3	1.08	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Dysuria								
White	3	(0.2)	4	0.30	2	(0.1)	2	0.14
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	2	(0.4)	2	0.55
Other	0				0			
Missing	0				0			
Ureterolithiasis								
White	3	(0.2)	3	0.24	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.43
Other	0				0			
Missing	0				0			
Renal pain								
White	3	(0.2)	3	0.32	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic nephropathy								
White	3	(0.2)	3	0.23	3	(0.2)	3	0.36
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Acute kidney injury								
White	2	(0.1)	2	0.18	2	(0.1)	2	0.13
Black or African American	1	(1.1)	1	1.91	2	(2.6)	2	2.75
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Microalbuminuria								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urine odour abnormal								
White	2	(0.1)	2	0.16	1	(0.1)	1	0.11
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Haematuria								
White	1	(0.1)	2	0.23	4	(0.3)	4	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Hypertonic bladder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nocturia								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Proteinuria								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary incontinence								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary retention								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal failure								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Renal impairment								
White	1	(0.1)	1	0.11	3	(0.2)	3	0.20
Black or African American	1	(1.5)	1	2.48	0			
Asian	1	(0.2)	1	0.22	0			
Other	1		1		0			
Missing	0				0			
Calculus urinary								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Pyelocaliectasis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal colic								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Bladder prolapse								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hydronephrosis								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Polyuria								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Urethral stenosis								
White	1	(0.1)	1	0.10	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bladder mass								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chromaturia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Cystitis haemorrhagic								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hydrocalyx								
White	0				2	(0.1)	2	0.25
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypertensive nephropathy								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Micturition urgency								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Nephropathy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Nephrotic syndrome								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Renal mass								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Strangury								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Stress urinary incontinence								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary tract disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Urinary tract inflammation								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary tract obstruction								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Psychiatric disorders								
All								
White	33	(2.1)	37	3.07	34	(2.2)	36	3.39
Black or African American	0				1	(1.3)	1	1.37
Asian	7	(1.5)	7	2.00	5	(0.9)	5	1.54
Other	1		1		2		2	
Missing	0				1		2	
Depression								
White	8	(0.5)	8	0.60	11	(0.7)	11	1.05
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Anxiety								
White	6	(0.4)	6	0.49	10	(0.7)	10	0.92
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Insomnia								
White	6	(0.4)	6	0.57	3	(0.2)	3	0.20
Black or African American	0				0			
Asian	5	(1.1)	5	1.26	2	(0.4)	2	0.55
Other	0				0			
Missing	0				1		2	
Sleep disorder								
White	5	(0.3)	5	0.38	3	(0.2)	3	0.35
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Depressed mood								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Mental status changes								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adjustment disorder with mixed anxiety and								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
depressed mood								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Disorientation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Irritability								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Listless								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post-traumatic stress disorder								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Drug abuse								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nightmare								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Attention deficit hyperactivity disorder								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Adjustment disorder								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adjustment disorder with depressed mood								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Affect lability								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Agitation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Anxiety disorder								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bruxism								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Drug dependence								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Emotional distress								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fear								
White	0				2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Major depression								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Mixed anxiety and depressive disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Mood swings								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Persistent depressive disorder								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Phobia								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Stress								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Blood and lymphatic system disorders								
All								
White	27	(1.7)	29	2.49	22	(1.4)	22	1.86
Black or African American	0				1	(1.1)	1	1.05
Asian	8	(1.6)	8	2.38	7	(1.4)	7	2.16
Other	1		1		3		3	
Missing	0				0			
Anaemia								
White	16	(1.0)	18	1.56	9	(0.6)	9	0.77
Black or African American	0				1	(1.1)	1	1.05
Asian	3	(0.6)	3	0.93	2	(0.4)	2	0.55
Other	1		1		2		2	
Missing	0				0			
Eosinophilia								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	1	(0.2)	1	0.36
Other	0				1		1	
Missing	0				0			
Lymphadenopathy								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Blood loss anaemia								
White	1	(0.1)	1	0.11	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lymphadenopathy mediastinal								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Leukocytosis								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Splenomegaly								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Iron deficiency anaemia								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.26
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Polycythaemia								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lymphadenitis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypochromic anaemia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Leukopenia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Normocytic anaemia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Pancytopenia								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Thrombocytopenia								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Thrombocytosis								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
White	24	(1.5)	32	2.59	19	(1.2)	29	2.20
Black or African American	2	(3.3)	2	3.52	1	(1.3)	1	1.37
Asian	9	(2.0)	9	3.12	8	(1.6)	11	2.99
Other	0				0			
Missing	0				1		2	
Eye naevus								
White	3	(0.2)	4	0.37	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adenocarcinoma pancreas								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colorectal cancer								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Pancreatic neoplasm								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metastases to liver								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Seborrhoeic keratosis								
White	2	(0.1)	3	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colon adenoma								
White	2	(0.1)	2	0.16	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Osteoma								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Small cell lung cancer								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Invasive ductal breast carcinoma								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Invasive lobular breast carcinoma								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipoma								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatic carcinoma								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal neoplasm								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Squamous cell carcinoma of skin								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bladder papilloma								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lung cancer metastatic								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Basal cell carcinoma								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.20
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Glioblastoma multiforme								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral fibroma								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Salivary gland neoplasm								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Melanocytic naevus								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acrochordon								
White	0				0			
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adenocarcinoma of colon								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Adrenal adenoma								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Benign neoplasm of thyroid gland								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Benign renal neoplasm								
White	0				0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Bladder cancer								
White	0				0			
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bowen's disease								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Breast cancer								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Breast cancer metastatic								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic myeloid leukaemia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Colon cancer								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Colon cancer stage II								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dysplastic naevus								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Endometrial adenocarcinoma								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric cancer								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Gastrointestinal tract adenoma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Haemangioma of liver								
White	0				0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	0			
Other	0				0			
Missing	0				0			
Hepatocellular carcinoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Invasive breast carcinoma								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lung adenocarcinoma								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Lymphangioma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Malignant melanoma								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malignant melanoma in situ								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malignant peritoneal neoplasm								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metastases to bone marrow								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metastases to lymph nodes								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myxoma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Neoplasm skin								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Ovarian cancer metastatic								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Pancreatic carcinoma metastatic								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Prostate cancer								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Prostatic adenoma								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal cell carcinoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Renal hamartoma								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin papilloma								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Small intestine neuroendocrine tumour								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine cancer								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine leiomyoma								
White	0				3	(0.2)	3	0.31
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.53
Other	0				0			
Missing	0				0			
Ear and labyrinth disorders								
All								
White	23	(1.5)	26	1.92	19	(1.3)	20	1.78
Black or African American	0				0			
Asian	5	(1.1)	5	1.82	5	(0.9)	5	1.39
Other	0				0			
Missing	0				0			
Vertigo								
White	7	(0.4)	8	0.58	4	(0.3)	5	0.38
Black or African American	0				0			
Asian	3	(0.6)	3	0.95	5	(0.9)	5	1.39

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Ear pain								
White	6	(0.4)	6	0.53	2	(0.1)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Deafness bilateral								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vertigo positional								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinnitus								
White	2	(0.1)	2	0.13	2	(0.1)	2	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerumen impaction								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
External ear pain								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoacusis								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Meniere's disease								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear inflammation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eustachian tube dysfunction								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Deafness neurosensory								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Deafness unilateral								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear discomfort								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Middle ear inflammation								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Motion sickness								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Presbyacusis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Reproductive system and breast disorders								
All								
White	22	(1.4)	22	1.97	20	(1.3)	26	2.20
Black or African American	2	(3.3)	2	3.52	2	(3.6)	2	6.03
Asian	7	(1.5)	7	2.02	5	(0.9)	5	1.28
Other	2		2		0			
Missing	0				0			
Benign prostatic hyperplasia								
White	4	(0.3)	4	0.37	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	2	(0.4)	2	0.61	0			
Other	0				0			
Missing	0				0			
Erectile dysfunction								
White	3	(0.2)	3	0.23	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	1		1		0			
Missing	0				0			
Intermenstrual bleeding								
White	2	(0.1)	2	0.22	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrophic vulvovaginitis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menstruation irregular								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Pelvic discomfort								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine polyp								
White	1	(0.1)	1	0.06	0			
Black or African American	1	(1.8)	1	1.92	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Breast pain								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menstruation delayed								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Breast mass								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine prolapse								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginal pruritus								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dysmenorrhoea								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.06
Black or African American	0				1	(2.3)	1	4.66
Asian	0				0			
Other	0				0			
Missing	0				0			
Premenstrual syndrome								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Prostatomegaly								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Prostatitis								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervical polyp								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Colpocele								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ectropion of cervix								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ejaculation failure								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fibrocystic breast disease								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Galactorrhoea								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Genital prolapse								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menopausal disorder								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
Menopausal symptoms								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Ovarian cyst								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Ovarian disorder								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Penile pain								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Penile rash								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Prostatic calcification								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Pruritus genital								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Testicular cyst								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine enlargement								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaginal discharge								
White	0				2	(0.1)	2	0.17
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaginal haemorrhage								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.06
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginal dryness								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Immune system disorders								
All								
White	12	(0.8)	13	1.15	14	(0.9)	15	1.41
Black or African American	2	(3.0)	2	4.08	1	(1.4)	1	2.29
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Seasonal allergy								
White	7	(0.4)	7	0.53	9	(0.6)	9	0.87
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypersensitivity								
White	3	(0.2)	3	0.37	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Drug hypersensitivity								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Food allergy								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Allergy to arthropod bite								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				1	(1.4)	1	2.29
Asian	0				0			
Other	0				0			
Missing	0				0			
Allergy to arthropod sting								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Anaphylactic reaction								
White	0				1	(0.1)	1	0.12
Black or African American	1	(1.5)	1	2.48	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Immunisation reaction								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatobiliary disorders								
All								
White	10	(0.6)	15	1.25	17	(1.1)	18	1.53
Black or African American	0				0			
Asian	12	(2.7)	13	4.52	8	(1.5)	11	3.22
Other	2		3		0			
Missing	0				0			
Hepatic steatosis								
White	5	(0.3)	5	0.38	5	(0.3)	5	0.38
Black or African American	0				0			
Asian	5	(1.1)	5	1.75	5	(1.0)	5	1.44
Other	1		1		0			
Missing	0				0			
Hepatomegaly								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cholelithiasis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Cholecystitis chronic								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatic mass								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gallbladder cholesterolosis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Non-alcoholic steatohepatitis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gallbladder polyp								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	3	(0.5)	3	1.03
Other	0				0			
Missing	0				0			
Hypertransaminasaemia								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	1		2		0			
Missing	0				0			
Alcoholic liver disease								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Bile duct stone								
White	0				1	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Biliary colic								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Biliary dyskinesia								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cholecystitis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Gallbladder disorder								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatic calcification								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Hepatic cirrhosis								
White	0				2	(0.1)	2	0.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hepatic cyst								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Hepatic function abnormal								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	2	(0.4)	2	0.55
Other	0				0			
Missing	0				0			
Hyperplastic cholecystopathy								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Liver disorder								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Nonalcoholic fatty liver disease								
White	0				2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Steatohepatitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Endocrine disorders								
All								
White	5	(0.3)	5	0.37	15	(1.0)	15	1.24
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	4	(0.8)	4	1.04
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypothyroidism								
White	2	(0.1)	2	0.18	4	(0.3)	4	0.33
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Thyroid mass								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Autoimmune thyroiditis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adrenal mass								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adrenocortical insufficiency acute								
White	0				2	(0.1)	2	0.23
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Goitre								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Hyperplasia adrenal								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperprolactinaemia								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Hyperthyroidism								
White	0				2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypogonadism								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Inappropriate antidiuretic hormone secretion								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Secondary hypogonadism								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Surgical and medical procedures								
All								
White	5	(0.3)	5	0.49	4	(0.3)	4	0.35
Black or African American	0				1	(1.1)	1	1.05
Asian	1	(0.2)	1	0.47	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Shoulder operation								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tooth extraction								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac pacemaker replacement								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Knee operation								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin neoplasm excision								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac ablation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.47	0			
Other	0				0			
Missing	0				0			
Large intestinal polypectomy								
White	0				0			
Black or African American	0				1	(1.1)	1	1.05
Asian	0				0			
Other	0				0			
Missing	0				0			
Removal of foreign body								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Spinal operation								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Toe amputation								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Congenital, familial and genetic disorders								
All								
White	1	(0.1)	1	0.11	4	(0.3)	4	0.25
Black or African American	1	(1.1)	1	1.82	0			
Asian	1	(0.2)	1	0.22	0			
Other	3		3		1		1	
Missing	0				0			
Cystic fibrosis lung								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial septal defect								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Congenital syphilitic osteochondritis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Corneal dystrophy								
White	0				0			
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hydrocele								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypertrophic cardiomyopathy								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myotonic dystrophy								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Type V hyperlipidaemia								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	3		3		1		1	
Missing	0				0			
Social circumstances								
All								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menopause								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.20 Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
White	1333				1304			
Black or African American	67				71			
Asian	418				452			
Other	47				34			
Missing	15				17			
PYE (years)								
White	1130.55				1112.99			
Black or African American	52.07				58.43			
Asian	306.31				328.07			
Other	40.57				26.92			
Missing	9.42				10.06			
Events								
White	808	(60.5)	2533	237.64	735	(56.4)	2220	214.20
Black or African American	42	(60.8)	155	315.76	48	(67.4)	153	290.78
Asian	247	(59.3)	675	223.89	257	(57.0)	806	244.82
Other	37		96		20		50	
Missing	5		19		13		30	
Infections and infestations								
All								
White	428	(32.0)	615	58.76	386	(29.6)	573	54.48
Black or African American	18	(24.8)	29	57.03	24	(33.7)	34	74.19
Asian	80	(19.3)	106	35.87	93	(20.7)	126	37.41
Other	15		20		13		15	
Missing	3		3		7		9	
COVID-19								
White	132	(9.9)	134	12.70	133	(10.2)	136	12.23
Black or African American	8	(12.0)	8	15.63	10	(13.6)	12	22.49
Asian	8	(1.8)	8	2.70	5	(1.1)	5	1.28
Other	4		5		8		8	
Missing	0				4		4	
Nasopharyngitis								
White	58	(4.3)	71	6.90	52	(4.0)	61	6.25
Black or African American	2	(2.7)	2	3.58	0			
Asian	21	(5.2)	24	8.18	25	(5.5)	29	8.30
Other	1		1		0			
Missing	1		1		2		2	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Upper respiratory tract infection								
White	47	(3.5)	58	4.98	31	(2.4)	33	2.88
Black or African American	1	(1.6)	2	5.20	1	(1.1)	1	1.10
Asian	13	(3.1)	14	5.18	13	(2.9)	14	4.97
Other	1		1		0			
Missing	0				0			
Urinary tract infection								
White	28	(2.1)	31	3.06	32	(2.5)	35	3.21
Black or African American	3	(3.9)	3	5.58	3	(3.9)	3	4.94
Asian	4	(0.9)	4	1.25	7	(1.7)	8	2.46
Other	1		1		2		2	
Missing	1		1		0			
Influenza								
White	26	(2.0)	28	3.28	22	(1.7)	24	2.84
Black or African American	1	(1.2)	2	4.00	3	(4.7)	4	11.36
Asian	0				2	(0.4)	2	0.78
Other	0				1		1	
Missing	1		1		0			
Bronchitis								
White	19	(1.4)	20	1.93	10	(0.8)	10	0.96
Black or African American	0				0			
Asian	5	(1.2)	5	2.05	6	(1.4)	6	1.71
Other	2		2		1		1	
Missing	0				0			
Gastroenteritis								
White	19	(1.4)	19	2.04	10	(0.8)	10	1.11
Black or African American	2	(2.3)	2	3.91	2	(3.7)	3	10.19
Asian	5	(1.2)	5	1.90	3	(0.7)	3	0.85
Other	0				0			
Missing	0				1		1	
COVID-19 pneumonia								
White	14	(1.0)	14	1.37	10	(0.8)	10	0.92
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pneumonia								
White	13	(1.0)	13	1.28	5	(0.4)	5	0.48
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Sinusitis								
White	13	(1.0)	14	1.25	16	(1.2)	19	1.81
Black or African American	1	(1.1)	2	3.82	1	(1.8)	1	3.40
Asian	0				0			
Other	0				0			
Missing	0				0			
Pharyngitis								
White	10	(0.7)	12	1.07	14	(1.1)	16	1.51
Black or African American	0				0			
Asian	2	(0.5)	2	0.64	2	(0.5)	3	1.19
Other	4		4		1		1	
Missing	0				0			
Respiratory tract infection viral								
White	9	(0.7)	10	1.16	8	(0.6)	9	1.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory tract infection								
White	8	(0.6)	8	0.77	5	(0.4)	5	0.50
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Tooth infection								
White	7	(0.5)	9	0.87	7	(0.6)	7	0.83
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	0			
Other	0				1		1	
Missing	0				0			
Fungal infection								
White	7	(0.5)	8	0.79	2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rhinitis								
White	7	(0.5)	7	0.58	7	(0.5)	9	1.00
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cystitis								
White	6	(0.5)	6	0.67	10	(0.8)	11	1.12
Black or African American	1	(1.2)	1	2.00	0			
Asian	5	(1.2)	6	1.68	6	(1.3)	7	1.81
Other	0				0			
Missing	0				0			
Tooth abscess								
White	6	(0.4)	6	0.60	6	(0.5)	7	0.70
Black or African American	0				1	(1.4)	1	1.44
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Otitis media								
White	6	(0.4)	6	0.69	3	(0.2)	3	0.28
Black or African American	0				1	(1.4)	1	2.40
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Acute sinusitis								
White	5	(0.4)	5	0.42	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Conjunctivitis								
White	5	(0.4)	5	0.43	3	(0.2)	3	0.28
Black or African American	0				0			
Asian	3	(0.7)	3	0.94	4	(0.9)	4	1.23
Other	0				0			
Missing	0				0			
Viral infection								
White	5	(0.4)	5	0.43	8	(0.6)	11	0.87
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Gastroenteritis viral								
White	5	(0.4)	5	0.43	3	(0.2)	3	0.28
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Herpes zoster								
White	4	(0.3)	4	0.36	12	(0.9)	13	1.10
Black or African American	0				0			
Asian	4	(0.9)	4	1.08	3	(0.6)	3	0.92
Other	2		2		0			
Missing	0				0			
Coronavirus infection								
White	4	(0.3)	4	0.30	4	(0.3)	6	0.58
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cellulitis								
White	4	(0.3)	4	0.34	7	(0.5)	8	0.84
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Lower respiratory tract infection								
White	4	(0.3)	4	0.30	2	(0.2)	4	0.32
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Genital infection								
White	3	(0.2)	3	0.28	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory syncytial virus infection								
White	3	(0.2)	3	0.28	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Erysipelas								
White	3	(0.2)	3	0.28	2	(0.2)	3	0.33
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Laryngitis								
White	3	(0.2)	3	0.22	4	(0.3)	4	0.42
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaginal infection								
White	3	(0.2)	3	0.27	3	(0.2)	3	0.29
Black or African American	0				0			
Asian	2	(0.5)	2	0.84	0			
Other	0				0			
Missing	0				0			
Wound infection								
White	3	(0.2)	3	0.32	0			
Black or African American	0				1	(1.8)	1	3.47
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear infection								
White	3	(0.2)	3	0.27	4	(0.3)	4	0.42
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	1		1		0			
Missing	0				0			
Vulvovaginal candidiasis								
White	3	(0.2)	4	0.34	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Acarodermatitis								
White	2	(0.2)	2	0.15	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Sepsis								
White	2	(0.2)	2	0.26	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Otitis externa								
White	2	(0.2)	2	0.20	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Abscess								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Osteomyelitis								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginal mycotic infection								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tonsillitis								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Tinea infection								
White	2	(0.1)	2	0.20	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Candida infection								
White	2	(0.1)	2	0.15	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gingivitis								
White	2	(0.1)	3	0.22	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				3	(0.7)	3	1.15
Other	0				0			
Missing	0				0			
Subcutaneous abscess								
White	2	(0.1)	2	0.19	0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				1	(0.2)	2	0.44
Other	0				0			
Missing	0				0			
Gastrointestinal infection								
White	2	(0.1)	2	0.25	3	(0.2)	4	0.29
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic foot infection								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Periodontitis								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	3	(0.7)	3	0.89	4	(0.9)	4	1.23
Other	0				0			
Missing	0				1		1	
Pharyngotonsillitis								
White	1	(0.1)	1	0.13	2	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pneumonia viral								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pulmonary tuberculoma								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Viral tracheitis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Appendicitis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic sinusitis								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.16
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Clostridium difficile colitis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear infection fungal								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gangrene								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Helicobacter infection								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	2	(0.4)	2	0.61
Other	0				0			
Missing	0				0			
Nail infection								
White	1	(0.1)	2	0.15	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Paronychia								
White	1	(0.1)	1	0.07	0			
Black or African American	0				1	(1.8)	1	3.47
Asian	1	(0.2)	1	0.40	1	(0.2)	2	0.82
Other	0				0			
Missing	0				0			
Peritonsillar abscess								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Post-acute COVID-19 syndrome								
White	1	(0.1)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pyelonephritis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin candida								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tinea cruris								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Genital candidiasis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral candidiasis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral herpes								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	1	(1.1)	2	3.82	0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Postoperative wound infection								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Suspected COVID-19								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinea pedis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asymptomatic COVID-19								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Balanitis candida								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic tonsillitis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Escherichia urinary tract infection								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Folliculitis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Genital infection fungal								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Helicobacter gastritis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Herpes simplex								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Herpes virus infection								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hordeolum								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.33
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Infected bite								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Laryngopharyngitis								
White	1	(0.1)	1	0.07	1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Localised infection								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.21
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Mastitis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oropharyngeal candidiasis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Otitis media chronic								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin infection								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Tracheitis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urethritis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Viral upper respiratory tract infection								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Abscess limb								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Fungal skin infection								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	0			
Other	0				0			
Missing	0				0			
Kidney infection								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Onychomycosis								
White	1	(0.1)	1	0.12	3	(0.2)	3	0.22
Black or African American	0				1	(1.4)	1	1.44
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Pulpitis dental								
White	1	(0.1)	1	0.12	2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.57
Other	0				0			
Missing	0				0			
Pustule								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinea versicolour								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Varicella zoster virus infection								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal abscess								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anal abscess								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Bacteraemia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Bacterial infection								
White	0				0			
Black or African American	0				1	(1.1)	1	1.10
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Bartholinitis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Body tinea								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Breast abscess								
White	0				2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast cellulitis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Campylobacter gastroenteritis								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chlamydial infection								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Cholecystitis infective								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Chronic hepatitis C								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Clostridium difficile infection								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Dermatophytosis of nail								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diverticulitis								
White	0				3	(0.2)	3	0.23
Black or African American	0				1	(1.1)	1	1.10
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Empyema								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Endophthalmitis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Enteritis infectious								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Epididymitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Escherichia bacteraemia								
White	0				0			
Black or African American	1	(1.2)	1	2.00	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye infection								
White	0				2	(0.2)	2	0.27
Black or African American	0				1	(1.8)	1	3.40
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eye infection bacterial								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fungal balanitis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Furuncle								
White	0				2	(0.2)	2	0.15
Black or African American	1	(1.2)	1	2.00	0			
Asian	1	(0.2)	2	0.50	0			
Other	0				0			
Missing	0				0			
Gastroenteritis norovirus								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Giardiasis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Herpes dermatitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Herpes zoster infection neurological								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Infected dermal cyst								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Infective iritis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site abscess								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Labyrinthitis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lyme disease								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oophoritis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Otitis media acute								
White	0				3	(0.2)	3	0.28
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Paraspinal abscess								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Parotitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Peri-implantitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Pericoronitis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Post procedural infection								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Purulence								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Rotavirus infection								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Salpingitis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinusitis bacterial								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin bacterial infection								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Soft tissue infection								
White	0				2	(0.2)	2	0.27
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sweat gland infection								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urosepsis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Varicella								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Viral pharyngitis								
White	0				1	(0.1)	1	0.08
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Viral rhinitis								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Vulvitis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Gastrointestinal disorders								
All								
White	176	(13.2)	270	24.82	141	(10.9)	190	18.79
Black or African American	8	(11.7)	11	23.09	12	(17.1)	16	36.01
Asian	56	(13.4)	86	28.34	63	(14.1)	90	27.10
Other	9		11		3		4	
Missing	2		2		2		2	
Diarrhoea								
White	52	(3.9)	66	6.07	33	(2.6)	33	3.47
Black or African American	6	(8.5)	6	13.13	6	(8.9)	6	13.49
Asian	19	(4.5)	23	7.83	11	(2.4)	12	3.63
Other	7		7		1		1	
Missing	0				0			
Nausea								
White	24	(1.8)	25	2.31	23	(1.8)	25	2.42
Black or African American	1	(1.9)	1	2.02	1	(1.8)	1	3.40
Asian	11	(2.7)	11	3.59	3	(0.6)	3	0.96
Other	1		1		0			
Missing	0				0			
Vomiting								
White	16	(1.2)	22	2.40	11	(0.9)	13	1.29
Black or African American	2	(2.8)	2	4.60	0			
Asian	4	(1.0)	6	2.10	4	(0.9)	5	1.23
Other	2		2		1		1	
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal pain								
White	15	(1.1)	15	1.43	12	(0.9)	13	1.31
Black or African American	0				2	(3.2)	2	4.84
Asian	1	(0.2)	1	0.19	4	(0.9)	4	1.24
Other	0				0			
Missing	0				0			
Abdominal pain upper								
White	12	(0.9)	14	1.34	10	(0.8)	11	1.01
Black or African American	0				1	(1.8)	1	3.40
Asian	1	(0.2)	1	0.19	4	(0.9)	4	1.06
Other	0				0			
Missing	0				0			
Constipation								
White	12	(0.9)	15	1.50	7	(0.5)	7	0.75
Black or African American	1	(1.6)	1	1.67	2	(2.5)	2	2.54
Asian	3	(0.8)	3	1.14	6	(1.4)	6	2.05
Other	0				0			
Missing	0				1		1	
Gastrooesophageal reflux disease								
White	11	(0.8)	11	0.93	9	(0.7)	9	0.86
Black or African American	0				0			
Asian	2	(0.5)	2	0.86	5	(1.1)	5	1.61
Other	0				0			
Missing	0				0			
Toothache								
White	8	(0.6)	8	0.66	6	(0.5)	8	0.98
Black or African American	0				1	(1.4)	1	2.40
Asian	5	(1.2)	5	1.43	3	(0.7)	4	1.60
Other	0				0			
Missing	0				0			
Dental caries								
White	7	(0.5)	9	0.67	4	(0.3)	4	0.35
Black or African American	0				1	(1.1)	1	1.10
Asian	4	(1.0)	4	0.99	5	(1.1)	5	1.93
Other	0				0			
Missing	0				0			
Gastritis								
White	6	(0.5)	6	0.60	6	(0.5)	6	0.55
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	2	(0.5)	2	0.66
Other	0				1		1	
Missing	0				0			
Chronic gastritis								
White	6	(0.4)	6	0.61	2	(0.2)	2	0.21

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			
Haemorrhoids								
White	6	(0.4)	6	0.49	3	(0.2)	3	0.36
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Abdominal distension								
White	5	(0.4)	5	0.37	2	(0.2)	2	0.20
Black or African American	0				1	(1.8)	1	3.40
Asian	2	(0.5)	2	0.67	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Food poisoning								
White	5	(0.4)	5	0.47	4	(0.3)	5	0.62
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Large intestine polyp								
White	4	(0.3)	4	0.34	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				4	(0.9)	5	1.28
Other	0				0			
Missing	0				0			
Dyspepsia								
White	4	(0.3)	4	0.38	4	(0.3)	4	0.36
Black or African American	0				0			
Asian	3	(0.7)	3	1.05	4	(1.0)	4	1.28
Other	0				0			
Missing	0				0			
Diverticulum intestinal								
White	3	(0.2)	3	0.22	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Flatulence								
White	3	(0.2)	3	0.27	2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	1		1		0			
Aphthous ulcer								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Inguinal hernia								
White	2	(0.2)	2	0.15	1	(0.1)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rectal polyp								
White	2	(0.2)	2	0.15	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Enterocolitis								
White	2	(0.1)	3	0.22	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Hiatus hernia								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Abdominal pain lower								
White	2	(0.1)	2	0.24	1	(0.1)	1	0.07
Black or African American	1	(1.6)	1	1.67	0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Pancreatic failure								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatitis chronic								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Abdominal wall disorder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anal fissure								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colitis microscopic								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic gastropathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eosinophilic oesophagitis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eructation								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric ulcer								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Gastrointestinal haemorrhage								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemorrhoidal haemorrhage								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoaesthesia oral								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	2	(0.5)	4	1.59	0			
Other	0				0			
Missing	0				0			
Impaired gastric emptying								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intestinal dilatation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lip swelling								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Umbilical hernia								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Noninfective gingivitis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vomiting projectile								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colitis								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry mouth								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	1		1		0			
Missing	0				0			
Frequent bowel movements								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haematochezia								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Loose tooth								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatitis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Tooth disorder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Diverticulum								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				1		1	
Gastrointestinal angiodysplasia								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gingival bleeding								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperaesthesia teeth								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Intra-abdominal haematoma								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Abdominal discomfort								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	3	(0.7)	3	0.89	3	(0.7)	4	1.43
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acid peptic disease								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			
Anal pruritus								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Colitis ischaemic								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Crohn's disease								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Duodenitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Enteritis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Epigastric discomfort								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Faeces pale								
White	0				1	(0.1)	1	0.13

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric dilatation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Gastric disorder								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric dysplasia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Gastric mucosal hypertrophy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Gastric polyps								
White	0				0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.67	2	(0.4)	2	0.57
Other	0				0			
Missing	0				0			
Gastrointestinal disorder								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastrointestinal inflammation								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Gastrointestinal sounds abnormal								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gingival disorder								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperchlorhydria								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Ileus								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Irritable bowel syndrome								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Melaena								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Mesenteric panniculitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Odynophagia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oesophageal pain								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oesophagitis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral discomfort								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Oral pain								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Pancreatic duct dilatation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Pancreatic pseudocyst								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatitis acute								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Peptic ulcer								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Periodontal disease								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	2	(0.4)	2	0.76
Other	0				0			
Missing	0				0			
Periodontal inflammation								
White	0				1	(0.1)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Proctalgia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Rectal prolapse								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Small intestinal obstruction								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Stomatitis								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tongue rough								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Tooth impacted								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Ulcerative gastritis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Upper gastrointestinal haemorrhage								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Musculoskeletal and connective tissue disorders								
All								
White	175	(13.1)	271	24.98	171	(13.2)	243	23.79
Black or African American	11	(16.8)	13	26.60	13	(16.1)	20	30.56
Asian	51	(12.3)	67	21.86	55	(12.3)	69	21.19
Other	7		15		4		4	
Missing	2		3		2		2	
Back pain								
White	46	(3.4)	50	4.69	40	(3.1)	42	4.46
Black or African American	1	(1.1)	1	1.91	8	(10.0)	9	14.49
Asian	15	(3.6)	15	4.67	12	(2.7)	12	3.74
Other	0				1		1	
Missing	0				0			
Arthralgia								
White	29	(2.2)	36	3.57	35	(2.7)	41	4.14
Black or African American	3	(4.6)	3	5.60	2	(2.5)	2	3.50
Asian	12	(2.9)	12	3.30	10	(2.2)	10	3.23
Other	1		2		1		1	
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pain in extremity								
White	23	(1.7)	25	2.17	19	(1.5)	24	2.43
Black or African American	1	(1.9)	1	2.02	2	(2.2)	2	2.20
Asian	5	(1.1)	5	1.12	9	(2.0)	10	3.57
Other	2		2		1		1	
Missing	0				0			
Osteoarthritis								
White	17	(1.3)	18	1.62	23	(1.8)	26	2.48
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.41
Other	2		3		0			
Missing	0				0			
Muscle spasms								
White	16	(1.2)	16	1.47	4	(0.3)	4	0.36
Black or African American	1	(1.6)	1	2.60	0			
Asian	4	(1.0)	6	2.62	5	(1.1)	5	1.47
Other	1		1		0			
Missing	1		1		0			
Myalgia								
White	12	(0.9)	12	1.25	4	(0.3)	4	0.47
Black or African American	0				2	(2.5)	2	2.54
Asian	1	(0.3)	1	0.44	3	(0.6)	3	0.96
Other	1		1		0			
Missing	0				0			
Neck pain								
White	10	(0.8)	10	0.98	6	(0.5)	6	0.53
Black or African American	2	(3.4)	2	4.62	0			
Asian	2	(0.5)	2	0.64	2	(0.4)	2	0.61
Other	1		1		0			
Missing	0				0			
Tendonitis								
White	8	(0.6)	10	0.92	4	(0.3)	4	0.42
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intervertebral disc protrusion								
White	5	(0.4)	9	0.67	2	(0.2)	3	0.23
Black or African American	0				1	(1.1)	1	1.10
Asian	2	(0.5)	2	0.64	2	(0.4)	2	0.78
Other	1		1		1		1	
Missing	0				0			
Arthritis								
White	5	(0.4)	5	0.41	5	(0.4)	5	0.62

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Trigger finger								
White	4	(0.3)	4	0.42	4	(0.3)	4	0.36
Black or African American	0				0			
Asian	3	(0.7)	3	1.24	1	(0.2)	3	0.66
Other	0				0			
Missing	0				0			
Spinal osteoarthritis								
White	4	(0.3)	4	0.30	3	(0.2)	4	0.29
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.40	2	(0.6)	2	0.54
Other	0				0			
Missing	0				0			
Periarthritis								
White	4	(0.3)	4	0.36	2	(0.2)	2	0.16
Black or African American	0				1	(1.4)	1	1.44
Asian	4	(1.0)	4	1.19	3	(0.7)	3	0.85
Other	0				0			
Missing	0				0			
Bursitis								
White	4	(0.3)	4	0.34	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Foot deformity								
White	3	(0.2)	5	0.43	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Exostosis								
White	3	(0.2)	3	0.22	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Tendon disorder								
White	3	(0.2)	3	0.33	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Rotator cuff syndrome								
White	3	(0.2)	3	0.28	4	(0.3)	4	0.29
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	0			
Other	0				0			
Missing	0				0			
Musculoskeletal chest pain								
White	3	(0.2)	3	0.22	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intervertebral disc disorder								
White	3	(0.2)	3	0.27	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Osteochondrosis								
White	2	(0.2)	2	0.21	4	(0.3)	4	0.41
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Back disorder								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Coccydynia								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chondropathy								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Polyarthritis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Musculoskeletal pain								
White	2	(0.1)	2	0.20	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Musculoskeletal stiffness								
White	2	(0.1)	2	0.20	0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Fibromyalgia								
White	2	(0.1)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Plantar fasciitis								
White	2	(0.1)	3	0.22	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	2		2		0			
Missing	0				0			
Acquired claw toe								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diastasis recti abdominis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facet joint syndrome								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Joint effusion								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	1		2		0			
Meniscopathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Psoriatic arthropathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sacroiliitis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle contracture								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscular weakness								
White	1	(0.1)	1	0.13	2	(0.2)	2	0.21
Black or African American	1	(1.2)	1	2.00	0			
Asian	1	(0.2)	1	0.19	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Torticollis								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Costochondritis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fistula								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Groin pain								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myositis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Osteopenia								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal pain								
White	1	(0.1)	1	0.07	4	(0.3)	4	0.37
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Synovial cyst								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Axillary mass								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.08
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Flank pain								
White	1	(0.1)	1	0.12	3	(0.2)	4	0.41
Black or African American	0				0			
Asian	0				3	(0.7)	3	0.83
Other	0				0			
Missing	0				0			
Osteoporosis								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Soft tissue swelling								
White	1	(0.1)	3	0.35	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal stenosis								
White	1	(0.1)	2	0.24	2	(0.2)	2	0.15
Black or African American	1	(1.9)	1	2.02	0			
Asian	2	(0.5)	3	1.14	0			
Other	0				0			
Missing	0				0			
Arthropathy								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Bone cyst								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Bone pain								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cervical spinal stenosis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dupuytren's contracture								
White	0				2	(0.2)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haemarthrosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intervertebral disc degeneration								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Intervertebral disc space narrowing								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Jaw disorder								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Joint swelling								
White	0				3	(0.2)	3	0.34
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Limb deformity								
White	0				1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lumbar spinal stenosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Mastication disorder								
White	0				1	(0.1)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle twitching								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Neuropathic arthropathy								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nodal osteoarthritis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Osteochondritis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pain in jaw								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Periostitis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Polymyalgia rheumatica								
White	0				1	(0.1)	3	0.42
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Rheumatoid arthritis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Scoliosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal retrolisthesis								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tenosynovitis								
White	0				3	(0.2)	3	0.22
Black or African American	0				1	(1.4)	1	2.40
Asian	0				5	(1.1)	6	1.51
Other	1		1		0			
Missing	0				0			
Tenosynovitis stenosans								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vertebral osteophyte								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nervous system disorders								
All								
White	134	(10.0)	187	17.66	125	(9.6)	162	16.53
Black or African American	10	(15.2)	16	34.59	8	(10.4)	14	22.42
Asian	36	(8.6)	49	16.64	47	(10.4)	69	21.01
Other	0				3		3	
Missing	0				0			
Headache								
White	39	(2.9)	49	4.96	33	(2.5)	37	3.80
Black or African American	5	(7.1)	8	17.99	3	(4.3)	4	9.37
Asian	13	(3.1)	16	5.25	17	(3.7)	25	6.82
Other	0				1		1	
Missing	0				0			
Dizziness								
White	29	(2.2)	37	3.45	22	(1.7)	29	3.19
Black or African American	1	(1.6)	2	5.20	1	(1.4)	1	1.44
Asian	8	(1.8)	9	3.11	14	(3.1)	14	4.23
Other	0				0			
Missing	0				0			
Carpal tunnel syndrome								
White	10	(0.7)	10	0.91	7	(0.5)	7	0.75
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Sciatica								
White	9	(0.7)	9	0.87	10	(0.8)	10	1.01
Black or African American	0				2	(2.5)	3	3.64
Asian	4	(1.0)	4	1.48	0			
Other	0				0			
Missing	0				0			
Paraesthesia								
White	8	(0.6)	9	0.72	8	(0.6)	8	0.82
Black or African American	0				1	(1.1)	1	1.10
Asian	0				3	(0.7)	3	1.21
Other	0				0			
Missing	0				0			
Tremor								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	7	(0.5)	8	0.65	3	(0.2)	3	0.28
Black or African American	0				0			
Asian	4	(0.9)	4	1.08	5	(1.1)	9	3.55
Other	0				0			
Missing	0				0			
Syncope								
White	6	(0.4)	6	0.49	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic neuropathy								
White	5	(0.4)	5	0.54	8	(0.6)	8	0.82
Black or African American	0				1	(1.1)	1	1.10
Asian	0				3	(0.7)	3	1.01
Other	0				0			
Missing	0				0			
Neuropathy peripheral								
White	5	(0.4)	5	0.49	8	(0.6)	8	0.72
Black or African American	0				0			
Asian	1	(0.2)	2	0.84	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Hypoaesthesia								
White	5	(0.4)	7	0.63	5	(0.4)	6	0.63
Black or African American	1	(1.9)	1	2.02	1	(1.4)	1	1.44
Asian	3	(0.7)	4	1.50	3	(0.7)	3	0.83
Other	0				0			
Missing	0				0			
Migraine								
White	4	(0.3)	4	0.34	3	(0.2)	3	0.34
Black or African American	1	(1.2)	1	2.00	0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Carotid artery stenosis								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Amnesia								
White	2	(0.2)	2	0.20	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Cerebrovascular disorder								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Memory impairment								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dysgeusia								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Transient ischaemic attack								
White	2	(0.1)	2	0.20	3	(0.2)	3	0.29
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post herpetic neuralgia								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral arteriosclerosis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vascular encephalopathy								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cerebral atrophy								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cluster headache								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cognitive disorder								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Disturbance in attention								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intracranial pressure increased								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vascular headache								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Balance disorder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Burning sensation								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.21
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Cerebral haemorrhage								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervical radiculopathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dizziness postural								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lumbar radiculopathy								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.16
Black or African American	0				1	(1.4)	2	2.88
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Presyncope								
White	1	(0.1)	1	0.07	4	(0.3)	4	0.30
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Trigeminal neuralgia								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Autonomic nervous system imbalance								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Carotid artery aneurysm								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervicobrachial syndrome								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neuralgia								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.08
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Piriformis syndrome								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Somnolence								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Tension headache								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	2	(0.5)	3	0.74	0			
Other	0				0			
Missing	0				0			
Thalamic infarction								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ageusia								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anosmia								
White	0				1	(0.1)	1	0.13
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Basilar migraine								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Brain injury								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Carotid arteriosclerosis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral artery embolism								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebral infarction								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerebrovascular accident								
White	0				2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Dementia Alzheimer's type								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Essential tremor								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facial nerve disorder								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facial paralysis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Hemiparesis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoglycaemic coma								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyporeflexia								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ischaemic stroke								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lethargy								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Loss of consciousness								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Mental impairment								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Meralgia paraesthetica								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Morton's neuralgia								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Myelopathy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Neuroglycopenia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	1	(0.2)	3	0.66

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Ophthalmic migraine								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Orthostatic tremor								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Parkinsonian gait								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Peripheral paralysis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Radiculopathy								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Restless legs syndrome								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sleep deficit								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Thrombotic stroke								
White	0				2	(0.2)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vertebral artery occlusion								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
White matter lesion								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
General disorders and administration site conditions								
All								
White	123	(9.2)	180	17.72	100	(7.7)	150	14.01
Black or African American	11	(17.7)	23	46.73	8	(11.4)	10	18.67
Asian	56	(13.5)	93	32.03	65	(14.4)	100	28.75
Other	7		11		1		1	
Missing	2		6		0			
Fatigue								
White	20	(1.5)	22	1.95	12	(0.9)	12	1.03
Black or African American	4	(5.7)	5	10.35	1	(1.8)	1	3.40
Asian	2	(0.5)	2	0.64	2	(0.4)	2	0.57
Other	1		1		0			
Missing	0				0			
Pyrexia								
White	12	(0.9)	12	1.06	13	(1.0)	13	1.47
Black or African American	2	(2.7)	2	4.51	0			
Asian	16	(4.0)	17	5.49	24	(5.3)	26	6.93
Other	2		2		0			
Missing	0				0			
Chest pain								
White	10	(0.8)	10	0.86	3	(0.2)	3	0.22
Black or African American	1	(1.6)	1	1.67	0			
Asian	3	(0.7)	3	1.26	2	(0.5)	2	0.49
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oedema peripheral								
White	10	(0.7)	10	1.05	8	(0.6)	9	0.81
Black or African American	2	(3.5)	2	3.69	1	(1.4)	1	1.44
Asian	3	(0.7)	3	1.06	0			
Other	2		2		0			
Missing	0				0			
Injection site reaction								
White	9	(0.7)	22	2.75	3	(0.2)	3	0.34
Black or African American	0				1	(1.8)	1	3.47
Asian	5	(1.1)	5	1.84	2	(0.5)	4	1.02
Other	0				0			
Missing	1		2		0			
Asthenia								
White	6	(0.4)	6	0.60	5	(0.4)	5	0.51
Black or African American	0				0			
Asian	3	(0.7)	3	0.89	3	(0.7)	3	0.85
Other	0				0			
Missing	1		1		0			
Pain								
White	5	(0.4)	5	0.49	8	(0.6)	9	0.85
Black or African American	4	(5.7)	5	10.35	1	(1.4)	1	1.44
Asian	1	(0.3)	1	0.44	4	(0.9)	4	1.23
Other	0				1		1	
Missing	0				0			
Medical device site bruise								
White	5	(0.4)	7	0.61	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malaise								
White	4	(0.3)	4	0.34	5	(0.4)	7	0.67
Black or African American	1	(1.6)	1	1.67	0			
Asian	7	(1.7)	8	2.48	7	(1.5)	9	2.50
Other	1		2		0			
Missing	0				0			
Influenza like illness								
White	4	(0.3)	5	0.52	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral swelling								
White	3	(0.2)	3	0.22	2	(0.2)	2	0.15

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	2	(0.5)	3	1.08	2	(0.5)	2	0.82
Other	0				0			
Missing	0				0			
Injection site bruising								
White	3	(0.2)	3	0.33	5	(0.4)	5	0.43
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chest discomfort								
White	3	(0.2)	3	0.28	2	(0.2)	2	0.21
Black or African American	2	(3.4)	2	4.62	0			
Asian	2	(0.5)	2	0.67	0			
Other	1		1		0			
Missing	0				0			
Drug intolerance								
White	3	(0.2)	3	0.22	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gait disturbance								
White	3	(0.2)	3	0.22	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site erythema								
White	3	(0.2)	5	0.59	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Medical device site reaction								
White	3	(0.2)	5	0.48	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Chills								
White	3	(0.2)	3	0.27	0			
Black or African American	0				1	(1.1)	1	1.10
Asian	1	(0.2)	1	0.25	0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Medical device site dermatitis								
White	3	(0.2)	6	0.49	1	(0.1)	1	0.08
Black or African American	0				1	(1.1)	1	1.10
Asian	1	(0.2)	1	0.40	6	(1.3)	12	2.65
Other	0				0			
Missing	0				0			
Medical device site pruritus								
White	3	(0.2)	3	0.27	0			
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Feeling abnormal								
White	2	(0.2)	2	0.27	0			
Black or African American	0				0			
Asian	1	(0.2)	3	0.74	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Thirst								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Injection site mass								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site haematoma								
White	2	(0.2)	6	0.77	3	(0.2)	8	1.05
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site haemorrhage								
White	2	(0.1)	2	0.15	0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.50	2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			
Injection site swelling								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	2	(0.1)	2	0.25	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hunger								
White	2	(0.1)	3	0.27	0			
Black or African American	0				0			
Asian	4	(1.0)	4	0.99	2	(0.4)	2	0.57
Other	0				0			
Missing	0				0			
Vaccination site pain								
White	2	(0.1)	3	0.27	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	8	(1.9)	9	3.26	5	(1.1)	5	1.87
Other	0				0			
Missing	0				0			
Medical device site erythema								
White	2	(0.1)	2	0.24	2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Multiple organ dysfunction syndrome								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oedema								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	0				1	(1.4)	1	1.44
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Xerosis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Early satiety								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Localised oedema								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Swelling face								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Application site pruritus								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site haemorrhage								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Injection site pain								
White	1	(0.1)	1	0.13	9	(0.7)	27	2.24
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	3	(0.7)	3	1.00
Other	0				0			
Missing	1		1		0			
Injection site rash								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Discomfort								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	8	3.28
Other	0				0			
Missing	1		1		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Feeling hot								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Implant site pruritus								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site hypersensitivity								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Medical device site eczema								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Swelling								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Application site bruise								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Axillary pain								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Condition aggravated								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Cyst								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Death								
White	0				3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facial pain								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hernia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Inflammation								
White	0				3	(0.2)	3	0.28
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Injection site dermatitis								
White	0				0			
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site hypertrophy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injection site induration								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Injection site oedema								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site pruritus								
White	0				0			
Black or African American	0				0			
Asian	4	(0.9)	19	7.49	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Injection site urticaria								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site haematoma								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site hypersensitivity								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Medical device site inflammation								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site pain								
White	0				2	(0.2)	2	0.21

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Medical device site rash								
White	0				0			
Black or African American	0				1	(1.4)	1	2.40
Asian	0				0			
Other	0				0			
Missing	0				0			
Non-cardiac chest pain								
White	0				3	(0.2)	5	0.37
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Oedema due to renal disease								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Procedural failure								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Systemic inflammatory response syndrome								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaccination site erythema								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaccination site inflammation								
White	0				0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Vaccination site pruritus								
White	0				0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaccination site reaction								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Vessel puncture site bruise								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Injury, poisoning and procedural complications								
All								
White	117	(8.7)	145	13.67	98	(7.5)	114	11.73
Black or African American	8	(11.6)	12	27.63	4	(6.3)	7	16.17
Asian	34	(8.2)	41	13.20	41	(9.0)	53	16.42
Other	4		4		2		2	
Missing	1		2		2		2	
Fall								
White	15	(1.1)	15	1.35	7	(0.5)	8	0.78
Black or African American	1	(1.9)	1	2.02	1	(1.4)	1	1.44
Asian	3	(0.7)	3	0.88	2	(0.5)	2	0.68
Other	0				0			
Missing	0				0			
Contusion								
White	9	(0.7)	10	0.84	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	5	(1.2)	5	1.73	5	(1.1)	5	1.29
Other	0				0			
Missing	0				0			
Vaccination complication								
White	8	(0.6)	8	0.74	10	(0.8)	13	1.23
Black or African American	1	(1.6)	4	10.41	0			
Asian	6	(1.5)	7	2.13	11	(2.4)	14	3.67

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Accidental overdose								
White	7	(0.5)	7	0.75	1	(0.1)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				1		1	
Ligament sprain								
White	6	(0.4)	6	0.60	5	(0.4)	5	0.55
Black or African American	0				0			
Asian	3	(0.7)	3	1.11	3	(0.7)	3	1.02
Other	0				0			
Missing	0				0			
Hand fracture								
White	5	(0.4)	5	0.52	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Skin laceration								
White	5	(0.4)	5	0.42	0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Ankle fracture								
White	4	(0.3)	4	0.30	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Joint injury								
White	4	(0.3)	4	0.45	4	(0.3)	4	0.36
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Skin abrasion								
White	4	(0.3)	6	0.54	2	(0.2)	2	0.21
Black or African American	0				0			
Asian	4	(1.0)	4	1.34	2	(0.5)	2	0.82
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Foot fracture								
White	3	(0.2)	3	0.34	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.57
Other	0				0			
Missing	0				0			
Tooth fracture								
White	3	(0.2)	3	0.28	1	(0.1)	1	0.08
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Procedural pain								
White	3	(0.2)	3	0.33	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Arthropod bite								
White	3	(0.2)	3	0.39	3	(0.2)	3	0.34
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Road traffic accident								
White	3	(0.2)	3	0.27	0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Limb injury								
White	3	(0.2)	3	0.28	6	(0.5)	7	0.82
Black or African American	0				0			
Asian	2	(0.5)	2	0.67	0			
Other	0				0			
Missing	0				0			
Rib fracture								
White	3	(0.2)	3	0.27	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.78
Other	0				0			
Missing	1		1		0			
Incorrect dose administered								
White	2	(0.2)	2	0.27	4	(0.3)	5	0.59
Black or African American	1	(1.1)	1	1.91	1	(1.8)	2	6.94

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Arthropod sting								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Back injury								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Upper limb fracture								
White	2	(0.2)	2	0.15	0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tendon rupture								
White	2	(0.2)	2	0.20	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Radius fracture								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Medication error								
White	2	(0.2)	2	0.26	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Thermal burn								
White	2	(0.1)	2	0.20	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Wound								
White	2	(0.1)	2	0.15	2	(0.2)	2	0.21
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	2	(0.4)	2	0.74
Other	0				0			
Missing	0				1		1	
Accidental underdose								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Extra dose administered								
White	1	(0.1)	1	0.13	0			
Black or African American	0				1	(1.8)	1	3.47
Asian	0				0			
Other	0				0			
Missing	0				0			
Subdural haematoma								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Animal bite								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				2	(0.5)	2	0.63
Other	0				0			
Missing	0				0			
Bone contusion								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Femoral neck fracture								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hip fracture								
White	1	(0.1)	1	0.07	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Inflammation of wound								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injury of conjunctiva								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Multiple injuries								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle injury								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.27
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neck injury								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Penile contusion								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural complication								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Post procedural inflammation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Radiation skin injury								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal compression fracture								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Gun shot wound								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ligament rupture								
White	1	(0.1)	2	0.26	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Procedural complication								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cervical vertebral fracture								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye injury								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fibula fracture								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Injury								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Meniscus injury								
White	1	(0.1)	1	0.07	5	(0.4)	5	0.42
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Overdose								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.34
Black or African American	2	(3.1)	2	5.20	0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Post procedural fistula								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural haemorrhage								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural hypothyroidism								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Traumatic haematoma								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Craniocerebral injury								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Face injury								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Facial bones fracture								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Subcutaneous haematoma								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Wrist fracture								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Burn oral cavity								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Burns first degree								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Chillblains								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Concussion								
White	0				2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Crush injury								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Deafness traumatic								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Endotracheal intubation complication								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Epicondylitis								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Exposure to SARS-CoV-2								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Head injury								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Heat illness								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	3	(0.6)	4	1.01
Other	0				0			
Missing	0				0			
Humerus fracture								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intentional overdose								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intentional product use issue								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Lower limb fracture								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Muscle contusion								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Muscle strain								
White	0				4	(0.3)	4	0.41
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Periprocedural myocardial infarction								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural haematuria								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Post procedural stroke								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post procedural swelling								
White	0				1	(0.1)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post-traumatic neck syndrome								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Product administration error								
White	0				2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Scar								
White	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Scratch								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Seroma								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Soft tissue injury								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal column injury								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Stab wound								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Sunburn								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tendon injury								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Tibia fracture								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Underdose								
White	0				5	(0.4)	5	0.63
Black or African American	1	(1.6)	1	2.60	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Wrong dose								
White	0				2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Wrong product administered								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	2	0.79	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Eye disorders								
All								
White	97	(7.3)	125	12.30	91	(6.9)	113	11.57
Black or African American	11	(15.2)	13	26.20	9	(14.3)	14	35.93
Asian	35	(8.3)	45	15.05	51	(11.5)	70	23.37
Other	3		4		1		2	
Missing	1		1		0			
Diabetic retinopathy								
White	32	(2.4)	34	3.67	35	(2.7)	38	4.04
Black or African American	2	(2.7)	2	3.58	2	(3.2)	2	4.84
Asian	17	(4.0)	20	7.48	21	(4.6)	22	7.54
Other	1		2		0			
Missing	0				0			
Cataract								
White	17	(1.3)	21	1.87	12	(0.9)	13	1.01
Black or African American	0				3	(4.2)	3	5.28
Asian	6	(1.4)	7	1.82	9	(2.0)	10	3.38
Other	0				1		2	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	1		1		0			
Macular oedema								
White	7	(0.5)	7	0.78	4	(0.3)	4	0.35
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Retinopathy hypertensive								
White	6	(0.5)	7	0.75	5	(0.4)	5	0.59
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry eye								
White	4	(0.3)	4	0.30	0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	6	(1.3)	6	1.50
Other	0				0			
Missing	0				0			
Retinal haemorrhage								
White	3	(0.2)	3	0.34	0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Eye pain								
White	3	(0.2)	3	0.22	2	(0.2)	2	0.21
Black or African American	1	(1.2)	1	2.00	0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Vision blurred								
White	3	(0.2)	3	0.28	2	(0.2)	2	0.15
Black or African American	1	(1.2)	1	2.00	2	(3.3)	2	5.80
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Diabetic retinal oedema								
White	3	(0.2)	3	0.37	4	(0.3)	5	0.54
Black or African American	0				1	(1.4)	1	1.44
Asian	1	(0.2)	1	0.40	4	(0.9)	4	1.38
Other	0				0			
Missing	0				0			
Age-related macular degeneration								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Glaucoma								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	2	(0.5)	2	0.62
Other	0				0			
Missing	0				0			
Blepharitis								
White	2	(0.2)	2	0.20	0			
Black or African American	1	(1.9)	1	2.02	0			
Asian	2	(0.5)	2	0.50	0			
Other	0				0			
Missing	0				0			
Astigmatism								
White	2	(0.2)	3	0.22	3	(0.2)	3	0.34
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Vitreous detachment								
White	2	(0.2)	2	0.15	0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye inflammation								
White	2	(0.1)	2	0.20	2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ocular hypertension								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Presbyopia								
White	1	(0.1)	1	0.13	2	(0.2)	2	0.28
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Retinal deposits								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal scar								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Amaurosis fugax								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Angle closure glaucoma								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arteriosclerotic retinopathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival hyperaemia								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival suffusion								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Maculopathy								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vitreous opacities								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Non-proliferative retinopathy								
White	1	(0.1)	2	0.26	2	(0.2)	2	0.27
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival erosion								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Conjunctival haemorrhage								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Diplopia								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Optic disc vascular disorder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post thrombotic retinopathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal aneurysm								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal tear								
White	1	(0.1)	1	0.07	0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry age-related macular degeneration								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Epiretinal membrane								
White	1	(0.1)	1	0.12	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye irritation								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lacrimation increased								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Myopia								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ocular hyperaemia								
White	1	(0.1)	1	0.12	1	(0.1)	2	0.26
Black or African American	1	(1.2)	2	4.00	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acquired epiblepharon								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Asthenopia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Cataract nuclear								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Chorioretinal atrophy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Conjunctivitis allergic								
White	0				0			
Black or African American	0				0			
Asian	2	(0.5)	3	0.91	0			
Other	0				0			
Missing	0				0			
Corneal bleeding								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Corneal erosion								
White	0				1	(0.1)	1	0.13

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cystoid macular oedema								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dacryoadenitis acquired								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye discharge								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Eye pruritus								
White	0				1	(0.1)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eyelid oedema								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypermetropia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Macular degeneration								
White	0				2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Macular hole								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Meibomianitis								
White	0				0			
Black or African American	0				1	(1.8)	1	3.40
Asian	0				0			
Other	0				0			
Missing	0				0			
Normal tension glaucoma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Ocular ischaemic syndrome								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Open angle glaucoma								
White	0				0			
Black or African American	0				1	(1.8)	2	6.79
Asian	0				0			
Other	0				0			
Missing	0				0			
Ophthalmic vein thrombosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Optic disc haemorrhage								
White	0				0			
Black or African American	0				1	(1.8)	1	3.47
Asian	0				0			
Other	0				0			
Missing	0				0			
Photophobia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Posterior capsule opacification								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Retinal artery occlusion								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Retinal degeneration								
White	0				0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Retinal detachment								
White	0				2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal drusen								
White	0				1	(0.1)	1	0.13
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinal exudates								
White	0				1	(0.1)	1	0.13
Black or African American	1	(1.6)	1	2.60	0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Retinal vascular disorder								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Retinal vein occlusion								
White	0				1	(0.1)	1	0.08
Black or African American	1	(1.6)	1	2.60	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Retinopathy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Scintillating scotoma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Uveitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Visual acuity reduced								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Visual impairment								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	1	(0.2)	9	3.69
Other	0				0			
Missing	0				0			
Vitreous degeneration								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vitreous floaters								
White	0				0			
Black or African American	0				1	(1.8)	1	3.47
Asian	0				0			
Other	0				0			
Missing	0				0			
Vitreous haemorrhage								
White	0				2	(0.2)	2	0.21
Black or African American	0				0			
Asian	2	(0.5)	2	0.84	0			
Other	0				0			
Missing	0				0			
Metabolism and nutrition disorders								
All								
White	83	(6.2)	109	9.98	82	(6.3)	98	9.54
Black or African American	4	(6.3)	5	9.38	6	(8.5)	8	14.10
Asian	30	(6.9)	32	9.85	31	(6.8)	46	12.94
Other	7		7		4		4	
Missing	0				2		2	
Vitamin D deficiency								
White	16	(1.2)	16	1.25	12	(0.9)	12	1.00
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperlipidaemia								
White	11	(0.8)	11	0.91	11	(0.9)	11	1.02
Black or African American	0				1	(1.4)	1	1.44
Asian	3	(0.7)	3	1.26	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Hypoglycaemia								
White	9	(0.7)	15	1.76	7	(0.5)	10	0.99
Black or African American	0				1	(1.4)	1	1.44
Asian	4	(1.0)	4	1.14	11	(2.4)	24	6.53
Other	0				0			
Missing	0				1		1	
Vitamin B12 deficiency								
White	7	(0.5)	7	0.52	1	(0.1)	1	0.07
Black or African American	1	(1.6)	1	1.67	0			
Asian	3	(0.6)	3	0.56	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dyslipidaemia								
White	7	(0.5)	7	0.69	12	(0.9)	12	1.36
Black or African American	1	(1.2)	1	2.00	0			
Asian	10	(2.3)	11	3.56	3	(0.7)	3	1.00
Other	3		3		2		2	
Missing	0				0			
Hyperglycaemia								
White	6	(0.4)	7	0.77	7	(0.5)	7	0.82
Black or African American	0				2	(3.3)	2	5.80
Asian	0				4	(0.9)	4	1.07
Other	0				1		1	
Missing	0				0			
Gout								
White	4	(0.3)	5	0.37	6	(0.5)	7	0.52
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Iron deficiency								
White	4	(0.3)	4	0.30	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	0			
Other	0				0			
Missing	0				0			
Hypertriglyceridaemia								
White	4	(0.3)	4	0.41	4	(0.3)	4	0.47
Black or African American	0				0			
Asian	5	(1.2)	5	1.39	3	(0.7)	3	0.66
Other	1		1		1		1	
Missing	0				0			
Hyperkalaemia								
White	4	(0.3)	4	0.36	6	(0.5)	6	0.68
Black or African American	1	(1.9)	2	4.03	2	(2.5)	2	2.54
Asian	3	(0.7)	3	1.11	2	(0.5)	2	0.63
Other	0				0			
Missing	0				0			
Increased appetite								
White	3	(0.2)	3	0.22	6	(0.5)	7	0.80
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperuricaemia								
White	3	(0.2)	3	0.27	2	(0.2)	2	0.14
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Decreased appetite								
White	3	(0.2)	3	0.28	5	(0.4)	5	0.42
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Hyponatraemia								
White	2	(0.2)	2	0.27	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetes mellitus								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Folate deficiency								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fluid retention								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypercholesterolaemia								
White	2	(0.2)	2	0.21	2	(0.2)	2	0.22
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	1		1		0			
Missing	0				0			
Hypokalaemia								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypoalbuminaemia								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dehydration								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Hypernatraemia								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Magnesium deficiency								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malnutrition								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Vitamin B complex deficiency								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Zinc deficiency								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Abnormal weight gain								
White	1	(0.1)	1	0.12	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Appetite disorder								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	2	0.44
Other	0				0			
Missing	0				0			
Diabetes mellitus inadequate control								
White	0				0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrolyte imbalance								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Food craving								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Hyperammonaemia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Hypercalcaemia								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Insulin resistance								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Lactic acidosis								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipomatosis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metabolic acidosis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Metabolic disorder								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Obesity								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	1		1		0			
Missing	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
White	81	(6.0)	119	11.34	70	(5.4)	85	8.32
Black or African American	8	(11.7)	8	16.47	3	(3.6)	3	3.64
Asian	19	(4.4)	20	6.25	23	(5.2)	27	8.35
Other	3		4		2		6	
Missing	0				3		3	
Cough								
White	15	(1.1)	16	1.51	13	(1.0)	13	1.26
Black or African American	2	(3.4)	2	4.62	2	(2.5)	2	2.54
Asian	5	(1.2)	5	1.52	5	(1.2)	6	1.75

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	1		1		0			
Missing	0				0			
Oropharyngeal pain								
White	13	(1.0)	14	1.15	9	(0.7)	10	1.06
Black or African American	0				1	(1.1)	1	1.10
Asian	5	(1.2)	6	1.94	5	(1.1)	6	1.84
Other	1		1		1		1	
Missing	0				0			
Rhinorrhoea								
White	9	(0.7)	12	1.15	6	(0.5)	6	0.52
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Nasal congestion								
White	8	(0.6)	8	0.70	4	(0.3)	4	0.30
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	1		1		0			
Missing	0				0			
Sleep apnoea syndrome								
White	6	(0.4)	6	0.54	0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dyspnoea								
White	5	(0.4)	5	0.54	10	(0.8)	11	1.16
Black or African American	0				0			
Asian	4	(0.9)	4	1.21	3	(0.7)	3	0.71
Other	0				0			
Missing	0				0			
Respiratory disorder								
White	4	(0.3)	4	0.48	5	(0.4)	5	0.50
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Asthma								
White	4	(0.3)	5	0.49	0			
Black or African American	1	(1.2)	1	2.00	0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Productive cough								
White	4	(0.3)	4	0.38	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Epistaxis								
White	3	(0.2)	7	0.84	1	(0.1)	2	0.26
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	1	(0.2)	2	0.44
Other	1		1		0			
Missing	0				0			
Chronic obstructive pulmonary disease								
White	3	(0.2)	3	0.36	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Emphysema								
White	2	(0.2)	2	0.21	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Pulmonary fibrosis								
White	2	(0.2)	3	0.28	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus pain								
White	2	(0.2)	3	0.28	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus congestion								
White	2	(0.2)	3	0.22	1	(0.1)	1	0.08
Black or African American	2	(2.3)	2	3.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Interstitial lung disease								
White	2	(0.1)	2	0.15	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute respiratory failure								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.08
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sneezing								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal septum deviation								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	1	(1.6)	1	2.60	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pleurisy								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary hypertension								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Increased viscosity of upper respiratory secretion								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rhinitis allergic								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.78
Other	0				1		5	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Upper respiratory tract inflammation								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bronchospasm								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acquired diaphragmatic eventration								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bronchiectasis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Laryngeal cyst								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal dryness								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal turbinate hypertrophy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary embolism								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary mass								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.78
Other	0				0			
Missing	0				0			
Throat irritation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Upper-airway cough syndrome								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nasal obstruction								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory failure								
White	1	(0.1)	1	0.12	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute pulmonary oedema								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Allergic bronchitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Allergic cough								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aphonia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bronchitis chronic								
White	0				2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dry throat								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Dysphonia								
White	0				1	(0.1)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dyspnoea exertional								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Haemoptysis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lung disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Paranasal cyst								
White	0				2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Paranasal sinus discomfort								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pleural disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Pleural effusion								
White	0				3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pleuritic pain								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory tract inflammation								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

Cardiac disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
White	66	(4.9)	102	8.38	59	(4.5)	88	7.89
Black or African American	5	(7.7)	5	9.61	5	(6.9)	5	7.20
Asian	11	(2.6)	13	4.70	15	(3.4)	16	4.75
Other	3		3		0			
Missing	1		1		0			
Coronary artery disease								
White	12	(0.9)	12	1.00	10	(0.8)	10	0.85
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial fibrillation								
White	12	(0.9)	13	1.01	5	(0.4)	5	0.44
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Cardiac failure								
White	8	(0.6)	8	0.65	2	(0.2)	3	0.33
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute myocardial infarction								
White	7	(0.5)	7	0.58	7	(0.5)	7	0.65
Black or African American	1	(1.2)	1	2.00	0			
Asian	1	(0.3)	1	0.44	1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Angina pectoris								
White	6	(0.5)	6	0.51	3	(0.2)	3	0.27
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Tachycardia								
White	3	(0.2)	3	0.22	4	(0.3)	4	0.35
Black or African American	0				1	(1.4)	1	1.44
Asian	0				2	(0.4)	2	0.78
Other	0				0			
Missing	0				0			
Acute coronary syndrome								
White	3	(0.2)	3	0.22	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Palpitations								
White	3	(0.2)	3	0.28	3	(0.2)	3	0.23
Black or African American	1	(1.9)	1	2.02	0			
Asian	1	(0.2)	1	0.25	2	(0.5)	2	0.63
Other	1		1		0			
Missing	0				0			
Cardiac failure congestive								
White	3	(0.2)	3	0.22	2	(0.2)	3	0.39
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Left ventricular hypertrophy								
White	3	(0.2)	3	0.22	2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Angina unstable								
White	3	(0.2)	3	0.22	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Ventricular extrasystoles								
White	3	(0.2)	3	0.22	1	(0.1)	2	0.14
Black or African American	1	(1.9)	1	2.02	0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Myocardial infarction								
White	3	(0.2)	3	0.27	2	(0.2)	2	0.15
Black or African American	0				1	(1.4)	1	1.44
Asian	2	(0.5)	2	0.79	1	(0.2)	1	0.22
Other	1		1		0			
Missing	0				0			
Atrioventricular block first degree								
White	2	(0.2)	2	0.20	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Myocardial ischaemia								
White	2	(0.2)	2	0.21	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Cardiac failure chronic								
White	2	(0.1)	2	0.15	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Coronary artery occlusion								
White	2	(0.1)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Supraventricular tachycardia								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic valve sclerosis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arrhythmia								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				2	(0.4)	2	0.61
Other	0				0			
Missing	0				0			
Arteriosclerosis coronary artery								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bundle branch block left								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Cardio-respiratory arrest								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Mitral valve stenosis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic valve incompetence								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial flutter								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial thrombosis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bradycardia								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bundle branch block right								
White	1	(0.1)	1	0.07	5	(0.4)	6	0.57
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Cardiac ventricular thrombosis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic coronary syndrome								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diastolic dysfunction								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Left atrial dilatation								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Left ventricular dysfunction								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Mitral valve incompetence								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	2	(0.4)	2	0.61	0			
Other	0				0			
Missing	0				0			
Pericardial effusion								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pericarditis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus tachycardia								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tricuspid valve incompetence								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac flutter								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic valve calcification								
White	0				2	(0.2)	2	0.21
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial enlargement								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrioventricular block complete								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac arrest								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Cardiac dysfunction								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Cardiac failure acute								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac perfusion defect								
White	0				1	(0.1)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Coronary artery stenosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Left atrial enlargement								
White	0				0			
Black or African American	1	(1.1)	1	1.91	1	(1.4)	1	1.44
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Sinus arrhythmia								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sinus bradycardia								
White	0				3	(0.2)	3	0.28
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Subendocardial ischaemia								
White	0				2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Supraventricular extrasystoles								
White	0				1	(0.1)	1	0.08
Black or African American	0				1	(1.4)	1	1.44
Asian	2	(0.5)	2	0.67	0			
Other	0				0			
Missing	1		1		0			
Ventricular arrhythmia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ventricular tachycardia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Investigations								
All								
White	62	(4.7)	70	6.84	49	(3.7)	51	4.85
Black or African American	4	(5.1)	6	10.84	3	(3.9)	3	3.98
Asian	14	(3.3)	18	5.24	13	(2.9)	18	5.98
Other	0				1		1	
Missing	0				0			
Weight increased								
White	16	(1.2)	16	1.65	14	(1.1)	14	1.47
Black or African American	0				1	(1.4)	1	1.44
Asian	3	(0.7)	3	0.74	3	(0.7)	3	0.66
Other	0				0			
Missing	0				0			
SARS-CoV-2 test positive								
White	6	(0.4)	6	0.66	0			
Black or African American	1	(1.2)	1	2.00	0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood creatinine increased								
White	5	(0.4)	5	0.57	0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	2	(0.5)	2	0.86	0			
Other	0				0			
Missing	0				0			
Blood immunoglobulin E increased								
White	3	(0.2)	3	0.22	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood triglycerides increased								
White	3	(0.2)	3	0.28	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Blood alkaline phosphatase increased								
White	3	(0.2)	3	0.39	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood pressure increased								
White	3	(0.2)	3	0.28	4	(0.3)	4	0.36
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Weight decreased								
White	3	(0.2)	3	0.22	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Prostatic specific antigen increased								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Occult blood								
White	2	(0.2)	2	0.20	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood cholesterol increased								
White	2	(0.1)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Alanine aminotransferase increased								
White	2	(0.1)	2	0.25	0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.67	0			
Other	0				0			
Missing	0				0			
Eosinophil count increased								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Liver function test abnormal								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	2	0.70
Other	0				0			
Missing	0				0			
Electrocardiogram abnormal								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram ST segment abnormal								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram T wave inversion								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hepatic enzyme increased								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Liver function test increased								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
QRS axis abnormal								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Thyroid function test abnormal								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arthroscopy								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood glucose fluctuation								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood potassium increased								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Monofilament pressure perception test								
White	1	(0.1)	1	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood creatine increased								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Body temperature increased								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
International normalised ratio abnormal								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
International normalised ratio decreased								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
International normalised ratio increased								
White	1	(0.1)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Transferrin saturation decreased								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Amylase increased								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Antinuclear antibody positive								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aspartate aminotransferase increased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Blood creatine phosphokinase increased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Blood glucose decreased								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood glucose increased								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood pressure decreased								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood urine present								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	3	0.56	0			
Other	0				1		1	
Missing	0				0			
Bone density decreased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	0			
Other	0				0			
Missing	0				0			
Breath sounds abnormal								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Carbohydrate antigen 19-9 increased								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac murmur								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac stress test abnormal								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Catheterisation cardiac								
White	0				0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ejection fraction decreased								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram P wave biphasic								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Electrocardiogram repolarisation abnormality								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Electrocardiogram ST segment depression								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Free fatty acids increased								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Glomerular filtration rate decreased								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Glycosylated haemoglobin increased								
White	0				2	(0.2)	3	0.22
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Grip strength decreased								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Haematocrit increased								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Haemoglobin decreased								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Haemoglobin increased								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intraocular pressure increased								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipase increased								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipids increased								
White	0				0			
Black or African American	0				1	(1.1)	1	1.10
Asian	0				0			
Other	0				0			
Missing	0				0			
Low density lipoprotein increased								
White	0				0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				2	(0.4)	2	0.78
Other	0				0			
Missing	0				0			
Monocyte count decreased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Platelet count decreased								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				2	(0.5)	2	0.80
Other	0				0			
Missing	0				0			
Red blood cell count decreased								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Transaminases increased								
White	0				1	(0.1)	1	0.13
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vitamin D decreased								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin and subcutaneous tissue disorders								
All								
White	58	(4.3)	63	5.60	63	(4.8)	77	7.07
Black or African American	3	(3.9)	4	7.40	5	(6.3)	5	6.52
Asian	33	(7.9)	35	11.50	34	(7.5)	39	11.50
Other	4		4		1		1	
Missing	1		1		1		1	
Pruritus								
White	6	(0.4)	6	0.49	7	(0.5)	7	0.69
Black or African American	1	(1.1)	1	1.91	1	(1.4)	1	1.44
Asian	1	(0.2)	1	0.42	2	(0.5)	2	0.80
Other	0				1		1	
Missing	0				0			
Eczema								
White	5	(0.4)	5	0.37	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	5	(1.2)	5	1.75	4	(0.9)	4	1.37
Other	0				0			
Missing	0				0			
Urticaria								
White	5	(0.4)	5	0.46	7	(0.5)	7	0.58
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	2	(0.5)	2	0.84	2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			
Skin ulcer								
White	4	(0.3)	4	0.42	3	(0.2)	3	0.33
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.78
Other	0				0			
Missing	0				0			
Rash								
White	4	(0.3)	4	0.39	9	(0.7)	10	0.81
Black or African American	2	(2.7)	2	3.58	0			
Asian	4	(1.0)	4	1.32	2	(0.4)	2	0.57
Other	1		1		0			
Missing	0				0			
Alopecia								
White	4	(0.3)	4	0.34	2	(0.2)	2	0.16
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Dermatitis								
White	3	(0.2)	3	0.28	6	(0.5)	7	0.71
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Night sweats								
White	2	(0.2)	2	0.20	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Dermatitis allergic								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Ingrowing nail								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Psoriasis								
White	2	(0.1)	2	0.15	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin irritation								
White	2	(0.1)	3	0.22	2	(0.2)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperhidrosis								
White	2	(0.1)	2	0.19	4	(0.3)	4	0.42
Black or African American	0				1	(1.4)	1	1.44
Asian	6	(1.4)	6	1.89	0			
Other	0				0			
Missing	0				0			
Intertrigo								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Umbilical haematoma								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acne								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Diabetic foot								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Erythema								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.21

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Livedo reticularis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nail bed inflammation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Decubitus ulcer								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ecchymosis								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Rash erythematous								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin odour abnormal								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dermatitis contact								
White	1	(0.1)	1	0.07	5	(0.4)	5	0.45
Black or African American	0				1	(1.1)	1	1.10
Asian	2	(0.5)	3	0.74	2	(0.5)	2	0.63
Other	2		2		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Dry skin								
White	1	(0.1)	1	0.07	4	(0.3)	4	0.35
Black or African American	0				0			
Asian	2	(0.5)	2	0.50	0			
Other	0				0			
Missing	0				0			
Granuloma annulare								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperkeratosis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Lipodystrophy acquired								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin exfoliation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Skin lesion								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blister								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Actinic keratosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Alopecia areata								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Angioedema								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Asteatosis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Cold sweat								
White	0				0			
Black or African American	0				0			
Asian	4	(0.9)	4	1.29	3	(0.7)	3	0.85
Other	0				0			
Missing	0				0			
Cold urticaria								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Dermal cyst								
White	0				2	(0.2)	2	0.22
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Drug eruption								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Haemorrhage subcutaneous								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Hidradenitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lentigo								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Leukoplakia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Lipohypertrophy								
White	0				0			
Black or African American	0				0			
Asian	0				2	(0.5)	2	0.63
Other	0				0			
Missing	0				0			
Macule								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Miliaria								
White	0				0			
Black or African American	0				1	(1.1)	1	1.10
Asian	2	(0.5)	2	0.89	3	(0.7)	3	0.66
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Myxoid cyst								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Neurodermatitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Pruritus allergic								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Purpura								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Rash maculo-papular								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Rash papular								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Seborrhoea								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin discolouration								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Skin fissures								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Skin reaction								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Urticaria contact								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Urticaria thermal								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vascular disorders								
All								
White	56	(4.2)	64	6.05	53	(4.0)	65	6.14
Black or African American	1	(1.9)	1	2.02	4	(5.6)	6	9.60
Asian	15	(3.5)	16	4.63	17	(3.7)	21	6.99
Other	1		1		1		1	
Missing	0				1		2	
Hypertension								
White	22	(1.6)	22	2.13	21	(1.6)	24	2.25
Black or African American	1	(1.9)	1	2.02	1	(1.4)	1	2.40
Asian	8	(1.9)	8	2.39	12	(2.6)	14	4.41
Other	1		1		1		1	
Missing	0				0			
Hypotension								
White	6	(0.4)	6	0.55	2	(0.2)	2	0.21
Black or African American	0				1	(1.4)	1	1.44

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral arterial occlusive disease								
White	4	(0.3)	5	0.49	2	(0.2)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Arteriosclerosis								
White	3	(0.2)	3	0.22	5	(0.4)	5	0.43
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.78
Other	0				0			
Missing	0				0			
Superficial vein thrombosis								
White	3	(0.2)	3	0.22	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral artery stenosis								
White	2	(0.2)	5	0.55	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral venous disease								
White	2	(0.2)	2	0.21	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Aortic arteriosclerosis								
White	2	(0.1)	2	0.15	3	(0.2)	3	0.34
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Deep vein thrombosis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diabetic vascular disorder								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Haematoma								
White	1	(0.1)	1	0.13	3	(0.2)	3	0.34
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Hypertensive crisis								
White	1	(0.1)	1	0.13	2	(0.2)	4	0.47
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Blood pressure inadequately controlled								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	0			
Other	0				0			
Missing	0				0			
Hot flush								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Venous stenosis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Varicose ulceration								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic stenosis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Brachiocephalic arteriosclerosis								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Flushing								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypertensive urgency								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				1	(1.4)	2	2.88
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral artery occlusion								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral coldness								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.50	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Peripheral vascular disorder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Orthostatic hypotension								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Aneurysm								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic aneurysm								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Aortic dilatation								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Arterial insufficiency								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Blood pressure fluctuation								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Iliac artery stenosis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Intermittent claudication								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Macroangiopathy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neovascularisation								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Peripheral artery aneurysm								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Peripheral ischaemia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Phlebitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Thrombophlebitis								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Thrombosis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Varicose vein								
White	0				1	(0.1)	1	0.08
Black or African American	0				1	(1.4)	1	1.44
Asian	1	(0.2)	1	0.25	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Renal and urinary disorders								
All								
White	38	(2.8)	49	4.68	33	(2.5)	40	3.39
Black or African American	2	(2.8)	2	4.60	2	(2.8)	2	2.88
Asian	9	(2.2)	9	3.28	15	(3.4)	19	5.66
Other	2		2		0			
Missing	0				1		3	
Nephrolithiasis								
White	5	(0.4)	5	0.37	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				2	(0.5)	3	0.93
Other	0				0			
Missing	0				1		2	
Chronic kidney disease								
White	4	(0.3)	4	0.47	4	(0.3)	4	0.35
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Pollakiuria								
White	4	(0.3)	4	0.46	0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	2	(0.4)	2	0.44
Other	0				0			
Missing	0				0			
Renal cyst								
White	4	(0.3)	4	0.34	4	(0.3)	4	0.35
Black or African American	0				0			
Asian	3	(0.7)	3	1.23	0			
Other	0				0			
Missing	0				0			
Dysuria								
White	3	(0.2)	4	0.36	2	(0.2)	2	0.16
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	2	(0.5)	2	0.63
Other	0				0			
Missing	0				0			
Ureterolithiasis								
White	3	(0.2)	3	0.28	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				2	(0.5)	2	0.49

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Diabetic nephropathy								
White	3	(0.2)	3	0.27	2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acute kidney injury								
White	2	(0.2)	2	0.21	2	(0.2)	2	0.15
Black or African American	1	(1.2)	1	2.00	2	(2.8)	2	2.88
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Urine odour abnormal								
White	2	(0.1)	2	0.19	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Haematuria								
White	1	(0.1)	2	0.27	4	(0.3)	4	0.31
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Hypertonic bladder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nocturia								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Proteinuria								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Renal pain								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary incontinence								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary retention								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal failure								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal impairment								
White	1	(0.1)	1	0.13	3	(0.2)	3	0.23
Black or African American	1	(1.6)	1	2.60	0			
Asian	1	(0.2)	1	0.25	0			
Other	1		1		0			
Missing	0				0			
Calculus urinary								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Microalbuminuria								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pyelocaliectasis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal colic								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Bladder prolapse								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hydronephrosis								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Polyuria								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Urethral stenosis								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bladder mass								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chromaturia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cystitis haemorrhagic								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hydrocalyx								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Micturition urgency								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Nephropathy								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Nephrotic syndrome								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Renal mass								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Strangury								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Stress urinary incontinence								
White	0				1	(0.1)	1	0.07

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary tract disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Urinary tract inflammation								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urinary tract obstruction								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Psychiatric disorders								
All								
White	28	(2.1)	32	2.83	29	(2.2)	30	3.02
Black or African American	0				1	(1.4)	1	1.44
Asian	7	(1.7)	7	2.27	4	(0.9)	4	1.37
Other	1		1		2		2	
Missing	0				1		2	
Depression								
White	8	(0.6)	8	0.70	9	(0.7)	9	0.92
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anxiety								
White	5	(0.4)	5	0.43	6	(0.5)	6	0.45
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Insomnia								
White	5	(0.4)	5	0.51	3	(0.2)	3	0.23

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	5	(1.2)	5	1.43	2	(0.5)	2	0.63
Other	0				0			
Missing	0				1		2	
Sleep disorder								
White	4	(0.3)	4	0.30	3	(0.2)	3	0.41
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Mental status changes								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adjustment disorder with mixed anxiety and depressed mood								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Disorientation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Irritability								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Listless								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Post-traumatic stress disorder								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Drug abuse								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Depressed mood								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Nightmare								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adjustment disorder								
White	1	(0.1)	1	0.12	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adjustment disorder with depressed mood								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Affect lability								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Agitation								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Anxiety disorder								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bruxism								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Drug dependence								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Emotional distress								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fear								
White	0				2	(0.2)	2	0.26
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Major depression								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Mixed anxiety and depressive disorder								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Mood swings								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Persistent depressive disorder								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Phobia								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Stress								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Blood and lymphatic system disorders								
All								
White	24	(1.8)	26	2.46	19	(1.5)	19	1.70
Black or African American	0				1	(1.1)	1	1.10
Asian	8	(1.8)	8	2.71	7	(1.6)	7	2.46
Other	1		1		3		3	
Missing	0				0			
Anaemia								
White	15	(1.1)	17	1.67	9	(0.7)	9	0.90
Black or African American	0				1	(1.1)	1	1.10
Asian	3	(0.7)	3	1.06	2	(0.5)	2	0.63
Other	1		1		2		2	
Missing	0				0			
Eosinophilia								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	1	(0.2)	1	0.41
Other	0				1		1	
Missing	0				0			
Blood loss anaemia								
White	1	(0.1)	1	0.13	2	(0.2)	2	0.15
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				0			
Other	0				0			
Missing	0				0			
Lymphadenopathy mediastinal								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Leukocytosis								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Splenomegaly								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Iron deficiency anaemia								
White	1	(0.1)	1	0.07	2	(0.2)	2	0.15
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Lymphadenopathy								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.19	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Polycythaemia								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypochromic anaemia								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Leukopenia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Normocytic anaemia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			
Pancytopenia								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Thrombocytopenia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Thrombocytosis								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
White	22	(1.7)	30	2.73	18	(1.4)	28	2.42
Black or African American	2	(3.5)	2	3.69	1	(1.4)	1	1.44
Asian	7	(1.7)	7	2.47	7	(1.6)	9	2.64
Other	0				0			
Missing	0				1		2	
Eye naevus								
White	2	(0.2)	3	0.28	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Adenocarcinoma pancreas								
White	2	(0.2)	2	0.20	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colorectal cancer								
White	2	(0.2)	2	0.20	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatic neoplasm								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metastases to liver								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Seborrhoeic keratosis								
White	2	(0.1)	3	0.22	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Colon adenoma								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Osteoma								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Small cell lung cancer								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Invasive ductal breast carcinoma								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Invasive lobular breast carcinoma								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lipoma								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pancreatic carcinoma								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal neoplasm								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Squamous cell carcinoma of skin								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bladder papilloma								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Lung cancer metastatic								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Basal cell carcinoma								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.23
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Glioblastoma multiforme								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral fibroma								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Salivary gland neoplasm								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Acrochordon								
White	0				0			
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adenocarcinoma of colon								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Adrenal adenoma								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Benign renal neoplasm								
White	0				0			
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Bladder cancer								
White	0				0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Bowen's disease								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Breast cancer								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Breast cancer metastatic								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic myeloid leukaemia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Colon cancer								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Colon cancer stage II								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dysplastic naevus								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Endometrial adenocarcinoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastric cancer								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Gastrointestinal tract adenoma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Haemangioma of liver								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Hepatocellular carcinoma								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Invasive breast carcinoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lung adenocarcinoma								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Lymphangioma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Malignant melanoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malignant melanoma in situ								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Malignant peritoneal neoplasm								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metastases to bone marrow								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Metastases to lymph nodes								
White	0				1	(0.1)	1	0.07

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myxoma								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Neoplasm skin								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Ovarian cancer metastatic								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Pancreatic carcinoma metastatic								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Prostate cancer								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Prostatic adenoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Renal cell carcinoma								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Renal hamartoma								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin papilloma								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Small intestine neuroendocrine tumour								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine cancer								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine leiomyoma								
White	0				2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Ear and labyrinth disorders								
All								
White	22	(1.6)	25	2.10	18	(1.4)	19	1.92
Black or African American	0				0			
Asian	4	(1.0)	4	1.53	4	(0.9)	4	1.20
Other	0				0			
Missing	0				0			
Vertigo								
White	7	(0.5)	8	0.68	4	(0.3)	5	0.45
Black or African American	0				0			
Asian	3	(0.7)	3	1.08	4	(0.9)	4	1.20
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Ear pain								
White	5	(0.4)	5	0.47	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Deafness bilateral								
White	2	(0.2)	2	0.15	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vertigo positional								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinnitus								
White	2	(0.2)	2	0.15	2	(0.2)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cerumen impaction								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
External ear pain								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypoacusis								
White	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Meniere's disease								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear inflammation								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eustachian tube dysfunction								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Deafness unilateral								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear discomfort								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Middle ear inflammation								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Motion sickness								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Presbyacusis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Reproductive system and breast disorders								
All								
White	18	(1.4)	18	1.70	18	(1.4)	22	1.94
Black or African American	2	(3.5)	2	3.69	1	(1.4)	1	1.44
Asian	7	(1.7)	7	2.30	4	(0.9)	4	1.07
Other	2		2		0			
Missing	0				0			
Benign prostatic hyperplasia								
White	3	(0.2)	3	0.28	3	(0.2)	3	0.28
Black or African American	0				0			
Asian	2	(0.5)	2	0.69	0			
Other	0				0			
Missing	0				0			
Erectile dysfunction								
White	3	(0.2)	3	0.27	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	1		1		0			
Missing	0				0			
Intermenstrual bleeding								
White	2	(0.2)	2	0.26	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrophic vulvovaginitis								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menstruation irregular								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pelvic discomfort								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	0				0			
Missing	0				0			
Uterine polyp								
White	1	(0.1)	1	0.07	0			
Black or African American	1	(1.9)	1	2.02	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Breast pain								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menstruation delayed								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Breast mass								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine prolapse								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginal pruritus								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Prostatitis								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cervical polyp								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Colpocele								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dysmenorrhoea								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ejaculation failure								
White	0				0			
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Galactorrhoea								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Genital prolapse								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menopausal disorder								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Menopausal symptoms								
White	0				0			
Black or African American	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Ovarian cyst								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Penile rash								
White	0				1	(0.1)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Prostatic calcification								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Pruritus genital								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Testicular cyst								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Uterine enlargement								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vaginal discharge								
White	0				2	(0.2)	2	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vaginal haemorrhage								
White	0				1	(0.1)	1	0.07
Black or African American	0				1	(1.4)	1	1.44
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginal dryness								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Immune system disorders								
All								
White	10	(0.8)	11	1.04	13	(1.0)	14	1.49
Black or African American	2	(3.2)	2	4.27	1	(1.4)	1	2.40
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Seasonal allergy								
White	7	(0.5)	7	0.62	8	(0.6)	8	0.86
Black or African American	1	(1.6)	1	1.67	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Drug hypersensitivity								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypersensitivity								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Food allergy								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Allergy to arthropod bite								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				1	(1.4)	1	2.40
Asian	0				0			
Other	0				0			
Missing	0				0			
Allergy to arthropod sting								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Anaphylactic reaction								
White	0				1	(0.1)	1	0.14
Black or African American	1	(1.6)	1	2.60	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Immunisation reaction								
White	0				1	(0.1)	2	0.16
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatobiliary disorders								
All								
White	8	(0.6)	12	1.01	15	(1.1)	16	1.47
Black or African American	0				0			
Asian	9	(2.2)	10	3.53	6	(1.3)	9	2.90
Other	2		3		0			
Missing	0				0			
Hepatic steatosis								
White	4	(0.3)	4	0.30	4	(0.3)	4	0.29
Black or African American	0				0			
Asian	3	(0.7)	3	0.91	5	(1.1)	5	1.64
Other	1		1		0			
Missing	0				0			
Hepatomegaly								
White	2	(0.2)	2	0.21	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cholelithiasis								
White	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Cholecystitis chronic								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatic mass								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gallbladder cholesterolosis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Non-alcoholic steatohepatitis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Alcoholic liver disease								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	0			
Other	0				0			
Missing	0				0			
Bile duct stone								
White	0				1	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Biliary colic								
White	0				1	(0.1)	1	0.13

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Biliary dyskinesia								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cholecystitis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	0			
Other	0				0			
Missing	0				0			
Gallbladder polyp								
White	0				0			
Black or African American	0				0			
Asian	1	(0.3)	1	0.44	1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
Hepatic cirrhosis								
White	0				2	(0.2)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hepatic cyst								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Hepatic function abnormal								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.42	2	(0.5)	2	0.63
Other	0				0			
Missing	0				0			
Hyperplastic cholecystopathy								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Hypertransaminasaemia								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		2		0			
Missing	0				0			
Liver disorder								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Nonalcoholic fatty liver disease								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Steatohepatitis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Endocrine disorders								
All								
White	5	(0.4)	5	0.43	14	(1.1)	14	1.29
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	4	(0.9)	4	1.18
Other	0				0			
Missing	0				0			
Hypothyroidism								
White	2	(0.2)	2	0.21	3	(0.2)	3	0.22
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.35
Other	0				0			
Missing	0				0			
Thyroid mass								
White	2	(0.1)	2	0.15	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.39
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Autoimmune thyroiditis								
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adrenal mass								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Adrenocortical insufficiency acute								
White	0				2	(0.2)	2	0.27
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Goitre								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Hyperplasia adrenal								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hyperprolactinaemia								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Hyperthyroidism								
White	0				2	(0.2)	2	0.15
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hypogonadism								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.40	0			
Other	0				0			
Missing	0				0			
Inappropriate antidiuretic hormone secretion								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Secondary hypogonadism								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Surgical and medical procedures								
All								
White	4	(0.3)	4	0.42	4	(0.3)	4	0.41
Black or African American	0				1	(1.1)	1	1.10
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Shoulder operation								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tooth extraction								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cardiac pacemaker replacement								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Knee operation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.07	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Large intestinal polypectomy								
White	0				0			
Black or African American	0				1	(1.1)	1	1.10
Asian	0				0			
Other	0				0			
Missing	0				0			
Removal of foreign body								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.22
Other	0				0			
Missing	0				0			
Skin neoplasm excision								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Spinal operation								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Toe amputation								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Congenital, familial and genetic disorders								
All								
White	1	(0.1)	1	0.13	4	(0.3)	4	0.29
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	1	0.25	0			
Other	3		3		1		1	
Missing	0				0			
Cystic fibrosis lung								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Atrial septal defect								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Congenital syphilitic osteochondritis								
White	0				1	(0.1)	1	0.08
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Corneal dystrophy								
White	0				0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hydrocele								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.25	0			
Other	0				0			
Missing	0				0			
Hypertrophic cardiomyopathy								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Myotonic dystrophy								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Type V hyperlipidaemia								
White	0				0			
Black or African American	0				0			
Asian	0				0			


%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Other	3		3		1		1	
Missing	0				0			
Social circumstances								
All								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Menopause								
White	0				1	(0.1)	1	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.21 Adverse events by race and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): RACE2; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS RACE2; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:51 - faedotgrp/faesocgrpracedotontp3asas.png

7.7.22 Adverse events by race and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): RACE2; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS RACE2; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:57 - faedotgrp/faesocgrpracedotontt2dsas.png

7.7.23 Adverse events by race and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): RACE2; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD RACE2; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:04 - faedotgrp/faept5pctgrpracedotontp3asas.png

7.7.24 Adverse events by race and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool



% of subjects: Percentage of subjects with one or more events, N: Number of subjects, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): RACE2; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD RACE2; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:10 - faedotgrp/faept5pctgrpracedotontt2dsas.png

7.7.25 Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Hispanic or Latino	257				264			
Not Hispanic or Latino	1898				1889			
Missing	15				17			
PYE (years)								
Hispanic or Latino	191.00				195.23			
Not Hispanic or Latino	1481.32				1475.30			
Missing	8.92				10.06			
Events								
Hispanic or Latino	171	(66.8)	456	255.40	159	(60.2)	467	253.58
Not Hispanic or Latino	1152	(60.7)	3510	254.77	1091	(57.8)	3381	250.48
Missing	5		19		13		30	
Serious								
Yes								
Hispanic or Latino	15	(5.8)	17	9.58	11	(4.2)	22	9.78
Not Hispanic or Latino	151	(8.0)	228	15.64	156	(8.2)	212	13.97
Missing	0				2		4	
No								
Hispanic or Latino	167	(65.3)	439	245.83	159	(60.2)	445	243.80
Not Hispanic or Latino	1115	(58.7)	3282	239.13	1051	(55.6)	3169	236.51
Missing	5		19		13		26	
Missing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
Hispanic or Latino	14	(5.4)	16	8.25	8	(3.1)	18	8.04
Not Hispanic or Latino	78	(4.1)	105	7.68	80	(4.2)	114	7.19
Missing	0				1		1	
Moderate								
Hispanic or Latino	61	(23.9)	104	58.96	67	(25.5)	115	62.83
Not Hispanic or Latino	447	(23.6)	820	56.76	409	(21.6)	736	51.12
Missing	4		7		2		5	
Mild								
Hispanic or Latino	143	(56.0)	336	188.19	132	(50.0)	334	182.71
Not Hispanic or Latino	966	(50.9)	2585	190.32	928	(49.1)	2531	192.17
Missing	4		12		13		24	
Missing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Related to basal insulin								
Probable								
Hispanic or Latino	12	(4.8)	18	12.13	15	(5.6)	38	17.82
Not Hispanic or Latino	70	(3.7)	102	7.80	61	(3.2)	95	6.87
Missing	0				0			
Possible								
Hispanic or Latino	7	(2.7)	10	6.24	12	(4.6)	13	6.53
Not Hispanic or Latino	117	(6.2)	165	12.94	92	(4.9)	164	13.36
Missing	1		4		1		1	
Unlikely								
Hispanic or Latino	161	(62.8)	426	235.97	152	(57.6)	416	229.23
Not Hispanic or Latino	1110	(58.5)	3233	233.18	1062	(56.2)	3116	229.83
Missing	5		15		12		29	
Missing								
Hispanic or Latino	2	(0.8)	2	1.06	0			
Not Hispanic or Latino	6	(0.3)	10	0.85	6	(0.3)	6	0.43
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
Hispanic or Latino	4	(1.6)	4	2.75	2	(0.7)	3	1.98
Not Hispanic or Latino	7	(0.4)	7	0.62	5	(0.3)	5	0.46
Missing	0				0			
No								
Hispanic or Latino	170	(66.4)	450	251.60	158	(59.8)	463	250.97
Not Hispanic or Latino	1150	(60.6)	3492	253.21	1087	(57.5)	3369	249.50
Missing	5		19		13		30	
NA								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Missing								
Hispanic or Latino	2	(0.8)	2	1.06	0			
Not Hispanic or Latino	6	(0.3)	10	0.85	7	(0.4)	7	0.52
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
Hispanic or Latino	2	(0.7)	2	0.75	0			
Not Hispanic or Latino	12	(0.6)	16	1.23	13	(0.7)	15	0.93
Missing	0				0			
Not recovered/not resolved								
Hispanic or Latino	73	(28.5)	109	60.10	60	(22.7)	112	63.08
Not Hispanic or Latino	513	(27.0)	975	68.96	507	(26.8)	920	65.40
Missing	3		3		3		10	
Recovered/resolved with sequelae								
Hispanic or Latino	4	(1.6)	4	2.19	2	(0.7)	2	0.99
Not Hispanic or Latino	6	(0.3)	6	0.32	14	(0.7)	16	1.12
Missing	0				0			
Recovering/resolving								
Hispanic or Latino	18	(7.1)	27	14.09	20	(7.6)	21	10.39
Not Hispanic or Latino	78	(4.1)	109	8.46	72	(3.8)	90	7.00
Missing	0				0			
Recovered/resolved								
Hispanic or Latino	146	(57.0)	314	178.28	132	(50.0)	332	179.12
Not Hispanic or Latino	972	(51.2)	2403	175.75	896	(47.4)	2338	175.94
Missing	4		16		11		20	
Unknown								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.10
Missing	0				0			
Missing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.26 Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Hispanic or Latino	247				254			
Not Hispanic or Latino	1618				1607			
Missing	15				17			
PYE (years)								
Hispanic or Latino	185.98				190.17			
Not Hispanic or Latino	1344.03				1336.23			
Missing	8.92				10.06			
Events								
Hispanic or Latino	162	(65.9)	439	252.06	153	(60.2)	455	254.22
Not Hispanic or Latino	972	(60.1)	3020	236.97	907	(56.4)	2774	218.07
Missing	5		19		13		30	
Serious								
Yes								
Hispanic or Latino	15	(6.1)	17	9.96	11	(4.4)	22	10.17
Not Hispanic or Latino	140	(8.7)	213	16.46	149	(9.3)	203	15.28
Missing	0				2		4	
No								
Hispanic or Latino	158	(64.3)	422	242.10	153	(60.2)	433	244.05
Not Hispanic or Latino	939	(58.0)	2807	220.51	870	(54.2)	2571	202.78
Missing	5		19		13		26	
Missing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
Hispanic or Latino	14	(5.6)	16	8.58	8	(3.2)	18	8.36
Not Hispanic or Latino	69	(4.3)	95	7.75	76	(4.7)	109	7.81
Missing	0				1		1	
Moderate								
Hispanic or Latino	59	(24.1)	101	58.92	66	(26.1)	113	63.76
Not Hispanic or Latino	398	(24.6)	733	55.61	359	(22.3)	649	49.13
Missing	4		7		2		5	
Mild								
Hispanic or Latino	135	(55.0)	322	184.55	126	(49.6)	324	182.10
Not Hispanic or Latino	805	(49.7)	2192	173.60	764	(47.6)	2016	161.12
Missing	4		12		13		24	
Missing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Related to basal insulin								
Probable								
Hispanic or Latino	12	(5.0)	18	12.62	15	(5.8)	38	18.54
Not Hispanic or Latino	53	(3.3)	82	6.62	54	(3.4)	87	7.06
Missing	0				0			
Possible								
Hispanic or Latino	7	(2.9)	10	6.49	12	(4.8)	13	6.79
Not Hispanic or Latino	95	(5.9)	139	11.90	75	(4.7)	123	10.55
Missing	1		4		1		1	
Unlikely								
Hispanic or Latino	152	(61.8)	409	231.85	146	(57.5)	404	228.89
Not Hispanic or Latino	941	(58.2)	2789	217.46	879	(54.7)	2558	199.95
Missing	5		15		12		29	
Missing								
Hispanic or Latino	2	(0.8)	2	1.10	0			
Not Hispanic or Latino	6	(0.4)	10	1.00	6	(0.4)	6	0.50
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
Hispanic or Latino	4	(1.6)	4	2.86	2	(0.8)	3	2.06
Not Hispanic or Latino	7	(0.4)	7	0.73	5	(0.3)	5	0.54
Missing	0				0			
No								
Hispanic or Latino	161	(65.5)	433	248.10	152	(59.8)	451	251.51
Not Hispanic or Latino	970	(59.9)	3002	235.13	903	(56.2)	2762	216.91
Missing	5		19		13		30	
NA								
Hispanic or Latino	0				1	(0.4)	1	0.65
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Missing								
Hispanic or Latino	2	(0.8)	2	1.10	0			
Not Hispanic or Latino	6	(0.4)	10	1.00	7	(0.4)	7	0.61
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
Hispanic or Latino	2	(0.8)	2	0.78	0			
Not Hispanic or Latino	11	(0.7)	15	1.32	13	(0.8)	15	1.10
Missing	0				0			
Not recovered/not resolved								
Hispanic or Latino	69	(28.1)	104	58.51	58	(22.8)	108	62.44
Not Hispanic or Latino	431	(26.6)	846	64.61	426	(26.5)	780	59.25
Missing	3		3		3		10	
Recovered/resolved with sequelae								
Hispanic or Latino	4	(1.7)	4	2.28	2	(0.8)	2	1.03
Not Hispanic or Latino	6	(0.4)	6	0.37	11	(0.7)	13	0.93
Missing	0				0			
Recovering/resolving								
Hispanic or Latino	18	(7.4)	27	14.65	20	(7.9)	21	10.80
Not Hispanic or Latino	72	(4.4)	103	9.17	67	(4.2)	82	7.21
Missing	0				0			
Recovered/resolved								
Hispanic or Latino	138	(56.1)	302	175.84	126	(49.6)	324	179.95
Not Hispanic or Latino	820	(50.7)	2049	161.44	741	(46.1)	1882	149.45
Missing	4		16		11		20	
Unknown								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Missing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.27 Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Hispanic or Latino	257				264			
Not Hispanic or Latino	1898				1889			
Missing	15				17			
PYE (years)								
Hispanic or Latino	191.00				195.23			
Not Hispanic or Latino	1481.32				1475.30			
Missing	8.92				10.06			
Events								
Hispanic or Latino	171	(66.8)	456	255.40	159	(60.2)	467	253.58
Not Hispanic or Latino	1152	(60.7)	3510	254.77	1091	(57.8)	3381	250.48
Missing	5		19		13		30	
Infections and infestations								
All								
Hispanic or Latino	91	(35.7)	120	70.24	85	(32.2)	124	66.73
Not Hispanic or Latino	554	(29.2)	797	59.31	532	(28.1)	772	56.48
Missing	3		3		7		9	
COVID-19								
Hispanic or Latino	31	(12.2)	32	18.18	30	(11.5)	31	16.04
Not Hispanic or Latino	150	(7.9)	153	11.20	158	(8.3)	164	11.46
Missing	0				4		4	
Nasopharyngitis								
Hispanic or Latino	11	(4.3)	12	7.29	5	(1.8)	5	2.89
Not Hispanic or Latino	105	(5.5)	128	10.45	108	(5.7)	128	10.49
Missing	1		1		2		2	
Upper respiratory tract infection								
Hispanic or Latino	7	(2.7)	7	4.23	6	(2.3)	6	3.11
Not Hispanic or Latino	61	(3.2)	74	4.97	46	(2.4)	50	3.66
Missing	0				0			
Urinary tract infection								
Hispanic or Latino	5	(2.0)	5	2.93	12	(4.6)	13	5.77
Not Hispanic or Latino	37	(1.9)	40	2.99	38	(2.0)	43	3.10
Missing	1		1		0			
Bronchitis								
Hispanic or Latino	1	(0.4)	1	0.36	2	(0.8)	2	1.45
Not Hispanic or Latino	29	(1.5)	30	2.29	17	(0.9)	17	1.19
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gastroenteritis								
Hispanic or Latino	6	(2.3)	6	3.15	4	(1.5)	4	2.07
Not Hispanic or Latino	26	(1.4)	27	2.37	13	(0.7)	14	1.16
Missing	0				1		1	
Influenza								
Hispanic or Latino	12	(4.9)	15	10.19	11	(4.1)	12	7.54
Not Hispanic or Latino	16	(0.8)	16	1.26	22	(1.2)	24	2.04
Missing	1		1		0			
Sinusitis								
Hispanic or Latino	4	(1.5)	4	2.20	3	(1.2)	4	1.85
Not Hispanic or Latino	15	(0.8)	17	1.31	16	(0.8)	18	1.29
Missing	0				0			
Pharyngitis								
Hispanic or Latino	6	(2.3)	6	2.95	8	(3.1)	9	4.69
Not Hispanic or Latino	15	(0.8)	17	1.26	10	(0.5)	12	0.85
Missing	0				0			
Pneumonia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	15	(0.8)	15	1.10	6	(0.3)	6	0.44
Missing	0				0			
COVID-19 pneumonia								
Hispanic or Latino	1	(0.4)	1	0.68	1	(0.4)	1	0.60
Not Hispanic or Latino	14	(0.7)	14	0.98	10	(0.5)	10	0.66
Missing	0				0			
Respiratory tract infection viral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	12	(0.6)	13	1.12	10	(0.5)	11	0.97
Missing	0				0			
Cystitis								
Hispanic or Latino	3	(1.2)	3	2.07	1	(0.4)	1	0.69
Not Hispanic or Latino	12	(0.6)	13	0.96	16	(0.8)	18	1.24
Missing	0				0			
Conjunctivitis								
Hispanic or Latino	2	(0.7)	2	0.75	0			
Not Hispanic or Latino	10	(0.5)	10	0.82	7	(0.4)	7	0.49
Missing	0				0			
Herpes zoster								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.39
Not Hispanic or Latino	10	(0.5)	10	0.66	16	(0.8)	17	1.15
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Respiratory tract infection								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	9	(0.5)	9	0.64	5	(0.3)	5	0.34
Missing	0				0			
Rhinitis								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.60
Not Hispanic or Latino	8	(0.4)	8	0.54	10	(0.5)	13	1.12
Missing	0				0			
Tooth infection								
Hispanic or Latino	1	(0.4)	2	1.33	2	(0.7)	2	1.23
Not Hispanic or Latino	8	(0.4)	9	0.60	6	(0.3)	6	0.47
Missing	0				0			
Viral infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.50	13	(0.7)	16	1.09
Missing	0				0			
Otitis media								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	7	(0.4)	7	0.55	4	(0.2)	4	0.30
Missing	0				0			
Tooth abscess								
Hispanic or Latino	2	(0.8)	2	1.43	1	(0.4)	2	1.38
Not Hispanic or Latino	7	(0.4)	7	0.54	6	(0.3)	6	0.35
Missing	0				0			
Gastroenteritis viral								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	6	(0.3)	6	0.41	5	(0.3)	5	0.37
Missing	0				0			
Vaginal infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.3)	7	0.58	3	(0.2)	3	0.20
Missing	0				0			
Lower respiratory tract infection								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	5	(0.3)	5	0.32	3	(0.2)	5	0.32
Missing	0				0			
Periodontitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.40	6	(0.3)	6	0.46
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute sinusitis								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	4	(0.2)	4	0.21	6	(0.3)	6	0.52
Missing	0				0			
Coronavirus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.21	5	(0.3)	7	0.50
Missing	0				0			
Tonsillitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.30	2	(0.1)	2	0.14
Missing	0				0			
Fungal infection								
Hispanic or Latino	3	(1.2)	3	1.77	2	(0.8)	2	1.08
Not Hispanic or Latino	4	(0.2)	5	0.34	0			
Missing	0				0			
Cellulitis								
Hispanic or Latino	1	(0.4)	1	0.66	1	(0.4)	2	1.25
Not Hispanic or Latino	3	(0.2)	3	0.16	7	(0.4)	7	0.49
Missing	0				0			
Fungal skin infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.25	1	(0.1)	1	0.09
Missing	0				0			
Ear infection								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.60
Not Hispanic or Latino	3	(0.2)	3	0.19	4	(0.2)	4	0.25
Missing	0				0			
Gingivitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	4	0.27	5	(0.3)	5	0.44
Missing	0				0			
Hordeolum								
Hispanic or Latino	0				1	(0.4)	1	0.76
Not Hispanic or Latino	3	(0.2)	3	0.22	3	(0.2)	3	0.24
Missing	0				0			
Vulvovaginal candidiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	4	0.25	4	(0.2)	4	0.21
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Respiratory syncytial virus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.20	0			
Missing	0				0			
Localised infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.20	3	(0.2)	3	0.25
Missing	0				0			
Genital infection								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	3	(0.2)	3	0.19	0			
Missing	0				0			
Erysipelas								
Hispanic or Latino	0				1	(0.4)	2	1.21
Not Hispanic or Latino	3	(0.2)	3	0.19	1	(0.1)	1	0.05
Missing	0				0			
Wound infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	1	(0.1)	1	0.09
Missing	0				0			
Gastrointestinal infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.29	5	(0.3)	7	0.53
Missing	0				0			
Acarodermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	4	(0.2)	4	0.21
Missing	0				0			
Tinea cruris								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Helicobacter infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	2	0.15
Missing	0				0			
Laryngitis								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.60
Not Hispanic or Latino	2	(0.1)	2	0.10	4	(0.2)	4	0.31
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Subcutaneous abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	3	0.16
Missing	0				0			
Abscess limb								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	2	(0.1)	3	0.30
Missing	0				0			
Vulvitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	0			
Missing	0				0			
Onychomycosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	4	(0.2)	4	0.20
Missing	0				0			
Paronychia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	3	0.28
Missing	0				0			
Osteomyelitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Tinea pedis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	2	(0.1)	2	0.20
Missing	0				0			
Skin infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	3	(0.2)	3	0.31
Missing	0				0			
Oral herpes								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.27	2	(0.1)	2	0.11
Missing	0				0			
Sepsis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.18	1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Chronic sinusitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Missing	0				0			
Clostridium difficile colitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Clostridium difficile infection								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Ear infection fungal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Gangrene								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Nail infection								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	2	0.10	0			
Missing	0				0			
Otitis externa								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.76
Not Hispanic or Latino	1	(0.1)	1	0.05	5	(0.3)	5	0.37
Missing	0				0			
Peritonsillar abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Post-acute COVID-19 syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	2	0.10	0			
Missing	0				0			
Pyelonephritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin candida								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Viral pharyngitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Breast abscess								
Hispanic or Latino	0				2	(0.8)	2	1.08
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Eye infection								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.18
Missing	0				0			
Genital infection fungal								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	2	0.22	2	(0.1)	2	0.10
Missing	0				0			
Norovirus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Severe acute respiratory syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Vulvovaginitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Anal abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Enteritis infectious								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Kidney infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Paraspinal abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Pulpitis dental								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	1	(0.1)	1	0.09	3	(0.2)	3	0.24
Missing	0				0			
Pustule								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Tinea versicolour								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Varicella zoster virus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Asymptomatic COVID-19								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.15
Missing	0				0			
Bacterial infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Balanitis candida								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Candida infection								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Chlamydial infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Chronic tonsillitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Missing	0				0			
Dermatophytosis of nail								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.10
Missing	0				0			
Escherichia urinary tract infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Folliculitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.14
Missing	0				0			
Furuncle								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	2	0.11	1	(0.1)	1	0.05
Missing	0				0			
Helicobacter gastritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Herpes simplex								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Herpes virus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Infected bite								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Laryngopharyngitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	2	0.10
Missing	0				0			
Mastitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Oropharyngeal candidiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Otitis media chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pericoronitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Purulence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Tinea infection								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Tracheitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Urethritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Viral upper respiratory tract infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vulvovaginal mycotic infection								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Abscess								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Bacteraemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Cholecystitis infective								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Infected dermal cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Pneumonia viral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Pulmonary tuberculoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Viral tracheitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Escherichia bacteraemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Injection site abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Postoperative wound infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Suspected COVID-19								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Abdominal abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Appendicitis								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Bartholinitis								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Body tinea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Breast cellulitis								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Campylobacter gastroenteritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Chronic hepatitis C								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Cystitis escherichia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diabetic foot infection								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Diverticulitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				5	(0.3)	5	0.27
Missing	0				0			
Empyema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Endophthalmitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Epididymitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Eye infection bacterial								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Fungal balanitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Gastric infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Gastroenteritis norovirus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Genital candidiasis								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Giardiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Herpes dermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Herpes zoster infection neurological								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Infected cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Infective iritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Labyrinthitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Lyme disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Oophoritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Oral candidiasis								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Otitis media acute								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.20
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Parotitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Peri-implantitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Pharyngotonsillitis								
Hispanic or Latino	1	(0.4)	1	0.68	2	(0.8)	3	1.16
Not Hispanic or Latino	0				0			
Missing	0				0			
Post procedural infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Rotavirus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Salpingitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Sinusitis bacterial								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Skin bacterial infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Soft tissue infection								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Sweat gland infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Urosepsis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Varicella								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Viral rhinitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Gastrointestinal disorders								
All								
Hispanic or Latino	28	(10.9)	37	20.58	27	(10.2)	45	24.94
Not Hispanic or Latino	247	(13.0)	379	26.59	216	(11.4)	296	21.62
Missing	2		2		2		2	
Diarrhoea								
Hispanic or Latino	14	(5.5)	16	8.53	9	(3.4)	9	4.98
Not Hispanic or Latino	75	(4.0)	92	6.45	46	(2.4)	48	3.55
Missing	0				0			
Nausea								
Hispanic or Latino	3	(1.1)	3	1.42	7	(2.7)	8	4.40
Not Hispanic or Latino	38	(2.0)	39	2.76	28	(1.5)	29	2.22
Missing	0				0			
Vomiting								
Hispanic or Latino	4	(1.5)	4	2.17	4	(1.5)	4	2.37
Not Hispanic or Latino	27	(1.4)	35	2.87	17	(0.9)	20	1.44
Missing	0				0			
Constipation								
Hispanic or Latino	2	(0.8)	2	1.09	4	(1.5)	4	2.20
Not Hispanic or Latino	15	(0.8)	18	1.33	11	(0.6)	11	0.78
Missing	0				1		1	
Abdominal pain upper								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	15	(0.8)	17	1.24	16	(0.8)	17	1.14
Missing	0				0			
Toothache								
Hispanic or Latino	1	(0.4)	1	0.68	1	(0.4)	1	0.69
Not Hispanic or Latino	14	(0.7)	14	0.89	12	(0.6)	17	1.56
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal pain								
Hispanic or Latino	3	(1.2)	3	2.05	3	(1.2)	4	2.46
Not Hispanic or Latino	14	(0.7)	14	0.90	15	(0.8)	15	1.03
Missing	0				0			
Dental caries								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	12	(0.6)	14	0.79	9	(0.5)	9	0.66
Missing	0				0			
Gastrooesophageal reflux disease								
Hispanic or Latino	2	(0.8)	2	0.78	3	(1.1)	3	1.59
Not Hispanic or Latino	12	(0.6)	12	0.83	12	(0.6)	12	0.84
Missing	0				0			
Chronic gastritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	9	(0.5)	9	0.68	6	(0.3)	6	0.47
Missing	0				0			
Dyspepsia								
Hispanic or Latino	0				2	(0.8)	2	0.99
Not Hispanic or Latino	8	(0.4)	8	0.62	7	(0.4)	7	0.50
Missing	0				0			
Gastritis								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	8	(0.4)	8	0.61	8	(0.4)	8	0.53
Missing	0				0			
Haemorrhoids								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.44	4	(0.2)	4	0.34
Missing	0				0			
Abdominal distension								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.39
Not Hispanic or Latino	7	(0.4)	7	0.46	4	(0.2)	4	0.34
Missing	0				0			
Food poisoning								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.33	4	(0.2)	5	0.42
Missing	0				0			
Diverticulum intestinal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.26	1	(0.1)	1	0.05
Missing	0				0			
Large intestine polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.24	6	(0.3)	7	0.40
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal pain lower								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.28	2	(0.1)	2	0.10
Missing	0				0			
Abdominal discomfort								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	4	(0.2)	4	0.31	5	(0.3)	6	0.49
Missing	0				0			
Enterocolitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	4	0.21	0			
Missing	0				0			
Flatulence								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	3	(0.2)	3	0.20	1	(0.1)	1	0.09
Missing	1		1		0			
Aphthous ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			
Inguinal hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	2	0.11
Missing	0				0			
Anal fissure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.10
Missing	0				0			
Impaired gastric emptying								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.27	0			
Missing	0				0			
Dry mouth								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Hiatus hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	2	0.16
Missing	0				0			
Rectal polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	2	(0.1)	2	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Hyperaesthesia teeth								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Hypoaesthesia oral								
Hispanic or Latino	1	(0.4)	3	2.04	0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Pancreatic failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	0			
Missing	0				0			
Gastric polyps								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	4	(0.2)	4	0.36
Missing	0				0			
Abdominal wall disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Colitis microscopic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Diabetic gastropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Eosinophilic oesophagitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Eructation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Gastric ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Gastrointestinal haemorrhage								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.14
Missing	0				0			
Haemorrhoidal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Intestinal dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Lip swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Umbilical hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Missing	0				0			
Faeces soft								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Irritable bowel syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Diverticulum								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	2	0.11
Missing	0				1		1	
Gastrointestinal angiodysplasia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Gingival bleeding								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Intra-abdominal haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Tongue rough								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Anal pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Colitis								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Colitis ischaemic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Frequent bowel movements								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Haematochezia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Loose tooth								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Oral discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pancreatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Periodontal disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.18
Missing	0				0			
Tooth disorder								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tooth impacted								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Pancreatic duct dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Pancreatitis chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Proctalgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Gastric dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Vomiting projectile								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Acid peptic disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.11
Missing	0				0			
Crohn's disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Duodenitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Enteritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Epigastric discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Faeces pale								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gastric disorder								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Gastric dysplasia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gastric mucosal hypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gastritis erosive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.21
Missing	0				0			
Gastrointestinal disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gastrointestinal inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Gastrointestinal sounds abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gingival disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gingival recession								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.21
Missing	0				0			
Hyperchlorhydria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Ileus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Lumbar hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Melaena								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Mesenteric panniculitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Noninfective gingivitis								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Odynophagia								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Oesophageal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Oesophagitis								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Oral pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	1		1		0			
Pancreatic pseudocyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Pancreatitis acute								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Peptic ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Periodontal inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.11
Missing	0				0			
Pneumatosis intestinalis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Rectal prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Small intestinal obstruction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Stomatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.11
Missing	0				0			
Ulcerative gastritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Upper gastrointestinal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Musculoskeletal and connective tissue disorders								
All								
Hispanic or Latino	38	(14.9)	68	35.74	30	(11.3)	40	22.63
Not Hispanic or Latino	233	(12.3)	329	22.92	252	(13.3)	359	26.50
Missing	2		3		2		2	
Back pain								
Hispanic or Latino	6	(2.3)	6	3.61	6	(2.2)	7	4.46

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	59	(3.1)	63	4.28	66	(3.5)	82	6.62
Missing	0				0			
Arthralgia								
Hispanic or Latino	6	(2.4)	9	5.28	5	(1.9)	6	3.32
Not Hispanic or Latino	45	(2.4)	50	3.49	52	(2.8)	57	4.31
Missing	0				0			
Pain in extremity								
Hispanic or Latino	6	(2.3)	7	3.54	5	(1.9)	5	2.70
Not Hispanic or Latino	31	(1.6)	32	2.17	32	(1.7)	38	2.98
Missing	0				0			
Muscle spasms								
Hispanic or Latino	2	(0.8)	2	1.07	1	(0.4)	1	0.69
Not Hispanic or Latino	22	(1.2)	24	1.82	8	(0.4)	8	0.50
Missing	1		1		0			
Osteoarthritis								
Hispanic or Latino	7	(2.7)	8	3.99	5	(1.9)	6	3.45
Not Hispanic or Latino	17	(0.9)	18	1.27	21	(1.1)	23	1.55
Missing	0				0			
Neck pain								
Hispanic or Latino	2	(0.8)	2	1.06	1	(0.4)	1	0.69
Not Hispanic or Latino	14	(0.7)	14	1.02	7	(0.4)	7	0.42
Missing	0				0			
Myalgia								
Hispanic or Latino	4	(1.6)	4	2.77	2	(0.8)	2	1.32
Not Hispanic or Latino	12	(0.6)	12	0.89	14	(0.7)	15	1.34
Missing	0				0			
Tendonitis								
Hispanic or Latino	0				3	(1.2)	3	1.46
Not Hispanic or Latino	8	(0.4)	10	0.67	2	(0.1)	2	0.20
Missing	0				0			
Periarthritis								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	7	(0.4)	7	0.45	9	(0.5)	9	0.68
Missing	0				0			
Trigger finger								
Hispanic or Latino	2	(0.7)	2	1.04	1	(0.4)	1	0.39
Not Hispanic or Latino	7	(0.4)	7	0.63	5	(0.3)	7	0.46
Missing	0				0			
Intervertebral disc protrusion								
Hispanic or Latino	2	(0.7)	3	1.14	1	(0.4)	1	0.39
Not Hispanic or Latino	6	(0.3)	9	0.55	5	(0.3)	6	0.40
Missing	0				0			
Arthritis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	6	(0.3)	6	0.44	6	(0.3)	6	0.47
Missing	0				0			
Bursitis								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	4	(0.2)	4	0.24	3	(0.2)	3	0.21
Missing	0				0			
Musculoskeletal stiffness								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	4	(0.2)	4	0.30	2	(0.1)	2	0.16
Missing	0				0			
Spinal stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	6	0.46	2	(0.1)	2	0.10
Missing	0				0			
Spinal osteoarthritis								
Hispanic or Latino	2	(0.7)	2	0.75	0			
Not Hispanic or Latino	4	(0.2)	4	0.29	5	(0.3)	6	0.31
Missing	0				0			
Plantar fasciitis								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	3	(0.2)	4	0.21	3	(0.2)	3	0.15
Missing	0				0			
Rotator cuff syndrome								
Hispanic or Latino	2	(0.8)	2	1.07	0			
Not Hispanic or Latino	3	(0.2)	3	0.20	4	(0.2)	4	0.20
Missing	0				0			
Muscular weakness								
Hispanic or Latino	2	(0.8)	2	1.41	0			
Not Hispanic or Latino	2	(0.1)	2	0.16	3	(0.2)	3	0.24
Missing	0				0			
Chondropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			
Exostosis								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Polyarthritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Synovial cyst								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.05
Missing	0				0			
Osteoporosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.18	0			
Missing	0				0			
Fibromyalgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	0			
Missing	0				0			
Groin pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	2	(0.1)	2	0.16
Missing	0				0			
Intervertebral disc disorder								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.05
Missing	0				1		1	
Musculoskeletal chest pain								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	2	(0.1)	2	0.11	2	(0.1)	2	0.10
Missing	0				0			
Foot deformity								
Hispanic or Latino	1	(0.4)	2	0.72	0			
Not Hispanic or Latino	2	(0.1)	3	0.19	2	(0.1)	2	0.14
Missing	0				1		1	
Osteochondrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	4	(0.2)	4	0.29
Missing	0				0			
Back disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Coccydynia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.05
Missing	0				0			
Musculoskeletal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acquired claw toe								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Diastasis recti abdominis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Meniscopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Psoriatic arthropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Sacroiliitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Tendon disorder								
Hispanic or Latino	2	(0.8)	2	1.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Limb discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Tenosynovitis								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	1	0.11	9	(0.5)	10	0.61
Missing	0				0			
Axillary mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Polymyalgia rheumatica								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	3	0.27
Missing	0				0			
Soft tissue swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	3	0.27	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Costochondritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Fistula								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Lumbar spinal stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Myositis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Spinal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	4	(0.2)	4	0.26
Missing	0				0			
Arthropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Pain in jaw								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Torticollis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Bone cyst								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Bone pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Cervical spinal stenosis								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Chondromalacia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Dupuytren's contracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.11
Missing	0				0			
Facet joint syndrome								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Flank pain								
Hispanic or Latino	1	(0.4)	1	0.66	2	(0.8)	2	1.32
Not Hispanic or Latino	0				4	(0.2)	5	0.30
Missing	0				0			
Haemarthrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Intervertebral disc degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Intervertebral disc space narrowing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.10
Missing	0				0			
Jaw disorder								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				0			
Missing	0				0			
Joint effusion								
Hispanic or Latino	1	(0.4)	1	0.36	1	(0.4)	1	0.39
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	1		2		0			
Joint swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.24
Missing	0				0			
Limb deformity								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Limb mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Mastication disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.11
Missing	0				0			
Muscle contracture								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Muscle twitching								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Neuropathic arthropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Nodal osteoarthritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.16
Missing	0				0			
Osteochondritis								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Osteopenia								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Periostitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Rheumatoid arthritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				4	(0.2)	4	0.36
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Scoliosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Spinal retrolisthesis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.10
Missing	0				0			
Tenosynovitis stenosans								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Vertebral osteophyte								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
General disorders and administration site conditions								
All								
Hispanic or Latino	19	(7.4)	33	17.24	15	(5.7)	36	16.33
Not Hispanic or Latino	219	(11.5)	324	24.82	193	(10.2)	308	23.87
Missing	2		6		0			
Pyrexia								
Hispanic or Latino	1	(0.4)	1	0.36	2	(0.8)	2	1.32
Not Hispanic or Latino	40	(2.1)	42	3.22	41	(2.2)	43	3.12
Missing	0				0			
Fatigue								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.39
Not Hispanic or Latino	31	(1.6)	35	2.59	15	(0.8)	15	0.99
Missing	0				0			
Oedema peripheral								
Hispanic or Latino	3	(1.2)	3	1.75	3	(1.2)	4	1.85
Not Hispanic or Latino	16	(0.8)	16	1.17	7	(0.4)	7	0.46
Missing	0				0			
Malaise								
Hispanic or Latino	1	(0.4)	2	0.72	0			
Not Hispanic or Latino	15	(0.8)	16	1.16	15	(0.8)	60	5.74
Missing	0				0			
Injection site reaction								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	14	(0.7)	27	2.31	5	(0.3)	7	0.44
Missing	1		2		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pain								
Hispanic or Latino	2	(0.8)	2	1.47	3	(1.1)	4	2.20
Not Hispanic or Latino	11	(0.6)	12	0.97	11	(0.6)	11	0.70
Missing	0				0			
Chest pain								
Hispanic or Latino	3	(1.2)	3	1.46	0			
Not Hispanic or Latino	11	(0.6)	11	0.72	7	(0.4)	7	0.47
Missing	0				0			
Vaccination site pain								
Hispanic or Latino	1	(0.4)	2	0.78	0			
Not Hispanic or Latino	9	(0.5)	10	0.79	9	(0.5)	9	0.72
Missing	0				0			
Hunger								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	8	0.52	3	(0.2)	4	0.36
Missing	0				0			
Medical device site reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	9	0.76	1	(0.1)	1	0.05
Missing	0				0			
Asthenia								
Hispanic or Latino	2	(0.8)	2	1.07	0			
Not Hispanic or Latino	7	(0.4)	7	0.48	10	(0.5)	10	0.76
Missing	1		1		0			
Influenza like illness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	8	0.69	4	(0.2)	4	0.26
Missing	0				0			
Medical device site rash								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.3)	6	0.65	8	(0.4)	8	0.84
Missing	0				0			
Chest discomfort								
Hispanic or Latino	2	(0.8)	2	1.37	0			
Not Hispanic or Latino	6	(0.3)	6	0.39	2	(0.1)	2	0.15
Missing	0				0			
Medical device site bruise								
Hispanic or Latino	2	(0.8)	3	1.72	0			
Not Hispanic or Latino	5	(0.3)	6	0.43	1	(0.1)	1	0.05
Missing	0				0			
Medical device site dermatitis								
Hispanic or Latino	2	(0.8)	5	1.95	1	(0.4)	1	0.39
Not Hispanic or Latino	5	(0.3)	5	0.50	10	(0.5)	17	1.12
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Peripheral swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	6	0.38	4	(0.2)	4	0.29
Missing	0				0			
Chills								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.25	1	(0.1)	1	0.05
Missing	0				0			
Medical device site haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.21	3	(0.2)	3	0.21
Missing	0				0			
Injection site pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	19	1.60	1	(0.1)	1	0.09
Missing	0				0			
Drug intolerance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.16	0			
Missing	0				0			
Gait disturbance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.16	1	(0.1)	1	0.05
Missing	0				0			
Medical device site pruritus								
Hispanic or Latino	2	(0.8)	2	1.06	0			
Not Hispanic or Latino	3	(0.2)	3	0.22	4	(0.2)	4	0.37
Missing	0				0			
Feeling abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	5	0.34	1	(0.1)	1	0.05
Missing	0				0			
Thirst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	1	(0.1)	1	0.09
Missing	0				0			
Injection site bruising								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	5	(0.3)	5	0.30
Missing	0				0			
Swelling face								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.15

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Injection site mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.11
Missing	0				0			
Medical device site pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	3	(0.2)	3	0.25
Missing	0				0			
Injection site hypersensitivity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	0			
Missing	0				0			
Injection site swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.18	1	(0.1)	1	0.09
Missing	0				0			
Injection site haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	6	0.53	3	(0.2)	8	0.76
Missing	0				0			
Injection site haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.18	2	(0.1)	2	0.15
Missing	0				0			
Injection site pain								
Hispanic or Latino	0				1	(0.4)	19	7.41
Not Hispanic or Latino	2	(0.1)	2	0.18	12	(0.6)	12	0.97
Missing	1		1		0			
Early satiety								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Localised oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Vessel puncture site bruise								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Inflammation								
Hispanic or Latino	0				1	(0.4)	1	0.69

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.10
Missing	1		1		0			
Injection site urticaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	2	0.22	1	(0.1)	1	0.05
Missing	0				0			
Medical device site haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Medical device site irritation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Medical device site erythema								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	1	(0.1)	1	0.09	5	(0.3)	6	0.57
Missing	0				0			
Discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	8	0.73
Missing	1		1		0			
Feeling hot								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Implant site pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Injection site dermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Medical device site eczema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Missing	0				0			
Medical device site hypersensitivity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Swelling								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Vaccination site reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Multiple organ dysfunction syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Oedema due to renal disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Vaccination site inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Vaccination site pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Xerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Application site bruise								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Injection site erythema								
Hispanic or Latino	2	(0.8)	2	1.09	1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	3	0.26	3	(0.2)	3	0.16
Missing	0				0			
Injection site rash								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Application site pruritus								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Axillary pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Condition aggravated								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.14
Missing	0				0			
Death								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.15
Missing	0				0			
Facial pain								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				0			
Missing	0				0			
Hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Hyperthermia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Injection site hypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Injection site induration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Injection site oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Medical device site inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Non-cardiac chest pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				4	(0.2)	6	0.31
Missing	0				0			
Oedema								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	0				3	(0.2)	3	0.20
Missing	0				0			
Procedural failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Systemic inflammatory response syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Vaccination site erythema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Nervous system disorders								
All								
Hispanic or Latino	24	(9.4)	32	19.51	25	(9.5)	36	21.13
Not Hispanic or Latino	183	(9.6)	266	19.77	182	(9.6)	290	22.91
Missing	0				0			
Headache								
Hispanic or Latino	7	(2.8)	8	5.22	11	(4.2)	14	8.50
Not Hispanic or Latino	63	(3.3)	84	6.76	53	(2.8)	66	4.93
Missing	0				0			
Dizziness								
Hispanic or Latino	7	(2.6)	10	5.87	2	(0.7)	3	1.98
Not Hispanic or Latino	33	(1.7)	41	2.84	37	(2.0)	44	3.27
Missing	0				0			
Tremor								
Hispanic or Latino	0				0			
Not Hispanic or Latino	12	(0.6)	13	0.81	10	(0.5)	61	6.26
Missing	0				0			
Sciatica								
Hispanic or Latino	2	(0.7)	2	1.04	0			
Not Hispanic or Latino	11	(0.6)	11	0.80	12	(0.6)	13	0.85
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Carpal tunnel syndrome								
Hispanic or Latino	1	(0.4)	1	0.68	2	(0.8)	2	1.45
Not Hispanic or Latino	10	(0.5)	10	0.64	6	(0.3)	6	0.43
Missing	0				0			
Hypoaesthesia								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	8	(0.4)	11	0.76	10	(0.5)	11	0.79
Missing	0				0			
Migraine								
Hispanic or Latino	1	(0.4)	1	0.70	2	(0.7)	2	1.37
Not Hispanic or Latino	7	(0.4)	8	0.66	3	(0.2)	3	0.25
Missing	0				0			
Syncope								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.46	1	(0.1)	1	0.05
Missing	0				0			
Paraesthesia								
Hispanic or Latino	2	(0.8)	2	0.78	2	(0.7)	2	0.99
Not Hispanic or Latino	6	(0.3)	7	0.40	10	(0.5)	10	0.77
Missing	0				0			
Neuropathy peripheral								
Hispanic or Latino	0				3	(1.2)	3	1.54
Not Hispanic or Latino	6	(0.3)	7	0.51	7	(0.4)	7	0.49
Missing	0				0			
Diabetic neuropathy								
Hispanic or Latino	3	(1.2)	3	2.07	3	(1.2)	3	1.38
Not Hispanic or Latino	3	(0.2)	3	0.21	9	(0.5)	9	0.67
Missing	0				0			
Burning sensation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.22	3	(0.2)	3	0.20
Missing	0				0			
Carotid artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Disturbance in attention								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	10	1.02	0			
Missing	0				0			
Dysgeusia								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Neuralgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.05
Missing	0				0			
Transient ischaemic attack								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	2	(0.1)	2	0.10	3	(0.2)	3	0.20
Missing	0				0			
Autonomic nervous system imbalance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	0			
Missing	0				0			
Cervicobrachial syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	1	(0.1)	1	0.05
Missing	0				0			
Somnolence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	1	(0.1)	1	0.05
Missing	0				0			
Post herpetic neuralgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.11
Missing	0				0			
Tension headache								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	2	(0.1)	3	0.16	0			
Missing	0				0			
Cerebrovascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Memory impairment								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Amnesia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Cerebral atrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Cluster headache								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cognitive disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Intracranial pressure increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Haemorrhage intracranial								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Hypoglycaemic seizure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Loss of consciousness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.16
Missing	0				0			
Sinus headache								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Speech disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Carotid artery aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Facial paralysis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Peripheral paralysis								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Piriformis syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Thalamic infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Ageusia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Anosmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Balance disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cerebral haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cervical radiculopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Dizziness postural								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.20
Missing	0				0			
Lumbar radiculopathy								
Hispanic or Latino	0				2	(0.8)	2	0.77
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	3	0.15
Missing	0				0			
Neuroglycopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	3	0.16
Missing	0				0			
Presyncope								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	4	(0.2)	4	0.21
Missing	0				0			
Trigeminal neuralgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cerebral arteriosclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Vascular encephalopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Basilar migraine								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				0			
Missing	0				0			
Brain injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Carotid arteriosclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cerebral artery embolism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cerebral infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Cerebrovascular accident								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.14
Missing	0				0			
Dementia Alzheimer's type								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Encephalopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Essential tremor								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Facial nerve disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Hemiparesis								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				0			
Missing	0				0			
Hypoglycaemic coma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Hypoglycaemic unconsciousness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hyporeflexia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Hypotonia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Ischaemic stroke								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Lethargy								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Mental impairment								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Meralgia paraesthetica								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Morton's neuralgia								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				0			
Missing	0				0			
Myelopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Ophthalmic migraine								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Orthostatic tremor								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Parkinsonian gait								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Radiculopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Restless legs syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Sleep deficit								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Thrombotic stroke								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.14
Missing	0				0			
Vascular headache								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Vertebral artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
White matter lesion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Injury, poisoning and procedural complications								
All								
Hispanic or Latino	23	(9.0)	31	17.73	26	(9.8)	31	18.63
Not Hispanic or Latino	170	(9.0)	208	15.40	152	(8.0)	184	14.15
Missing	1		2		2		2	
Fall								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.63
Not Hispanic or Latino	19	(1.0)	19	1.27	10	(0.5)	11	0.74
Missing	0				0			
Vaccination complication								
Hispanic or Latino	2	(0.8)	2	0.78	1	(0.4)	1	0.39
Not Hispanic or Latino	18	(0.9)	22	1.77	28	(1.5)	37	2.87
Missing	0				0			
Accidental overdose								
Hispanic or Latino	0				2	(0.8)	3	2.07
Not Hispanic or Latino	14	(0.7)	15	1.42	1	(0.1)	1	0.11
Missing	0				1		1	
Contusion								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	14	(0.7)	15	0.99	9	(0.5)	9	0.62
Missing	0				0			
Ligament sprain								
Hispanic or Latino	2	(0.8)	2	1.41	1	(0.4)	1	0.63
Not Hispanic or Latino	10	(0.5)	10	0.80	7	(0.4)	7	0.53
Missing	0				0			
Skin abrasion								
Hispanic or Latino	1	(0.4)	3	1.08	1	(0.4)	1	0.39
Not Hispanic or Latino	8	(0.4)	9	0.73	4	(0.2)	4	0.38
Missing	0				0			
Skin laceration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.48	1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Hand fracture								
Hispanic or Latino	1	(0.4)	1	0.77	0			
Not Hispanic or Latino	6	(0.3)	6	0.42	1	(0.1)	1	0.05
Missing	0				0			
Prescribed overdose								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.54	0			
Missing	0				0			
Incorrect dose administered								
Hispanic or Latino	1	(0.4)	1	0.68	4	(1.5)	6	3.79
Not Hispanic or Latino	5	(0.3)	5	0.51	1	(0.1)	1	0.05
Missing	0				0			
Limb injury								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.60
Not Hispanic or Latino	5	(0.3)	5	0.36	5	(0.3)	6	0.47
Missing	0				0			
Procedural pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.39	1	(0.1)	1	0.09
Missing	0				0			
Road traffic accident								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	5	0.41	1	(0.1)	1	0.05
Missing	1		1		0			
Overdose								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	4	(0.2)	4	0.32	2	(0.1)	2	0.15
Missing	0				0			
Upper limb fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.15	0			
Missing	0				0			
Rib fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	5	(0.3)	5	0.34
Missing	1		1		0			
Joint injury								
Hispanic or Latino	2	(0.8)	2	1.39	0			
Not Hispanic or Latino	3	(0.2)	3	0.20	5	(0.3)	5	0.35
Missing	0				0			
Arthropod sting								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	3	(0.2)	3	0.20	1	(0.1)	1	0.09
Missing	0				0			
Tooth fracture								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	3	(0.2)	3	0.20	3	(0.2)	3	0.25
Missing	0				0			
Wound								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.20	5	(0.3)	5	0.44
Missing	0				1		1	
Thermal burn								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	2	(0.1)	2	0.15
Missing	0				0			
Back injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	2	(0.1)	2	0.16
Missing	0				0			
Ankle fracture								
Hispanic or Latino	2	(0.7)	2	0.72	0			
Not Hispanic or Latino	2	(0.1)	2	0.10	3	(0.2)	3	0.15
Missing	0				0			
Radius fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	2	(0.1)	2	0.16
Missing	0				0			
Face injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	1	(0.1)	1	0.11
Missing	0				0			
Injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	0			
Missing	0				0			
Meniscus injury								
Hispanic or Latino	0				2	(0.8)	2	1.08
Not Hispanic or Latino	2	(0.1)	2	0.11	3	(0.2)	3	0.15
Missing	0				0			
Foot fracture								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	2	(0.1)	2	0.14	3	(0.2)	3	0.20
Missing	0				0			
Arthropod bite								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	1	(0.4)	1	0.66	2	(0.8)	2	1.32
Not Hispanic or Latino	2	(0.1)	2	0.18	2	(0.1)	2	0.16
Missing	0				0			
Bone contusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.14
Missing	0				0			
Femoral neck fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Hip fracture								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Inflammation of wound								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Injury of conjunctiva								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Multiple injuries								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Muscle injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.18
Missing	0				0			
Neck injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Penile contusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Post procedural complication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Post procedural haematuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Post procedural inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Radiation skin injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Spinal compression fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Tendon rupture								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Epicondylitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Product administration error								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Product dispensing error								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Craniocerebral injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Subcutaneous haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Underdose								
Hispanic or Latino	0				4	(1.5)	4	2.48
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Wrist fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Burn oral cavity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Burns first degree								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.11
Missing	0				0			
Cervical vertebral fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Eye injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Fibula fracture								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.16
Missing	0				0			
Heat illness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	4	0.25
Missing	0				0			
Post procedural fistula								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Post procedural haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Post procedural hypothyroidism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Scar								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Traumatic haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Chillblains								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Subdural haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Wrong product administered								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	2	0.18	6	(0.3)	6	0.61
Missing	0				0			
Medication error								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	1	(0.1)	1	0.09	3	(0.2)	3	0.29
Missing	0				0			
Procedural complication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Accidental underdose								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Anaemia postoperative								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Animal bite								
Hispanic or Latino	1	(0.4)	1	0.36	1	(0.4)	1	0.39
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Animal scratch								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Clavicle fracture								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Concussion								
Hispanic or Latino	0				2	(0.8)	2	1.38
Not Hispanic or Latino	0				0			
Missing	0				0			
Corneal abrasion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Crush injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Deafness traumatic								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Endotracheal intubation complication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Exposure to SARS-CoV-2								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Extra dose administered								
Hispanic or Latino	1	(0.4)	1	0.68	1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Facial bones fracture								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Gun shot wound								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Head injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Heat stroke								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Humerus fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Intentional overdose								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Intentional product use issue								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Ligament rupture								
Hispanic or Latino	1	(0.4)	2	1.41	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Lower limb fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Muscle contusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Muscle strain								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	0				5	(0.3)	5	0.40
Missing	0				0			
Nerve injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Periprocedural myocardial infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Post procedural stroke								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Post procedural swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.11
Missing	0				0			
Post-traumatic neck syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Scratch								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Seroma								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Soft tissue injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Spinal column injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Stab wound								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Sunburn								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Tendon injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Tibia fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Wound dehiscence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Wrong dose								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Eye disorders								
All								
Hispanic or Latino	17	(6.7)	17	10.90	14	(5.4)	16	9.04
Not Hispanic or Latino	158	(8.3)	207	15.90	166	(8.8)	220	17.50
Missing	1		1		0			
Diabetic retinopathy								
Hispanic or Latino	4	(1.6)	4	2.79	8	(3.1)	8	4.38
Not Hispanic or Latino	60	(3.2)	66	5.48	64	(3.4)	68	5.64
Missing	0				0			
Cataract								
Hispanic or Latino	3	(1.2)	3	2.09	1	(0.4)	1	0.39
Not Hispanic or Latino	24	(1.3)	29	1.89	26	(1.4)	29	2.05
Missing	1		1		0			
Macular oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	12	(0.6)	13	1.13	5	(0.3)	5	0.35
Missing	0				0			
Dry eye								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.46	7	(0.4)	7	0.47
Missing	0				0			
Retinopathy hypertensive								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	7	(0.4)	8	0.64	5	(0.3)	5	0.42
Missing	0				0			
Diabetic retinal oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.3)	6	0.58	10	(0.5)	11	0.86
Missing	0				0			
Blepharitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.30	0			
Missing	0				0			
Eye pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.24	3	(0.2)	3	0.20
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Glaucoma								
Hispanic or Latino	1	(0.4)	1	0.77	0			
Not Hispanic or Latino	3	(0.2)	3	0.15	6	(0.3)	6	0.52
Missing	0				0			
Vision blurred								
Hispanic or Latino	3	(1.2)	3	1.77	0			
Not Hispanic or Latino	3	(0.2)	3	0.27	5	(0.3)	5	0.34
Missing	0				0			
Non-proliferative retinopathy								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	3	(0.2)	4	0.39	3	(0.2)	3	0.30
Missing	0				0			
Arteriosclerotic retinopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Astigmatism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.16	5	(0.3)	5	0.39
Missing	0				0			
Ocular hypertension								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	3	0.27
Missing	0				0			
Retinal haemorrhage								
Hispanic or Latino	2	(0.8)	2	1.36	0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Conjunctival haemorrhage								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	2	(0.1)	2	0.20	0			
Missing	0				0			
Epiretinal membrane								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	3	(0.2)	3	0.25
Missing	0				0			
Posterior capsule opacification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Age-related macular degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vitreous haemorrhage								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	2	(0.1)	2	0.18	1	(0.1)	1	0.09
Missing	0				0			
Diplopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.09
Missing	0				0			
Vitreous detachment								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	2	0.21
Missing	0				0			
Conjunctivitis allergic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.19	0			
Missing	0				0			
Eye inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	2	0.18
Missing	0				0			
Ocular hyperaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.26	1	(0.1)	2	0.19
Missing	0				0			
Amaurosis fugax								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Angle closure glaucoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Conjunctival hyperaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Conjunctival suffusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Maculopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Retinal degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Visual impairment								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	10	0.88
Missing	0				0			
Vitreous opacities								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cataract nuclear								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Corneal erosion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.09
Missing	0				0			
Retinal vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.09
Missing	0				0			
Dry age-related macular degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Eye irritation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Lacrimation increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Myopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	3	(0.2)	3	0.21
Missing	0				0			
Retinal exudates								
Hispanic or Latino	0				1	(0.4)	1	0.69

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Retinal vein occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Acquired epiblepharon								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Asthenopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Conjunctival erosion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Optic disc vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Post thrombotic retinopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Retinal aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Retinal tear								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Presbyopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	3	(0.2)	3	0.29
Missing	0				0			
Retinal deposits								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Retinal drusen								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Retinal scar								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Chorioretinal atrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Corneal bleeding								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Cystoid macular oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Dacryoadenitis acquired								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Eye discharge								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Eye pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.19
Missing	0				0			
Eyelid oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Hypermetropia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Macular degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.19
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Macular hole								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Meibomianitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Normal tension glaucoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Ocular ischaemic syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Open angle glaucoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.18
Missing	0				0			
Ophthalmic vein thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Optic disc haemorrhage								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Photophobia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Photopsia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Pterygium								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Retinal artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Retinal detachment								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Retinopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.20
Missing	0				0			
Scintillating scotoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Uveitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Visual acuity reduced								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Vitreous degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Vitreous floaters								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				2	(0.1)	2	0.21
Missing	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
Hispanic or Latino	12	(4.6)	16	8.61	14	(5.3)	24	13.24
Not Hispanic or Latino	120	(6.3)	161	11.97	105	(5.6)	126	9.50
Missing	0				3		3	
Cough								
Hispanic or Latino	2	(0.7)	2	1.04	3	(1.2)	3	1.68
Not Hispanic or Latino	24	(1.3)	27	1.99	25	(1.3)	27	2.11
Missing	0				0			
Oropharyngeal pain								
Hispanic or Latino	1	(0.4)	1	0.66	3	(1.1)	3	2.14
Not Hispanic or Latino	23	(1.2)	25	1.74	16	(0.9)	18	1.34
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Rhinorrhoea								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	11	(0.6)	14	1.10	13	(0.7)	13	1.09
Missing	0				0			
Nasal congestion								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	9	(0.5)	9	0.55	5	(0.3)	5	0.32
Missing	0				0			
Dyspnoea								
Hispanic or Latino	0				1	(0.4)	2	1.38
Not Hispanic or Latino	9	(0.5)	9	0.65	12	(0.6)	12	0.79
Missing	0				0			
Respiratory disorder								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	8	(0.4)	8	0.76	6	(0.3)	6	0.50
Missing	0				0			
Epistaxis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.3)	10	0.91	2	(0.1)	4	0.29
Missing	0				0			
Sleep apnoea syndrome								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	6	(0.3)	6	0.35	0			
Missing	0				0			
Sinus congestion								
Hispanic or Latino	1	(0.4)	1	0.77	0			
Not Hispanic or Latino	5	(0.3)	6	0.45	2	(0.1)	2	0.16
Missing	0				0			
Productive cough								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.28	4	(0.2)	4	0.36
Missing	0				0			
Chronic obstructive pulmonary disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.32	1	(0.1)	1	0.05
Missing	0				0			
Acute respiratory failure								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	3	(0.2)	3	0.19	0			
Missing	0				0			
Rhinitis allergic								
Hispanic or Latino	0				1	(0.4)	5	1.94
Not Hispanic or Latino	2	(0.1)	2	0.16	5	(0.3)	5	0.48

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Dyspnoea exertional								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.10
Missing	0				0			
Sneezing								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	2	(0.1)	2	0.20	0			
Missing	0				0			
Upper-airway cough syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.11
Missing	0				0			
Nasal septum deviation								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	2	(0.1)	2	0.18	0			
Missing	0				0			
Emphysema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	2	0.15
Missing	0				0			
Pulmonary fibrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.20	0			
Missing	0				0			
Sinus pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.20	1	(0.1)	1	0.09
Missing	0				0			
Asthma								
Hispanic or Latino	4	(1.6)	5	2.85	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Upper respiratory tract inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Bronchial hyperreactivity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Hiccups								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Pulmonary congestion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Nasal obstruction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Respiratory failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	2	0.10
Missing	0				0			
Acquired diaphragmatic eventration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Bronchiectasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Interstitial lung disease								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Laryngeal cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Nasal dryness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Nasal turbinate hypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pulmonary embolism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pulmonary mass								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	4	(0.2)	4	0.29
Missing	0				0			
Throat irritation								
Hispanic or Latino	0				1	(0.4)	1	0.76
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Pleurisy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.11
Missing	0				0			
Pulmonary hypertension								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Acute pulmonary oedema								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Allergic bronchitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Allergic cough								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Aphonia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Bronchitis chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Bronchospasm								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			
Dry throat								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dysphonia								
Hispanic or Latino	0				1	(0.4)	2	1.21
Not Hispanic or Latino	0				0			
Missing	0				0			
Haemoptysis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Increased viscosity of upper respiratory secretion								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Lung disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Paranasal cyst								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Paranasal sinus discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Pleural disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Pleural effusion								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Pleuritic pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Respiratory tract inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

Skin and subcutaneous tissue disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Hispanic or Latino	8	(3.0)	9	4.09	17	(6.5)	21	10.24
Not Hispanic or Latino	114	(6.0)	121	9.01	110	(5.8)	133	9.98
Missing	1		1		1		1	
Rash								
Hispanic or Latino	0				4	(1.6)	5	2.25
Not Hispanic or Latino	14	(0.7)	14	1.08	7	(0.4)	7	0.41
Missing	0				0			
Eczema								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	9	(0.5)	9	0.58	7	(0.4)	7	0.58
Missing	0				0			
Urticaria								
Hispanic or Latino	0				3	(1.2)	3	1.38
Not Hispanic or Latino	7	(0.4)	7	0.51	9	(0.5)	9	0.63
Missing	0				0			
Dermatitis contact								
Hispanic or Latino	0				3	(1.1)	3	1.38
Not Hispanic or Latino	7	(0.4)	8	0.54	11	(0.6)	11	0.95
Missing	0				0			
Pruritus								
Hispanic or Latino	1	(0.4)	1	0.36	3	(1.1)	3	1.77
Not Hispanic or Latino	7	(0.4)	7	0.48	9	(0.5)	9	0.65
Missing	0				0			
Hyperhidrosis								
Hispanic or Latino	1	(0.4)	1	0.36	1	(0.4)	1	0.63
Not Hispanic or Latino	7	(0.4)	7	0.52	4	(0.2)	4	0.25
Missing	0				0			
Alopecia								
Hispanic or Latino	2	(0.8)	2	0.78	1	(0.4)	1	0.39
Not Hispanic or Latino	6	(0.3)	6	0.56	1	(0.1)	1	0.05
Missing	0				1		1	
Dermatitis								
Hispanic or Latino	2	(0.7)	2	1.13	0			
Not Hispanic or Latino	5	(0.3)	5	0.47	7	(0.4)	8	0.60
Missing	0				0			
Skin irritation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	5	0.38	3	(0.2)	3	0.21
Missing	0				0			
Dry skin								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.27	5	(0.3)	5	0.35
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cold sweat								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.29	8	(0.4)	12	1.16
Missing	0				0			
Night sweats								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	0			
Missing	0				0			
Dermatitis allergic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.09
Missing	0				0			
Ingrowing nail								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	3	(0.2)	3	0.16
Missing	0				0			
Blister								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	2	(0.1)	2	0.15
Missing	0				0			
Skin lesion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.16
Missing	0				0			
Miliaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.18	4	(0.2)	4	0.21
Missing	0				0			
Psoriasis								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	2	(0.1)	2	0.11	1	(0.1)	1	0.05
Missing	0				0			
Skin ulcer								
Hispanic or Latino	2	(0.8)	2	1.07	1	(0.4)	1	0.69
Not Hispanic or Latino	2	(0.1)	2	0.14	4	(0.2)	4	0.33
Missing	0				0			
Acne								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Rash erythematous								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Diabetic foot								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.10
Missing	0				0			
Erythema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	4	(0.2)	4	0.31
Missing	0				0			
Livedo reticularis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Nail bed inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Dermal cyst								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.11	3	(0.2)	3	0.25
Missing	0				0			
Hidradenitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Ingrown hair								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Lichen sclerosus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Macule								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Xeroderma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Rash papular								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Angioedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.21
Missing	0				0			
Granuloma annulare								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Hyperkeratosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.20
Missing	1		1		0			
Lipodystrophy acquired								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Myxoid cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Skin exfoliation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Skin fissures								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Urticaria contact								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Intertrigo								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Umbilical haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Decubitus ulcer								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Ecchymosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	2	0.11
Missing	0				0			
Skin odour abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Actinic keratosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Alopecia areata								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Asteatosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Chronic spontaneous urticaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Cold urticaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Dermatitis atopic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.21
Missing	0				0			
Drug eruption								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Haemorrhage subcutaneous								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lentigo								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Leukoplakia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Lipohypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Neurodermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Pruritus allergic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Purpura								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Rash maculo-papular								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Seborrhoea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Skin discolouration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Skin reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Telangiectasia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Urticaria thermal								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Metabolism and nutrition disorders								
All								
Hispanic or Latino	23	(9.0)	25	13.36	24	(9.0)	27	14.38
Not Hispanic or Latino	109	(5.7)	138	9.20	108	(5.7)	140	9.70
Missing	0				2		2	
Vitamin D deficiency								
Hispanic or Latino	1	(0.4)	1	0.39	2	(0.7)	2	0.99
Not Hispanic or Latino	16	(0.8)	16	0.92	12	(0.6)	12	0.77
Missing	0				0			
Hypoglycaemia								
Hispanic or Latino	2	(0.8)	3	2.09	0			
Not Hispanic or Latino	16	(0.8)	23	1.96	22	(1.2)	39	2.80
Missing	0				1		1	
Hyperlipidaemia								
Hispanic or Latino	1	(0.4)	1	0.39	3	(1.2)	3	1.41
Not Hispanic or Latino	13	(0.7)	13	0.86	10	(0.5)	10	0.64
Missing	0				0			
Dyslipidaemia								
Hispanic or Latino	9	(3.5)	9	4.42	8	(2.9)	8	4.40
Not Hispanic or Latino	12	(0.6)	13	0.95	9	(0.5)	9	0.68
Missing	0				0			
Vitamin B12 deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	11	(0.6)	11	0.56	1	(0.1)	1	0.05
Missing	0				0			
Hypertriglyceridaemia								
Hispanic or Latino	2	(0.8)	2	1.09	3	(1.1)	3	1.90
Not Hispanic or Latino	8	(0.4)	8	0.50	5	(0.3)	5	0.31
Missing	0				0			
Iron deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.26	3	(0.2)	3	0.15
Missing	0				0			
Hyperglycaemia								
Hispanic or Latino	1	(0.4)	1	0.70	2	(0.7)	2	0.99
Not Hispanic or Latino	5	(0.3)	6	0.46	12	(0.6)	12	0.91
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperkalaemia								
Hispanic or Latino	3	(1.2)	3	1.46	1	(0.4)	1	0.69
Not Hispanic or Latino	5	(0.3)	6	0.39	9	(0.5)	9	0.63
Missing	0				0			
Gout								
Hispanic or Latino	0				2	(0.8)	2	0.78
Not Hispanic or Latino	4	(0.2)	5	0.26	4	(0.2)	5	0.26
Missing	0				0			
Hyperuricaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.30	3	(0.2)	3	0.15
Missing	0				0			
Increased appetite								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	3	(0.2)	3	0.16	5	(0.3)	6	0.48
Missing	0				0			
Decreased appetite								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.69
Not Hispanic or Latino	3	(0.2)	3	0.19	4	(0.2)	4	0.21
Missing	0				0			
Diabetes mellitus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Folate deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Zinc deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Hyponatraemia								
Hispanic or Latino	1	(0.4)	1	0.68	1	(0.4)	1	0.69
Not Hispanic or Latino	2	(0.1)	2	0.20	0			
Missing	0				0			
Fluid retention								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Hypercholesterolaemia								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	2	(0.1)	2	0.14	4	(0.2)	4	0.34
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypokalaemia								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Diabetes mellitus inadequate control								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Hypernatraemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Magnesium deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Malnutrition								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Vitamin B complex deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Obesity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.20
Missing	0				0			
Dehydration								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	3	0.27
Missing	0				0			
Hypoalbuminaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Abnormal weight gain								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Appetite disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Electrolyte imbalance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Food craving								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Hyperammonaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Hypercalcaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Insulin resistance								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Lactic acidosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Lipomatosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Metabolic acidosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Metabolic disorder								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Cardiac disorders								
All								
Hispanic or Latino	6	(2.3)	8	3.94	4	(1.5)	10	5.69
Not Hispanic or Latino	88	(4.6)	124	7.86	80	(4.2)	105	6.75
Missing	1		1		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Atrial fibrillation								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.39
Not Hispanic or Latino	12	(0.6)	13	0.78	5	(0.3)	5	0.30
Missing	0				0			
Coronary artery disease								
Hispanic or Latino	2	(0.8)	2	1.07	1	(0.4)	1	0.39
Not Hispanic or Latino	10	(0.5)	10	0.56	9	(0.5)	9	0.54
Missing	0				0			
Ventricular extrasystoles								
Hispanic or Latino	0				0			
Not Hispanic or Latino	8	(0.4)	8	0.59	2	(0.1)	3	0.15
Missing	0				0			
Acute myocardial infarction								
Hispanic or Latino	1	(0.4)	1	0.68	1	(0.4)	1	0.39
Not Hispanic or Latino	8	(0.4)	8	0.49	7	(0.4)	7	0.49
Missing	0				0			
Cardiac failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	8	(0.4)	8	0.46	3	(0.2)	4	0.34
Missing	0				0			
Angina pectoris								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	7	(0.4)	7	0.46	3	(0.2)	3	0.15
Missing	0				0			
Myocardial infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.3)	6	0.43	4	(0.2)	4	0.21
Missing	0				0			
Palpitations								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	6	(0.3)	6	0.41	7	(0.4)	7	0.52
Missing	0				0			
Acute coronary syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.21	0			
Missing	0				0			
Cardiac failure congestive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.25	2	(0.1)	3	0.28
Missing	0				0			
Tachycardia								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	3	(0.2)	3	0.15	6	(0.3)	6	0.39

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Left ventricular hypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.16	2	(0.1)	2	0.15
Missing	0				0			
Mitral valve incompetence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	2	(0.1)	2	0.10
Missing	0				0			
Arrhythmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	3	(0.2)	3	0.20
Missing	0				0			
Supraventricular tachycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Bundle branch block right								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	7	(0.4)	8	0.55
Missing	0				0			
Angina unstable								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	2	(0.1)	2	0.11	2	(0.1)	2	0.16
Missing	0				0			
Cardiac failure chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	1	(0.1)	1	0.05
Missing	0				0			
Coronary artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	0			
Missing	0				0			
Bundle branch block left								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Left ventricular dysfunction								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.09
Missing	0				0			
Myocardial ischaemia								
Hispanic or Latino	1	(0.4)	1	0.68	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	2	(0.1)	2	0.14	3	(0.2)	3	0.21
Missing	0				0			
Supraventricular extrasystoles								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	2	(0.1)	2	0.10
Missing	1		1		0			
Arteriosclerosis coronary artery								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cardiomegaly								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Cardiovascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Cardiac flutter								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Aortic valve incompetence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Atrial flutter								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Atrial thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Bradycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.14
Missing	0				0			
Cardiac ventricular thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Chronic coronary syndrome								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Diastolic dysfunction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Left atrial dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Pericardial effusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pericarditis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Sinus tachycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.15
Missing	0				0			
Tricuspid valve incompetence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.15
Missing	0				0			
Aortic valve sclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Left atrial enlargement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	2	0.15
Missing	0				0			
Atrioventricular block first degree								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Cardio-respiratory arrest								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Mitral valve stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Aortic valve calcification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.15
Missing	0				0			
Atrial enlargement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Atrioventricular block complete								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cardiac arrest								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Cardiac dysfunction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cardiac failure acute								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cardiac perfusion defect								
Hispanic or Latino	0				1	(0.4)	2	1.38
Not Hispanic or Latino	0				0			
Missing	0				0			
Coronary artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Sinus arrhythmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Sinus bradycardia								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Subendocardial ischaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Ventricular arrhythmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Ventricular tachycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Investigations								
All								
Hispanic or Latino	9	(3.5)	11	5.19	14	(5.5)	14	7.25
Not Hispanic or Latino	85	(4.5)	98	7.28	65	(3.4)	74	5.70
Missing	0				0			
Weight increased								
Hispanic or Latino	3	(1.2)	3	1.75	6	(2.3)	6	3.23
Not Hispanic or Latino	17	(0.9)	17	1.17	12	(0.6)	12	0.80
Missing	0				0			
Blood creatinine increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	8	(0.4)	8	0.64	0			
Missing	0				0			
SARS-CoV-2 test positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.55	4	(0.2)	4	0.43
Missing	0				0			
Blood pressure increased								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	5	(0.3)	5	0.41	3	(0.2)	3	0.20
Missing	0				0			
Weight decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.21	2	(0.1)	2	0.16
Missing	0				0			
Alanine aminotransferase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.32	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood immunoglobulin E increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.15	3	(0.2)	3	0.15
Missing	0				0			
Blood triglycerides increased								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.39
Not Hispanic or Latino	3	(0.2)	3	0.25	2	(0.1)	2	0.10
Missing	0				0			
Liver function test increased								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	3	(0.2)	3	0.23	0			
Missing	0				0			
Blood alkaline phosphatase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	0			
Missing	0				0			
Prostatic specific antigen increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			
Electrocardiogram abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.14
Missing	0				0			
Hepatic enzyme increased								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.11
Missing	0				0			
Low density lipoprotein increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.19
Missing	0				0			
Occult blood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Aspartate aminotransferase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	1	(0.1)	1	0.05
Missing	0				0			
Blood urine present								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	3	0.15	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bone density decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Electrocardiogram ST segment abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Electrocardiogram T wave inversion								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
QRS axis abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Thyroid function test abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Transaminases increased								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Angiogram								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Blood cholesterol increased								
Hispanic or Latino	2	(0.8)	2	0.78	0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Blood testosterone decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Heart rate increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Hepatitis B virus test positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Mycobacterium tuberculosis complex test positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Occult blood positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Blood creatine increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Blood creatine phosphokinase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Body temperature increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Glycosylated haemoglobin increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	3	0.15
Missing	0				0			
Red blood cell count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Transferrin saturation decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Catheterisation cardiac								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Eosinophil count increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	2	0.21
Missing	0				0			
Liver function test abnormal								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	2	0.18
Missing	0				0			
Arthroscopy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Blood potassium increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Monocyte count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Monofilament pressure perception test								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Amylase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Antinuclear antibody positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Blood glucose decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Blood glucose fluctuation								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Blood glucose increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.16
Missing	0				0			
Blood pressure decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood uric acid increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Breath sounds abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Carbohydrate antigen 19-9 increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cardiac murmur								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Cardiac stress test abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Ejection fraction decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Electrocardiogram P wave biphasic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Electrocardiogram repolarisation abnormality								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Electrocardiogram ST segment depression								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Free fatty acids increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Glomerular filtration rate decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Grip strength decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Haematocrit increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Haemoglobin decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.16
Missing	0				0			
Haemoglobin increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
International normalised ratio abnormal								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
International normalised ratio decreased								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
International normalised ratio increased								
Hispanic or Latino	1	(0.4)	2	0.78	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Intraocular pressure increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Lipase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Lipids abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Lipids increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Platelet count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.28
Missing	0				0			
Vitamin D decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
White blood cell count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Vascular disorders								
All								
Hispanic or Latino	12	(4.6)	12	5.82	4	(1.5)	4	2.50
Not Hispanic or Latino	67	(3.5)	76	5.27	75	(4.0)	93	6.44
Missing	0				1		2	
Hypertension								
Hispanic or Latino	7	(2.7)	7	3.30	3	(1.1)	3	1.81
Not Hispanic or Latino	30	(1.6)	30	2.26	35	(1.9)	40	2.85
Missing	0				0			
Hypotension								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	5	(0.3)	5	0.30	3	(0.2)	3	0.20
Missing	0				0			
Peripheral arterial occlusive disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	5	0.34	2	(0.1)	2	0.11
Missing	0				0			
Superficial vein thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.16	0			
Missing	0				0			
Arteriosclerosis								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	3	(0.2)	3	0.21	7	(0.4)	7	0.49
Missing	0				0			
Peripheral coldness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.16	1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Orthostatic hypotension								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.18	0			
Missing	0				0			
Haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	3	(0.2)	3	0.24
Missing	0				0			
Peripheral artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	5	0.38	0			
Missing	0				0			
Peripheral venous disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	3	(0.2)	3	0.20
Missing	0				0			
Blood pressure inadequately controlled								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.10
Missing	0				0			
Hot flush								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Venous stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Aortic arteriosclerosis								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.24
Missing	0				1		1	
Aortic stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Brachiocephalic arteriosclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Missing	0				0			
Flushing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Hypertensive urgency								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	2	0.10
Missing	0				0			
Peripheral artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Peripheral vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Varicose vein								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.21
Missing	0				0			
Deep vein thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Diabetic vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	2	0.19
Missing	0				0			
Hypertensive crisis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	4	0.33
Missing	0				0			
Arterial insufficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Aortic aneurysm								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Aortic dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Blood pressure fluctuation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Iliac artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Intermittent claudication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Macroangiopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Neovascularisation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Peripheral artery aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Peripheral ischaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Phlebitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Thrombophlebitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Varicose ulceration								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Renal and urinary disorders								
All								
Hispanic or Latino	3	(1.2)	5	3.11	9	(3.4)	9	4.22
Not Hispanic or Latino	51	(2.7)	60	4.19	44	(2.3)	58	3.79
Missing	0				1		3	
Renal cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.51	5	(0.3)	5	0.35
Missing	0				0			
Nephrolithiasis								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	5	(0.3)	5	0.26	2	(0.1)	3	0.20
Missing	0				1		2	
Pollakiuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.41	2	(0.1)	2	0.11
Missing	0				0			
Renal impairment								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	4	(0.2)	4	0.28	2	(0.1)	2	0.10
Missing	0				0			
Renal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	0			
Missing	0				0			
Dysuria								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	3	(0.2)	4	0.21	4	(0.2)	4	0.25
Missing	0				0			
Diabetic nephropathy								
Hispanic or Latino	0				2	(0.7)	2	1.21
Not Hispanic or Latino	3	(0.2)	3	0.20	2	(0.1)	2	0.21
Missing	0				0			
Chronic kidney disease								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.69
Not Hispanic or Latino	3	(0.2)	3	0.24	5	(0.3)	5	0.32
Missing	0				0			
Ureterolithiasis								
Hispanic or Latino	0				1	(0.4)	1	0.39

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	3	(0.2)	3	0.19	2	(0.1)	2	0.10
Missing	0				0			
Acute kidney injury								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.2)	4	0.20
Missing	0				0			
Nocturia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	2	(0.1)	2	0.11
Missing	0				0			
Microalbuminuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.05
Missing	0				0			
Urine odour abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.09
Missing	0				0			
Hypertonic bladder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Proteinuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Urinary incontinence								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.10
Missing	0				0			
Urinary tract disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Bladder prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Hydronephrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Nephrotic syndrome								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Polyuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Urethral stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Calculus urinary								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Pyelocaliectasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Renal colic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.24
Missing	0				0			
Chromaturia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Renal failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Bladder mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Cystitis haemorrhagic								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Haematuria								
Hispanic or Latino	1	(0.4)	2	1.36	0			
Not Hispanic or Latino	0				4	(0.2)	4	0.21
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hydrocalyx								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.20
Missing	0				0			
Hypertensive nephropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Micturition urgency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Nephropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Renal mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Strangury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Stress urinary incontinence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Urinary retention								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Urinary tract inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Urinary tract obstruction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Psychiatric disorders								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	7	(2.7)	7	3.98	6	(2.3)	7	4.30
Not Hispanic or Latino	34	(1.8)	38	2.55	36	(1.9)	37	2.76
Missing	0				1		2	
Insomnia								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	10	(0.5)	10	0.73	5	(0.3)	5	0.30
Missing	0				1		2	
Depression								
Hispanic or Latino	0				2	(0.8)	2	1.45
Not Hispanic or Latino	8	(0.4)	8	0.49	10	(0.5)	10	0.75
Missing	0				0			
Sleep disorder								
Hispanic or Latino	0				2	(0.8)	2	1.32
Not Hispanic or Latino	5	(0.3)	5	0.32	2	(0.1)	2	0.19
Missing	0				0			
Anxiety								
Hispanic or Latino	1	(0.4)	1	0.70	2	(0.8)	2	1.15
Not Hispanic or Latino	5	(0.3)	5	0.32	8	(0.4)	8	0.58
Missing	0				0			
Depressed mood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Irritability								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Adjustment disorder with mixed anxiety and depressed mood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Disorientation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Listless								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Post-traumatic stress disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Mental status changes								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Agitation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Adjustment disorder								
Hispanic or Latino	1	(0.4)	1	0.66	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Adjustment disorder with depressed mood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Affect lability								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Anxiety disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Attention deficit hyperactivity disorder								
Hispanic or Latino	1	(0.4)	1	0.77	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Bruxism								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				0			
Missing	0				0			
Drug abuse								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Drug dependence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Emotional distress								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Fear								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.18
Missing	0				0			
Major depression								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Mixed anxiety and depressive disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Mood swings								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Nightmare								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Persistent depressive disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Phobia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Stress								
Hispanic or Latino	1	(0.4)	1	0.36	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Hispanic or Latino	3	(1.2)	3	2.15	0			
Not Hispanic or Latino	32	(1.7)	40	2.66	28	(1.5)	41	2.68
Missing	0				1		2	
Colon adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Metastases to liver								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	1	(0.1)	1	0.05
Missing	0				0			
Haemangioma of liver								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Seborrhoeic keratosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.16	0			
Missing	0				0			
Pancreatic neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Colorectal cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Adenocarcinoma pancreas								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Bladder cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Eye naevus								
Hispanic or Latino	2	(0.8)	2	1.45	0			
Not Hispanic or Latino	1	(0.1)	2	0.10	0			
Missing	0				0			
Invasive ductal breast carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Invasive lobular breast carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Lipoma								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pancreatic carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Renal neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Squamous cell carcinoma of skin								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Benign neoplasm of thyroid gland								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Melanocytic naevus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Chronic myeloid leukaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Gastric cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Acrochordon								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Basal cell carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Missing	0				0			
Glioblastoma multiforme								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Neoplasm skin								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Oral fibroma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Prostate cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Salivary gland neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Osteoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Small cell lung cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Bladder papilloma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Lung cancer metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Skin papilloma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Adenocarcinoma of colon								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Adrenal adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				1		1	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Benign renal neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.16
Missing	0				0			
Bowen's disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Breast cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Breast cancer metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Colon cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Colon cancer stage II								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Dysplastic naevus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Endometrial adenocarcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Gastrointestinal tract adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Hepatocellular carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Invasive breast carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lung adenocarcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				1		1	
Lymphangioma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Malignant melanoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Malignant melanoma in situ								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Malignant peritoneal neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Metastases to bone marrow								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Metastases to lymph nodes								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Myxoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Ovarian cancer metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Pancreatic carcinoma metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Prostatic adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Renal cell carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Renal hamartoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Small intestine neuroendocrine tumour								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Uterine cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Uterine leiomyoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				5	(0.3)	5	0.41
Missing	0				0			
Blood and lymphatic system disorders								
All								
Hispanic or Latino	5	(2.0)	5	2.89	9	(3.4)	9	4.68
Not Hispanic or Latino	31	(1.6)	33	2.38	24	(1.3)	24	1.64
Missing	0				0			
Anaemia								
Hispanic or Latino	4	(1.6)	4	2.50	6	(2.3)	6	3.14
Not Hispanic or Latino	16	(0.8)	18	1.30	8	(0.4)	8	0.50
Missing	0				0			
Lymphadenopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.21	2	(0.1)	2	0.16
Missing	0				0			
Eosinophilia								
Hispanic or Latino	1	(0.4)	1	0.39	1	(0.4)	1	0.39
Not Hispanic or Latino	2	(0.1)	2	0.14	1	(0.1)	1	0.09
Missing	0				0			
Iron deficiency anaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	4	(0.2)	4	0.30
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Leukocytosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	3	(0.2)	3	0.15
Missing	0				0			
Splenomegaly								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Lymphadenitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Polycythaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Thrombocytopenia								
Hispanic or Latino	0				1	(0.4)	1	0.76
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Blood loss anaemia								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Lymphadenopathy mediastinal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Leukopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Hypochromic anaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Normocytic anaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Pancytopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Thrombocytosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Ear and labyrinth disorders								
All								
Hispanic or Latino	1	(0.4)	1	0.70	1	(0.4)	1	0.39
Not Hispanic or Latino	27	(1.4)	30	1.93	23	(1.2)	24	1.77
Missing	0				0			
Vertigo								
Hispanic or Latino	0				0			
Not Hispanic or Latino	10	(0.5)	11	0.72	9	(0.5)	10	0.70
Missing	0				0			
Ear pain								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	5	(0.3)	5	0.35	2	(0.1)	2	0.20
Missing	0				0			
Deafness bilateral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			
Vertigo positional								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			
Hypoacusis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	3	(0.2)	3	0.15
Missing	0				0			
Tinnitus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	2	(0.1)	2	0.14
Missing	0				0			
External ear pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Meniere's disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Deafness neurosensory								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Ear inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Eustachian tube dysfunction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Cerumen impaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Deafness unilateral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Ear discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Middle ear inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Motion sickness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Presbyacusis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Reproductive system and breast disorders								
All								
Hispanic or Latino	7	(2.8)	7	4.62	4	(1.5)	4	2.29
Not Hispanic or Latino	26	(1.4)	26	1.71	23	(1.2)	29	1.95
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Benign prostatic hyperplasia								
Hispanic or Latino	1	(0.4)	1	0.68	1	(0.4)	1	0.69
Not Hispanic or Latino	5	(0.3)	5	0.35	2	(0.1)	2	0.10
Missing	0				0			
Erectile dysfunction								
Hispanic or Latino	1	(0.4)	1	0.36	1	(0.4)	1	0.60
Not Hispanic or Latino	4	(0.2)	4	0.25	0			
Missing	0				0			
Uterine polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.10	0			
Missing	0				0			
Atrophic vulvovaginitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Ejaculation failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Menstruation irregular								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pelvic discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Dysmenorrhoea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.16
Missing	0				0			
Prostatomegaly								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Cervical polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Prostatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast mass								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Menopausal symptoms								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Ovarian cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Pruritus genital								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.14
Missing	0				0			
Uterine prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Missing	0				0			
Vulvovaginal pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.10
Missing	0				0			
Prostatic calcification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Breast pain								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Colpocele								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Ectropion of cervix								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Fibrocystic breast disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Galactorrhoea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Genital prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Intermenstrual bleeding								
Hispanic or Latino	2	(0.8)	2	1.41	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Menopausal disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Menstruation delayed								
Hispanic or Latino	1	(0.4)	1	0.70	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Ovarian disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Penile pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Penile rash								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.11
Missing	0				0			
Premenstrual syndrome								
Hispanic or Latino	1	(0.4)	1	0.77	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Testicular cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Uterine enlargement								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Vaginal discharge								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Vaginal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Vulvovaginal dryness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Hepatobiliary disorders								
All								
Hispanic or Latino	2	(0.8)	3	1.17	1	(0.4)	1	0.39
Not Hispanic or Latino	22	(1.2)	28	2.10	24	(1.3)	28	2.08
Missing	0				0			
Hepatic steatosis								
Hispanic or Latino	1	(0.4)	1	0.39	0			
Not Hispanic or Latino	10	(0.5)	10	0.73	10	(0.5)	10	0.70
Missing	0				0			
Cholelithiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.16	1	(0.1)	1	0.05
Missing	0				0			
Gallbladder polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.20	3	(0.2)	3	0.31
Missing	0				0			
Hepatomegaly								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.14	0			
Missing	0				0			
Hepatic mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Hepatic calcification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Hypertransaminasaemia								
Hispanic or Latino	1	(0.4)	2	0.78	0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Alcoholic liver disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Gallbladder cholesterolosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Liver disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Non-alcoholic steatohepatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Cholecystitis chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Hyperplastic cholecystopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Cholecystitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Hepatic function abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	2	(0.1)	2	0.15
Missing	0				0			
Bile duct stone								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.10
Missing	0				0			
Biliary colic								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Biliary dyskinesia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Gallbladder disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hepatic cirrhosis								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Hepatic cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Nonalcoholic fatty liver disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Steatohepatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Hispanic or Latino	2	(0.8)	2	1.35	5	(1.9)	5	2.70
Not Hispanic or Latino	12	(0.6)	13	0.91	11	(0.6)	12	0.93
Missing	0				0			
Seasonal allergy								
Hispanic or Latino	2	(0.8)	2	1.35	3	(1.1)	3	1.70
Not Hispanic or Latino	6	(0.3)	6	0.31	6	(0.3)	6	0.45
Missing	0				0			
Hypersensitivity								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	3	(0.2)	3	0.31	0			
Missing	0				0			
Food allergy								
Hispanic or Latino	0				1	(0.4)	1	0.39
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Anaphylactic reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Missing	0				0			
Allergy to arthropod bite								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	2	(0.1)	2	0.19
Missing	0				0			
Drug hypersensitivity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Allergy to arthropod sting								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Immunisation reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.11
Missing	0				0			
Surgical and medical procedures								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.3)	6	0.50	6	(0.3)	6	0.39
Missing	0				0			
Cardiac pacemaker replacement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	1	(0.1)	1	0.09
Missing	0				0			
Cardiac ablation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Skin neoplasm excision								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.05
Missing	0				0			
Knee operation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Shoulder operation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Tooth extraction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Large intestinal polypectomy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Removal of foreign body								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Spinal operation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Toe amputation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Endocrine disorders								
All								
Hispanic or Latino	1	(0.4)	1	0.68	2	(0.7)	2	1.29
Not Hispanic or Latino	5	(0.3)	5	0.30	17	(0.9)	17	1.10
Missing	0				0			
Thyroid mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.11	2	(0.1)	2	0.15
Missing	0				0			
Autoimmune thyroiditis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Hypothyroidism								
Hispanic or Latino	1	(0.4)	1	0.68	0			
Not Hispanic or Latino	1	(0.1)	1	0.05	5	(0.3)	5	0.35
Missing	0				0			
Hypogonadism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Missing	0				0			
Adrenal mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Adrenocortical insufficiency acute								
Hispanic or Latino	0				1	(0.4)	1	0.69
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Goitre								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.11
Missing	0				0			
Hyperplasia adrenal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperprolactinaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Hyperthyroidism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.10
Missing	0				0			
Inappropriate antidiuretic hormone secretion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Secondary hypogonadism								
Hispanic or Latino	0				1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Hispanic or Latino	3	(1.2)	3	1.80	1	(0.4)	1	0.60
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.2)	4	0.21
Missing	0				0			
Hydrocele								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.05	0			
Missing	0				0			
Corneal dystrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Cystic fibrosis lung								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.09	0			
Missing	0				0			
Atrial septal defect								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Congenital syphilitic osteochondritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Hypertrophic cardiomyopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Myotonic dystrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.05
Missing	0				0			
Type V hyperlipidaemia								
Hispanic or Latino	3	(1.2)	3	1.80	1	(0.4)	1	0.60
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Social circumstances								
All								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			
Menopause								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.09
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.28 Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Hispanic or Latino	247				254			
Not Hispanic or Latino	1618				1607			
Missing	15				17			
PYE (years)								
Hispanic or Latino	185.98				190.17			
Not Hispanic or Latino	1344.03				1336.23			
Missing	8.92				10.06			
Events								
Hispanic or Latino	162	(65.9)	439	252.06	153	(60.2)	455	254.22
Not Hispanic or Latino	972	(60.1)	3020	236.97	907	(56.4)	2774	218.07
Missing	5		19		13		30	
Infections and infestations								
All								
Hispanic or Latino	84	(34.3)	113	67.46	82	(32.3)	120	66.23
Not Hispanic or Latino	457	(28.3)	657	51.88	434	(27.0)	628	48.28
Missing	3		3		7		9	
COVID-19								
Hispanic or Latino	31	(12.7)	32	18.91	29	(11.5)	30	15.89
Not Hispanic or Latino	121	(7.5)	123	9.35	127	(7.9)	131	9.32
Missing	0				4		4	
Nasopharyngitis								
Hispanic or Latino	8	(3.3)	9	5.19	5	(1.9)	5	3.00
Not Hispanic or Latino	74	(4.6)	89	7.32	72	(4.5)	85	6.93
Missing	1		1		2		2	
Upper respiratory tract infection								
Hispanic or Latino	6	(2.4)	6	3.60	6	(2.4)	6	3.23
Not Hispanic or Latino	56	(3.5)	69	5.20	39	(2.4)	42	3.29
Missing	0				0			
Urinary tract infection								
Hispanic or Latino	4	(1.6)	4	2.24	12	(4.8)	13	6.00
Not Hispanic or Latino	32	(2.0)	35	2.87	32	(2.0)	35	2.64
Missing	1		1		0			
Bronchitis								
Hispanic or Latino	1	(0.4)	1	0.37	1	(0.4)	1	0.72
Not Hispanic or Latino	25	(1.5)	26	2.18	16	(1.0)	16	1.27
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gastroenteritis								
Hispanic or Latino	6	(2.4)	6	3.28	4	(1.6)	4	2.15
Not Hispanic or Latino	20	(1.2)	20	1.89	11	(0.7)	12	1.11
Missing	0				1		1	
Influenza								
Hispanic or Latino	12	(5.1)	15	10.60	11	(4.2)	12	7.84
Not Hispanic or Latino	15	(0.9)	15	1.35	17	(1.1)	19	1.77
Missing	1		1		0			
Pneumonia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	14	(0.9)	14	1.17	6	(0.4)	6	0.51
Missing	0				0			
COVID-19 pneumonia								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.63
Not Hispanic or Latino	13	(0.8)	13	1.02	9	(0.6)	9	0.65
Missing	0				0			
Sinusitis								
Hispanic or Latino	3	(1.2)	3	1.49	3	(1.2)	4	1.93
Not Hispanic or Latino	11	(0.7)	13	1.03	14	(0.9)	16	1.26
Missing	0				0			
Pharyngitis								
Hispanic or Latino	6	(2.4)	6	3.07	8	(3.2)	9	4.88
Not Hispanic or Latino	10	(0.6)	12	0.84	9	(0.6)	11	0.87
Missing	0				0			
Herpes zoster								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.41
Not Hispanic or Latino	9	(0.6)	9	0.65	14	(0.9)	15	1.10
Missing	0				0			
Respiratory tract infection viral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	9	(0.6)	10	0.94	8	(0.5)	9	0.88
Missing	0				0			
Cystitis								
Hispanic or Latino	3	(1.2)	3	2.15	1	(0.4)	1	0.72
Not Hispanic or Latino	9	(0.6)	10	0.75	15	(0.9)	17	1.33
Missing	0				0			
Respiratory tract infection								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	8	(0.5)	8	0.63	5	(0.3)	5	0.40
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tooth infection								
Hispanic or Latino	1	(0.4)	2	1.38	2	(0.8)	2	1.28
Not Hispanic or Latino	7	(0.4)	8	0.57	6	(0.4)	6	0.56
Missing	0				0			
Otitis media								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	7	(0.4)	7	0.65	3	(0.2)	3	0.23
Missing	0				0			
Rhinitis								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.63
Not Hispanic or Latino	6	(0.4)	6	0.38	6	(0.4)	8	0.68
Missing	0				0			
Conjunctivitis								
Hispanic or Latino	2	(0.8)	2	0.78	0			
Not Hispanic or Latino	6	(0.4)	6	0.46	7	(0.4)	7	0.58
Missing	0				0			
Viral infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.4)	6	0.46	9	(0.6)	12	0.78
Missing	0				0			
Tooth abscess								
Hispanic or Latino	1	(0.4)	1	0.69	1	(0.4)	2	1.43
Not Hispanic or Latino	6	(0.4)	6	0.51	6	(0.4)	6	0.42
Missing	0				0			
Gastroenteritis viral								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	5	(0.3)	5	0.36	3	(0.2)	3	0.18
Missing	0				0			
Vaginal infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.43	3	(0.2)	3	0.23
Missing	0				0			
Acute sinusitis								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	4	(0.2)	4	0.24	3	(0.2)	3	0.23
Missing	0				0			
Coronavirus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.25	4	(0.2)	6	0.47
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Fungal infection								
Hispanic or Latino	3	(1.2)	3	1.84	2	(0.8)	2	1.12
Not Hispanic or Latino	4	(0.2)	5	0.40	0			
Missing	0				0			
Lower respiratory tract infection								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	4	(0.2)	4	0.25	2	(0.1)	4	0.25
Missing	0				0			
Periodontitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.34	5	(0.3)	5	0.41
Missing	0				1		1	
Cellulitis								
Hispanic or Latino	1	(0.4)	1	0.69	1	(0.4)	2	1.30
Not Hispanic or Latino	3	(0.2)	3	0.18	7	(0.4)	7	0.57
Missing	0				0			
Ear infection								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.63
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.2)	4	0.29
Missing	0				0			
Tonsillitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	2	(0.1)	2	0.17
Missing	0				0			
Vulvovaginal candidiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	4	0.29	4	(0.2)	4	0.25
Missing	0				0			
Respiratory syncytial virus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	0			
Missing	0				0			
Localised infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	2	(0.1)	2	0.17
Missing	0				0			
Genital infection								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	3	(0.2)	3	0.22	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Erysipelas								
Hispanic or Latino	0				1	(0.4)	2	1.26
Not Hispanic or Latino	3	(0.2)	3	0.23	1	(0.1)	1	0.06
Missing	0				0			
Wound infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	1	(0.1)	1	0.11
Missing	0				0			
Acarodermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	4	(0.2)	4	0.24
Missing	0				0			
Fungal skin infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.11
Missing	0				0			
Helicobacter infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	2	0.17
Missing	0				0			
Subcutaneous abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	2	(0.1)	3	0.19
Missing	0				0			
Laryngitis								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.63
Not Hispanic or Latino	2	(0.1)	2	0.12	3	(0.2)	3	0.23
Missing	0				0			
Gingivitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.19	4	(0.3)	4	0.39
Missing	0				0			
Hordeolum								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	3	(0.2)	3	0.28
Missing	0				0			
Onychomycosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	4	(0.2)	4	0.24
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Paronychia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	3	0.33
Missing	0				0			
Osteomyelitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Gastrointestinal infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	3	(0.2)	4	0.24
Missing	0				0			
Skin infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.11
Missing	0				0			
Oral herpes								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.32	2	(0.1)	2	0.13
Missing	0				0			
Sepsis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	1	(0.1)	1	0.06
Missing	0				0			
Chronic sinusitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Missing	0				0			
Clostridium difficile colitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Clostridium difficile infection								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Ear infection fungal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gangrene								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Nail infection								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	2	0.12	0			
Missing	0				0			
Otitis externa								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.18
Missing	0				0			
Peritonsillar abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Post-acute COVID-19 syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	2	0.12	0			
Missing	0				0			
Pyelonephritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Skin candida								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Tinea cruris								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Viral pharyngitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Abscess limb								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Anal abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Enteritis infectious								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Kidney infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Paraspinal abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Pulpitis dental								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	1	(0.1)	1	0.10	3	(0.2)	3	0.28
Missing	0				0			
Pustule								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Tinea versicolour								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Varicella zoster virus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Vulvitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Asymptomatic COVID-19								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bacterial infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Balanitis candida								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Candida infection								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Chlamydial infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Chronic tonsillitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Missing	0				0			
Dermatophytosis of nail								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Escherichia urinary tract infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Folliculitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Furuncle								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	2	0.13	1	(0.1)	1	0.06
Missing	0				0			
Helicobacter gastritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Herpes simplex								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Herpes virus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Infected bite								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Laryngopharyngitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	2	0.12
Missing	0				0			
Mastitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Oropharyngeal candidiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Otitis media chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pericoronitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Purulence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Tinea infection								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tracheitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Urethritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Viral upper respiratory tract infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Missing	0				0			
Vulvovaginal mycotic infection								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Abscess								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Missing	0				0			
Bacteraemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Cholecystitis infective								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Infected dermal cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Pneumonia viral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Pulmonary tuberculoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Viral tracheitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Escherichia bacteraemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Injection site abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Postoperative wound infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Suspected COVID-19								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Tinea pedis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Abdominal abscess								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Appendicitis								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Bartholinitis								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Body tinea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast abscess								
Hispanic or Latino	0				2	(0.8)	2	1.12
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Breast cellulitis								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Campylobacter gastroenteritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Chronic hepatitis C								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Diabetic foot infection								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Diverticulitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				5	(0.3)	5	0.31
Missing	0				0			
Empyema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Endophthalmitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Epididymitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Eye infection								
Hispanic or Latino	0				1	(0.4)	1	0.65
Not Hispanic or Latino	0				2	(0.1)	2	0.22
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eye infection bacterial								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Fungal balanitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Gastroenteritis norovirus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Genital candidiasis								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Genital infection fungal								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Giardiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Herpes dermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Herpes zoster infection neurological								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Infective iritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Labyrinthitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lyme disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Oophoritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Oral candidiasis								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Otitis media acute								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.23
Missing	0				0			
Parotitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Peri-implantitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Pharyngotonsillitis								
Hispanic or Latino	1	(0.4)	1	0.71	2	(0.8)	3	1.21
Not Hispanic or Latino	0				0			
Missing	0				0			
Post procedural infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Rotavirus infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Salpingitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Sinusitis bacterial								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Skin bacterial infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Soft tissue infection								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Sweat gland infection								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Urosepsis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Varicella								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Viral rhinitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Gastrointestinal disorders								
All								
Hispanic or Latino	27	(10.9)	36	20.60	27	(10.6)	45	25.94
Not Hispanic or Latino	222	(13.7)	342	26.53	192	(11.9)	255	20.24
Missing	2		2		2		2	
Diarrhoea								
Hispanic or Latino	14	(5.7)	16	8.87	9	(3.5)	9	5.18
Not Hispanic or Latino	70	(4.3)	86	6.82	42	(2.6)	43	3.55
Missing	0				0			
Nausea								
Hispanic or Latino	3	(1.2)	3	1.48	7	(2.8)	8	4.58
Not Hispanic or Latino	34	(2.1)	35	2.74	20	(1.2)	21	1.60
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vomiting								
Hispanic or Latino	3	(1.1)	3	1.46	4	(1.6)	4	2.46
Not Hispanic or Latino	21	(1.3)	29	2.61	12	(0.7)	15	1.07
Missing	0				0			
Constipation								
Hispanic or Latino	2	(0.8)	2	1.14	4	(1.5)	4	2.29
Not Hispanic or Latino	14	(0.9)	17	1.44	11	(0.7)	11	0.92
Missing	0				1		1	
Abdominal pain								
Hispanic or Latino	3	(1.2)	3	2.13	3	(1.2)	4	2.56
Not Hispanic or Latino	13	(0.8)	13	0.93	15	(0.9)	15	1.21
Missing	0				0			
Toothache								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.72
Not Hispanic or Latino	12	(0.7)	12	0.79	9	(0.6)	12	1.21
Missing	0				0			
Abdominal pain upper								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	12	(0.7)	14	1.07	15	(0.9)	16	1.21
Missing	0				0			
Dental caries								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	11	(0.7)	13	0.80	9	(0.6)	9	0.78
Missing	0				0			
Gastrooesophageal reflux disease								
Hispanic or Latino	2	(0.8)	2	0.81	3	(1.1)	3	1.66
Not Hispanic or Latino	11	(0.7)	11	0.85	11	(0.7)	11	0.86
Missing	0				0			
Chronic gastritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	8	(0.5)	8	0.67	4	(0.2)	4	0.30
Missing	0				0			
Dyspepsia								
Hispanic or Latino	0				2	(0.8)	2	1.03
Not Hispanic or Latino	7	(0.4)	7	0.60	6	(0.4)	6	0.46
Missing	0				0			
Haemorrhoids								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.52	3	(0.2)	3	0.28
Missing	0				0			
Gastritis								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	7	(0.4)	7	0.59	8	(0.5)	8	0.63
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal distension								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.41
Not Hispanic or Latino	6	(0.4)	6	0.41	3	(0.2)	3	0.28
Missing	0				0			
Food poisoning								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.39	4	(0.3)	5	0.50
Missing	0				0			
Large intestine polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.29	6	(0.4)	7	0.47
Missing	0				0			
Abdominal pain lower								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.33	2	(0.1)	2	0.12
Missing	0				0			
Diverticulum intestinal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.18	1	(0.1)	1	0.06
Missing	0				0			
Enterocolitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	4	0.25	0			
Missing	0				0			
Flatulence								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	3	(0.2)	3	0.23	1	(0.1)	1	0.11
Missing	1		1		0			
Abdominal discomfort								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.3)	5	0.45
Missing	0				0			
Aphthous ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Inguinal hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	2	0.13
Missing	0				0			
Hiatus hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.06

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Dry mouth								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Rectal polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	2	(0.1)	2	0.12
Missing	0				0			
Hyperaesthesia teeth								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Hypoaesthesia oral								
Hispanic or Latino	1	(0.4)	3	2.13	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Gastric polyps								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	2	0.17
Missing	0				0			
Abdominal wall disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Anal fissure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Colitis microscopic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Diabetic gastropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Eosinophilic oesophagitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Eructation								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Gastric ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Gastrointestinal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Haemorrhoidal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Impaired gastric emptying								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Intestinal dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Lip swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Umbilical hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Missing	0				0			
Diverticulum								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.13
Missing	0				1		1	
Gastrointestinal angiodysplasia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Gingival bleeding								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Intra-abdominal haematoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Tongue rough								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Anal pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Colitis								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Colitis ischaemic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Frequent bowel movements								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Haematochezia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Loose tooth								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Oral discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pancreatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Periodontal disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.21
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tooth disorder								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Tooth impacted								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Pancreatic duct dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Pancreatic failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Pancreatitis chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Missing	0				0			
Proctalgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Gastric dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Vomiting projectile								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Acid peptic disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.13
Missing	0				0			
Crohn's disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Duodenitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Enteritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Epigastric discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Faeces pale								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Gastric disorder								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Gastric dysplasia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Gastric mucosal hypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Gastrointestinal disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Gastrointestinal inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Gastrointestinal sounds abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Gingival disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hyperchlorhydria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Ileus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Irritable bowel syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Melaena								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Mesenteric panniculitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Noninfective gingivitis								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Odynophagia								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Oesophageal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Oesophagitis								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Oral pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	1		1		0			
Pancreatic pseudocyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Pancreatitis acute								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Peptic ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Periodontal inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.13
Missing	0				0			
Rectal prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Small intestinal obstruction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Stomatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.13
Missing	0				0			
Ulcerative gastritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Upper gastrointestinal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Musculoskeletal and connective tissue disorders								
All								
Hispanic or Latino	37	(15.1)	67	36.37	30	(11.8)	40	23.54
Not Hispanic or Latino	207	(12.8)	299	23.11	213	(13.3)	296	23.23
Missing	2		3		2		2	
Back pain								
Hispanic or Latino	5	(2.0)	5	2.95	6	(2.3)	7	4.64
Not Hispanic or Latino	57	(3.5)	61	4.77	55	(3.4)	57	4.64
Missing	0				0			
Arthralgia								
Hispanic or Latino	6	(2.5)	9	5.49	5	(2.0)	6	3.45

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	39	(2.4)	44	3.34	43	(2.7)	48	3.93
Missing	0				0			
Pain in extremity								
Hispanic or Latino	6	(2.4)	7	3.68	5	(2.0)	5	2.80
Not Hispanic or Latino	25	(1.6)	26	1.78	26	(1.6)	32	2.75
Missing	0				0			
Muscle spasms								
Hispanic or Latino	2	(0.8)	2	1.12	1	(0.4)	1	0.72
Not Hispanic or Latino	20	(1.2)	22	1.88	8	(0.5)	8	0.59
Missing	1		1		0			
Osteoarthritis								
Hispanic or Latino	7	(2.8)	8	4.15	5	(2.0)	6	3.58
Not Hispanic or Latino	14	(0.9)	15	1.11	19	(1.2)	21	1.57
Missing	0				0			
Neck pain								
Hispanic or Latino	2	(0.8)	2	1.10	1	(0.4)	1	0.72
Not Hispanic or Latino	13	(0.8)	13	1.07	7	(0.4)	7	0.49
Missing	0				0			
Myalgia								
Hispanic or Latino	4	(1.7)	4	2.88	2	(0.8)	2	1.37
Not Hispanic or Latino	10	(0.6)	10	0.79	7	(0.4)	7	0.57
Missing	0				0			
Tendonitis								
Hispanic or Latino	0				3	(1.2)	3	1.52
Not Hispanic or Latino	8	(0.5)	10	0.78	1	(0.1)	1	0.11
Missing	0				0			
Periarthritis								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	7	(0.4)	7	0.53	6	(0.4)	6	0.42
Missing	0				0			
Intervertebral disc protrusion								
Hispanic or Latino	2	(0.8)	3	1.19	1	(0.4)	1	0.40
Not Hispanic or Latino	6	(0.4)	9	0.64	5	(0.3)	6	0.47
Missing	0				0			
Trigger finger								
Hispanic or Latino	2	(0.8)	2	1.08	1	(0.4)	1	0.41
Not Hispanic or Latino	5	(0.3)	5	0.49	4	(0.2)	6	0.42
Missing	0				0			
Arthritis								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	5	(0.3)	5	0.39	6	(0.4)	6	0.56
Missing	0				0			
Bursitis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	4	(0.2)	4	0.29	2	(0.1)	2	0.13
Missing	0				0			
Spinal stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	6	0.54	2	(0.1)	2	0.12
Missing	0				0			
Spinal osteoarthritis								
Hispanic or Latino	2	(0.8)	2	0.78	0			
Not Hispanic or Latino	4	(0.2)	4	0.34	5	(0.3)	6	0.36
Missing	0				0			
Musculoskeletal stiffness								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	3	(0.2)	3	0.23	1	(0.1)	1	0.06
Missing	0				0			
Plantar fasciitis								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	3	(0.2)	4	0.25	3	(0.2)	3	0.18
Missing	0				0			
Rotator cuff syndrome								
Hispanic or Latino	2	(0.8)	2	1.12	0			
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.2)	4	0.24
Missing	0				0			
Chondropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Exostosis								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Polyarthritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Osteoporosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	0			
Missing	0				0			
Fibromyalgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Groin pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Missing	0				0			
Intervertebral disc disorder								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.06
Missing	0				1		1	
Musculoskeletal chest pain								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	2	(0.1)	2	0.13	2	(0.1)	2	0.12
Missing	0				0			
Foot deformity								
Hispanic or Latino	1	(0.4)	2	0.75	0			
Not Hispanic or Latino	2	(0.1)	3	0.23	2	(0.1)	2	0.17
Missing	0				1		1	
Osteochondrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	4	(0.2)	4	0.34
Missing	0				0			
Back disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Coccydynia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.06
Missing	0				0			
Musculoskeletal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.06
Missing	0				0			
Acquired claw toe								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Diastasis recti abdominis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Meniscopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Muscular weakness								
Hispanic or Latino	2	(0.9)	2	1.46	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.29
Missing	0				0			
Psoriatic arthropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Sacroiliitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Tendon disorder								
Hispanic or Latino	2	(0.9)	2	1.46	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Axillary mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Polymyalgia rheumatica								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	3	0.32
Missing	0				0			
Soft tissue swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	3	0.31	0			
Missing	0				0			
Costochondritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Fistula								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Lumbar spinal stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Myositis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Spinal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	4	(0.3)	4	0.30
Missing	0				0			
Synovial cyst								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Arthropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Pain in jaw								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Torticollis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Bone cyst								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Bone pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Cervical spinal stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Dupuytren's contracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.13
Missing	0				0			
Facet joint syndrome								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Flank pain								
Hispanic or Latino	1	(0.4)	1	0.69	2	(0.8)	2	1.37

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				4	(0.2)	5	0.36
Missing	0				0			
Haemarthrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Intervertebral disc degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Intervertebral disc space narrowing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.12
Missing	0				0			
Jaw disorder								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				0			
Missing	0				0			
Joint effusion								
Hispanic or Latino	1	(0.4)	1	0.37	1	(0.4)	1	0.40
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	1		2		0			
Joint swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.29
Missing	0				0			
Limb deformity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Mastication disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.13
Missing	0				0			
Muscle contracture								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Muscle twitching								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Neuropathic arthropathy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Nodal osteoarthritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Osteochondritis								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Osteopenia								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Periostitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Rheumatoid arthritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Scoliosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Spinal retrolisthesis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.12
Missing	0				0			
Tenosynovitis								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				9	(0.6)	10	0.71
Missing	0				0			
Tenosynovitis stenosans								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Vertebral osteophyte								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
General disorders and administration site conditions								
All								
Hispanic or Latino	18	(7.3)	32	17.14	15	(5.9)	36	16.98
Not Hispanic or Latino	179	(11.0)	275	22.92	159	(9.9)	225	17.63
Missing	2		6		0			
Pyrexia								
Hispanic or Latino	1	(0.4)	1	0.37	2	(0.8)	2	1.37
Not Hispanic or Latino	31	(1.9)	32	2.51	35	(2.2)	37	2.91
Missing	0				0			
Fatigue								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.40
Not Hispanic or Latino	26	(1.6)	29	2.28	14	(0.9)	14	1.04
Missing	0				0			
Oedema peripheral								
Hispanic or Latino	3	(1.2)	3	1.82	3	(1.2)	4	1.93
Not Hispanic or Latino	14	(0.9)	14	1.12	6	(0.4)	6	0.42
Missing	0				0			
Injection site reaction								
Hispanic or Latino	0				1	(0.4)	1	0.65
Not Hispanic or Latino	14	(0.9)	27	2.71	5	(0.3)	7	0.52
Missing	1		2		0			
Malaise								
Hispanic or Latino	1	(0.4)	2	0.75	0			
Not Hispanic or Latino	12	(0.7)	13	0.98	12	(0.7)	16	1.23
Missing	0				0			
Chest pain								
Hispanic or Latino	3	(1.2)	3	1.52	0			
Not Hispanic or Latino	11	(0.7)	11	0.85	5	(0.3)	5	0.30
Missing	0				0			
Pain								
Hispanic or Latino	1	(0.4)	1	0.73	3	(1.1)	4	2.29
Not Hispanic or Latino	9	(0.6)	10	0.89	11	(0.7)	11	0.82
Missing	0				0			
Vaccination site pain								
Hispanic or Latino	1	(0.4)	2	0.81	0			
Not Hispanic or Latino	9	(0.6)	10	0.93	8	(0.5)	8	0.73
Missing	0				0			
Asthenia								
Hispanic or Latino	2	(0.8)	2	1.12	0			
Not Hispanic or Latino	7	(0.4)	7	0.56	8	(0.5)	8	0.64
Missing	1		1		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hunger								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.4)	7	0.48	2	(0.1)	2	0.17
Missing	0				0			
Chest discomfort								
Hispanic or Latino	2	(0.8)	2	1.42	0			
Not Hispanic or Latino	6	(0.4)	6	0.46	2	(0.1)	2	0.17
Missing	0				0			
Peripheral swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	6	0.45	4	(0.2)	4	0.34
Missing	0				0			
Chills								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.29	1	(0.1)	1	0.06
Missing	0				0			
Medical device site haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.25	2	(0.1)	2	0.13
Missing	0				0			
Medical device site reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	6	0.51	1	(0.1)	1	0.06
Missing	0				0			
Injection site pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	19	1.87	1	(0.1)	1	0.11
Missing	0				0			
Influenza like illness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	5	0.43	3	(0.2)	3	0.18
Missing	0				0			
Drug intolerance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	0			
Missing	0				0			
Gait disturbance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	1	(0.1)	1	0.06
Missing	0				0			
Medical device site bruise								
Hispanic or Latino	2	(0.8)	3	1.79	0			
Not Hispanic or Latino	3	(0.2)	4	0.25	1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Feeling abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	5	0.40	1	(0.1)	1	0.06
Missing	0				0			
Thirst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	1	(0.1)	1	0.11
Missing	0				0			
Injection site bruising								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	5	(0.3)	5	0.36
Missing	0				0			
Injection site mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Injection site hypersensitivity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	0			
Missing	0				0			
Medical device site pruritus								
Hispanic or Latino	2	(0.8)	2	1.10	0			
Not Hispanic or Latino	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Missing	0				0			
Medical device site dermatitis								
Hispanic or Latino	2	(0.8)	5	2.03	1	(0.4)	1	0.40
Not Hispanic or Latino	2	(0.1)	2	0.21	7	(0.4)	13	0.82
Missing	0				0			
Injection site swelling								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	1	(0.1)	1	0.11
Missing	0				0			
Injection site haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	6	0.62	3	(0.2)	8	0.89
Missing	0				0			
Injection site haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	2	(0.1)	2	0.17
Missing	0				0			
Injection site pain								
Hispanic or Latino	0				1	(0.4)	19	7.71
Not Hispanic or Latino	2	(0.1)	2	0.21	11	(0.7)	11	1.02

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	1		1		0			
Early satiety								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Localised oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Swelling face								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Vessel puncture site bruise								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Medical device site erythema								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.17
Missing	0				0			
Discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	8	0.86
Missing	1		1		0			
Feeling hot								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Implant site pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Injection site dermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Medical device site eczema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.13
Missing	0				0			
Medical device site hypersensitivity								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Medical device site pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Swelling								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Vaccination site reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Multiple organ dysfunction syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Oedema due to renal disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Vaccination site inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Vaccination site pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Xerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Application site bruise								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Injection site erythema								
Hispanic or Latino	2	(0.8)	2	1.14	1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	3	0.31	3	(0.2)	3	0.19
Missing	0				0			
Injection site rash								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Application site pruritus								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Axillary pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Condition aggravated								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Death								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.18
Missing	0				0			
Facial pain								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				0			
Missing	0				0			
Hernia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Inflammation								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	1		1		0			
Injection site hypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Injection site induration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injection site oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Injection site urticaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Medical device site haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Medical device site inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Medical device site rash								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Non-cardiac chest pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				4	(0.2)	6	0.36
Missing	0				0			
Oedema								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	0				3	(0.2)	3	0.23
Missing	0				0			
Procedural failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Systemic inflammatory response syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Vaccination site erythema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Nervous system disorders								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	24	(9.8)	32	20.29	23	(9.1)	33	19.59
Not Hispanic or Latino	156	(9.6)	220	17.37	160	(10.0)	215	17.51
Missing	0				0			
Headache								
Hispanic or Latino	7	(2.9)	8	5.43	11	(4.4)	14	8.84
Not Hispanic or Latino	50	(3.1)	65	5.52	43	(2.7)	53	4.16
Missing	0				0			
Dizziness								
Hispanic or Latino	7	(2.8)	10	6.11	2	(0.8)	3	2.06
Not Hispanic or Latino	31	(1.9)	38	2.95	35	(2.2)	41	3.47
Missing	0				0			
Tremor								
Hispanic or Latino	0				0			
Not Hispanic or Latino	11	(0.7)	12	0.83	8	(0.5)	12	1.21
Missing	0				0			
Sciatica								
Hispanic or Latino	2	(0.8)	2	1.08	0			
Not Hispanic or Latino	11	(0.7)	11	0.93	12	(0.7)	13	0.99
Missing	0				0			
Carpal tunnel syndrome								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.72
Not Hispanic or Latino	10	(0.6)	10	0.75	6	(0.4)	6	0.51
Missing	0				0			
Hypoaesthesia								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	8	(0.5)	11	0.89	9	(0.6)	10	0.81
Missing	0				0			
Syncope								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.4)	6	0.42	1	(0.1)	1	0.06
Missing	0				0			
Paraesthesia								
Hispanic or Latino	2	(0.8)	2	0.81	2	(0.8)	2	1.03
Not Hispanic or Latino	6	(0.4)	7	0.47	10	(0.6)	10	0.90
Missing	0				0			
Neuropathy peripheral								
Hispanic or Latino	0				2	(0.8)	2	0.81
Not Hispanic or Latino	6	(0.4)	7	0.60	7	(0.4)	7	0.57
Missing	0				0			
Migraine								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.63
Not Hispanic or Latino	5	(0.3)	5	0.39	2	(0.1)	2	0.17
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Carotid artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Neuralgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.06
Missing	0				0			
Diabetic neuropathy								
Hispanic or Latino	3	(1.2)	3	2.15	3	(1.2)	3	1.44
Not Hispanic or Latino	2	(0.1)	2	0.12	9	(0.6)	9	0.79
Missing	0				0			
Dysgeusia								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Transient ischaemic attack								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	2	(0.1)	2	0.12	3	(0.2)	3	0.23
Missing	0				0			
Burning sensation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	3	(0.2)	3	0.23
Missing	0				0			
Post herpetic neuralgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Tension headache								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	2	(0.1)	3	0.19	0			
Missing	0				0			
Cerebrovascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Memory impairment								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Amnesia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cerebral atrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Cluster headache								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cognitive disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Disturbance in attention								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Intracranial pressure increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Autonomic nervous system imbalance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Carotid artery aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Cervicobrachial syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Facial paralysis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Peripheral paralysis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Piriformis syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Somnolence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Thalamic infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Ageusia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Anosmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Balance disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cerebral haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cervical radiculopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Dizziness postural								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Lumbar radiculopathy								
Hispanic or Latino	0				2	(0.8)	2	0.81
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	3	0.18
Missing	0				0			
Neuroglycopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	3	0.19
Missing	0				0			
Presyncope								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.06	4	(0.2)	4	0.24
Missing	0				0			
Trigeminal neuralgia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cerebral arteriosclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Vascular encephalopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Basilar migraine								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				0			
Missing	0				0			
Brain injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Carotid arteriosclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cerebral artery embolism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cerebral infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Cerebrovascular accident								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Dementia Alzheimer's type								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Essential tremor								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Facial nerve disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hemiparesis								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				0			
Missing	0				0			
Hypoglycaemic coma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hyporeflexia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Ischaemic stroke								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Lethargy								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Loss of consciousness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Mental impairment								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Meralgia paraesthetica								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Morton's neuralgia								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Myelopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Ophthalmic migraine								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Orthostatic tremor								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Parkinsonian gait								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Radiculopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Restless legs syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Sleep deficit								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Thrombotic stroke								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Vascular headache								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Vertebral artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
White matter lesion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injury, poisoning and procedural complications								
All								
Hispanic or Latino	22	(8.9)	30	17.64	26	(10.2)	31	19.38
Not Hispanic or Latino	141	(8.7)	172	13.51	119	(7.4)	145	11.73
Missing	1		2		2		2	
Fall								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.65
Not Hispanic or Latino	18	(1.1)	18	1.36	9	(0.6)	10	0.74
Missing	0				0			
Contusion								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	13	(0.8)	14	1.04	7	(0.4)	7	0.48
Missing	0				0			
Vaccination complication								
Hispanic or Latino	2	(0.8)	2	0.81	1	(0.4)	1	0.40
Not Hispanic or Latino	13	(0.8)	17	1.44	20	(1.2)	26	2.00
Missing	0				0			
Accidental overdose								
Hispanic or Latino	0				2	(0.8)	3	2.15
Not Hispanic or Latino	7	(0.4)	7	0.65	0			
Missing	0				1		1	
Skin laceration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.57	0			
Missing	0				0			
Ligament sprain								
Hispanic or Latino	2	(0.9)	2	1.46	1	(0.4)	1	0.65
Not Hispanic or Latino	7	(0.4)	7	0.56	7	(0.4)	7	0.62
Missing	0				0			
Skin abrasion								
Hispanic or Latino	1	(0.4)	3	1.12	1	(0.4)	1	0.41
Not Hispanic or Latino	7	(0.4)	7	0.61	3	(0.2)	3	0.32
Missing	0				0			
Hand fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.4)	6	0.50	1	(0.1)	1	0.06
Missing	0				0			
Overdose								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	4	(0.2)	4	0.38	2	(0.1)	2	0.17
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Limb injury								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.63
Not Hispanic or Latino	4	(0.2)	4	0.29	5	(0.3)	6	0.55
Missing	0				0			
Procedural pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.33	1	(0.1)	1	0.11
Missing	0				0			
Upper limb fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.18	0			
Missing	0				0			
Road traffic accident								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.22	1	(0.1)	1	0.06
Missing	1		1		0			
Rib fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	5	(0.3)	5	0.40
Missing	1		1		0			
Joint injury								
Hispanic or Latino	2	(0.8)	2	1.44	0			
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.2)	4	0.29
Missing	0				0			
Arthropod sting								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	1	(0.1)	1	0.11
Missing	0				0			
Tooth fracture								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	3	(0.2)	3	0.23	2	(0.1)	2	0.17
Missing	0				0			
Wound								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.3)	4	0.39
Missing	0				1		1	
Thermal burn								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	2	(0.1)	2	0.17
Missing	0				0			
Back injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Ankle fracture								
Hispanic or Latino	2	(0.7)	2	0.75	0			
Not Hispanic or Latino	2	(0.1)	2	0.12	3	(0.2)	3	0.18
Missing	0				0			
Radius fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	0			
Missing	0				0			
Meniscus injury								
Hispanic or Latino	0				2	(0.8)	2	1.12
Not Hispanic or Latino	2	(0.1)	2	0.13	3	(0.2)	3	0.18
Missing	0				0			
Foot fracture								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	3	(0.2)	3	0.23
Missing	0				0			
Arthropod bite								
Hispanic or Latino	1	(0.4)	1	0.69	2	(0.8)	2	1.37
Not Hispanic or Latino	2	(0.1)	2	0.21	1	(0.1)	1	0.06
Missing	0				0			
Incorrect dose administered								
Hispanic or Latino	1	(0.4)	1	0.71	4	(1.5)	6	3.95
Not Hispanic or Latino	2	(0.1)	2	0.21	1	(0.1)	1	0.06
Missing	0				0			
Bone contusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Femoral neck fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Hip fracture								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Inflammation of wound								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Injury of conjunctiva								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Multiple injuries								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Muscle injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.21
Missing	0				0			
Neck injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Penile contusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post procedural complication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post procedural haematuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post procedural inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Radiation skin injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Spinal compression fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Tendon rupture								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Craniocerebral injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Face injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Subcutaneous haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Underdose								
Hispanic or Latino	0				4	(1.5)	4	2.58
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Wrist fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Burn oral cavity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Burns first degree								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cervical vertebral fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Eye injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Fibula fracture								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Heat illness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	4	0.30
Missing	0				0			
Post procedural fistula								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post procedural haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post procedural hypothyroidism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Scar								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Traumatic haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Chillblains								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Missing	0				0			
Subdural haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Wrong product administered								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	2	0.21	2	(0.1)	2	0.22
Missing	0				0			
Medication error								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.22
Missing	0				0			
Procedural complication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Accidental underdose								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Animal bite								
Hispanic or Latino	1	(0.4)	1	0.37	1	(0.4)	1	0.41
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Concussion								
Hispanic or Latino	0				2	(0.8)	2	1.43
Not Hispanic or Latino	0				0			
Missing	0				0			
Crush injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Deafness traumatic								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Endotracheal intubation complication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Epicondylitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Exposure to SARS-CoV-2								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Extra dose administered								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Facial bones fracture								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Gun shot wound								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Head injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Humerus fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Intentional overdose								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Intentional product use issue								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Ligament rupture								
Hispanic or Latino	1	(0.4)	2	1.46	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Lower limb fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Muscle contusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Muscle strain								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				4	(0.3)	4	0.34
Missing	0				0			
Periprocedural myocardial infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Post procedural stroke								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Post procedural swelling								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	2	0.13
Missing	0				0			
Post-traumatic neck syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Product administration error								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Scratch								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Seroma								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Soft tissue injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Spinal column injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Stab wound								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Sunburn								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Tendon injury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Tibia fracture								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Wrong dose								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Eye disorders								
All								
Hispanic or Latino	16	(6.6)	16	10.54	14	(5.6)	16	9.40
Not Hispanic or Latino	130	(8.0)	171	14.10	138	(8.6)	183	15.91
Missing	1		1		0			
Diabetic retinopathy								
Hispanic or Latino	4	(1.7)	4	2.91	8	(3.2)	8	4.56
Not Hispanic or Latino	48	(3.0)	54	4.92	50	(3.1)	54	4.87
Missing	0				0			
Cataract								
Hispanic or Latino	3	(1.3)	3	2.17	1	(0.4)	1	0.41
Not Hispanic or Latino	20	(1.2)	25	1.71	24	(1.5)	27	2.15
Missing	1		1		0			
Macular oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	9	(0.6)	9	0.82	4	(0.2)	4	0.29
Missing	0				0			
Dry eye								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.4)	6	0.41	6	(0.4)	6	0.43
Missing	0				0			
Blepharitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.35	0			
Missing	0				0			
Retinopathy hypertensive								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	5	(0.3)	6	0.50	5	(0.3)	5	0.49
Missing	0				0			
Diabetic retinal oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.42	9	(0.6)	10	0.89
Missing	0				0			
Eye pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.28	3	(0.2)	3	0.23
Missing	0				0			
Glaucoma								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	3	(0.2)	3	0.18	3	(0.2)	3	0.23
Missing	0				0			
Ocular hypertension								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	1	(0.1)	1	0.06
Missing	0				0			
Retinal haemorrhage								
Hispanic or Latino	2	(0.8)	2	1.42	0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Astigmatism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.18	4	(0.2)	4	0.33
Missing	0				0			
Age-related macular degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Vitreous haemorrhage								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	2	(0.1)	2	0.21	1	(0.1)	1	0.11
Missing	0				0			
Diplopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.11
Missing	0				0			
Vitreous detachment								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Ocular hyperaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.31	1	(0.1)	2	0.22
Missing	0				0			
Conjunctivitis allergic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.23	0			
Missing	0				0			
Eye inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	2	0.22
Missing	0				0			
Amaurosis fugax								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Angle closure glaucoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Arteriosclerotic retinopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Conjunctival hyperaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Conjunctival suffusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Maculopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Retinal degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Visual impairment								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	10	1.03
Missing	0				0			
Vitreous opacities								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Conjunctival haemorrhage								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Dry age-related macular degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Epiretinal membrane								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.17
Missing	0				0			
Eye irritation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Lacrimation increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Myopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.12
Missing	0				0			
Retinal exudates								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Retinal vein occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Acquired epiblepharon								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Asthenopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Conjunctival erosion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Optic disc vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post thrombotic retinopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Posterior capsule opacification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Retinal aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Retinal tear								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Vision blurred								
Hispanic or Latino	3	(1.2)	3	1.84	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	5	(0.3)	5	0.40
Missing	0				0			
Presbyopia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.21
Missing	0				0			
Retinal deposits								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Retinal drusen								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Retinal scar								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Non-proliferative retinopathy								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	1	(0.1)	2	0.21	1	(0.1)	1	0.11
Missing	0				0			
Cataract nuclear								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Chorioretinal atrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Corneal bleeding								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Corneal erosion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Cystoid macular oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Dacryoadenitis acquired								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Eye discharge								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Eye pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.22
Missing	0				0			
Eyelid oedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hypermetropia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Macular degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.23
Missing	0				0			
Macular hole								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Meibomianitis								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Normal tension glaucoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Ocular ischaemic syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Open angle glaucoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.22
Missing	0				0			
Ophthalmic vein thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Optic disc haemorrhage								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Photophobia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Retinal artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Retinal detachment								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Retinal vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Retinopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Scintillating scotoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Uveitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Visual acuity reduced								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Vitreous degeneration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Vitreous floaters								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Metabolism and nutrition disorders								
All								
Hispanic or Latino	23	(9.4)	25	13.89	24	(9.4)	27	14.96
Not Hispanic or Latino	101	(6.2)	128	9.54	99	(6.2)	129	10.01
Missing	0				2		2	
Vitamin D deficiency								
Hispanic or Latino	1	(0.4)	1	0.41	2	(0.8)	2	1.03
Not Hispanic or Latino	15	(0.9)	15	0.96	10	(0.6)	10	0.65
Missing	0				0			
Hyperlipidaemia								
Hispanic or Latino	1	(0.4)	1	0.41	3	(1.2)	3	1.46
Not Hispanic or Latino	13	(0.8)	13	1.01	10	(0.6)	10	0.75
Missing	0				0			
Dyslipidaemia								
Hispanic or Latino	9	(3.7)	9	4.60	8	(3.0)	8	4.57
Not Hispanic or Latino	12	(0.7)	13	1.11	9	(0.6)	9	0.80
Missing	0				0			
Vitamin B12 deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	11	(0.7)	11	0.66	1	(0.1)	1	0.06
Missing	0				0			
Hypoglycaemia								
Hispanic or Latino	2	(0.8)	3	2.17	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	11	(0.7)	16	1.42	19	(1.2)	35	2.78
Missing	0				1		1	
Hypertriglyceridaemia								
Hispanic or Latino	2	(0.8)	2	1.14	3	(1.1)	3	1.97
Not Hispanic or Latino	8	(0.5)	8	0.59	5	(0.3)	5	0.36
Missing	0				0			
Iron deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.30	3	(0.2)	3	0.18
Missing	0				0			
Hyperglycaemia								
Hispanic or Latino	1	(0.4)	1	0.73	2	(0.8)	2	1.03
Not Hispanic or Latino	5	(0.3)	6	0.54	12	(0.7)	12	1.07
Missing	0				0			
Hyperkalaemia								
Hispanic or Latino	3	(1.2)	3	1.52	1	(0.4)	1	0.72
Not Hispanic or Latino	5	(0.3)	6	0.46	9	(0.6)	9	0.74
Missing	0				0			
Gout								
Hispanic or Latino	0				2	(0.8)	2	0.81
Not Hispanic or Latino	4	(0.2)	5	0.31	4	(0.2)	5	0.30
Missing	0				0			
Hyperuricaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.22	3	(0.2)	3	0.18
Missing	0				0			
Increased appetite								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	3	(0.2)	3	0.19	5	(0.3)	6	0.57
Missing	0				0			
Decreased appetite								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.72
Not Hispanic or Latino	3	(0.2)	3	0.23	4	(0.2)	4	0.24
Missing	0				0			
Diabetes mellitus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Folate deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Zinc deficiency								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Fluid retention								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Hypercholesterolaemia								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	3	(0.2)	3	0.28
Missing	0				0			
Hypokalaemia								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Diabetes mellitus inadequate control								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Hypernatraemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Magnesium deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Malnutrition								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Vitamin B complex deficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Obesity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Dehydration								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypoalbuminaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Hyponatraemia								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Abnormal weight gain								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Appetite disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.13
Missing	0				0			
Electrolyte imbalance								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Food craving								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Hyperammonaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hypercalcaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Insulin resistance								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	0				0			
Missing	0				0			
Lactic acidosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Lipomatosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Metabolic acidosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Metabolic disorder								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
Hispanic or Latino	11	(4.4)	15	8.16	12	(4.7)	22	12.19
Not Hispanic or Latino	100	(6.2)	136	10.88	86	(5.4)	99	7.77
Missing	0				3		3	
Cough								
Hispanic or Latino	2	(0.8)	2	1.08	3	(1.2)	3	1.75
Not Hispanic or Latino	21	(1.3)	22	1.71	17	(1.1)	18	1.35
Missing	0				0			
Oropharyngeal pain								
Hispanic or Latino	1	(0.4)	1	0.69	2	(0.8)	2	1.43
Not Hispanic or Latino	18	(1.1)	20	1.41	14	(0.9)	16	1.33
Missing	0				0			
Nasal congestion								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	9	(0.6)	9	0.64	4	(0.2)	4	0.24
Missing	0				0			
Rhinorrhoea								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	9	(0.6)	12	1.04	7	(0.4)	7	0.52
Missing	0				0			
Dyspnoea								
Hispanic or Latino	0				1	(0.4)	2	1.43
Not Hispanic or Latino	9	(0.6)	9	0.76	12	(0.7)	12	0.92
Missing	0				0			
Sleep apnoea syndrome								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	6	(0.4)	6	0.41	0			
Missing	0				0			
Epistaxis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	9	0.95	2	(0.1)	4	0.34
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Productive cough								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.33	2	(0.1)	2	0.17
Missing	0				0			
Respiratory disorder								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	4	(0.2)	4	0.38	4	(0.2)	4	0.34
Missing	0				0			
Chronic obstructive pulmonary disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.38	1	(0.1)	1	0.06
Missing	0				0			
Sinus congestion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	5	0.40	1	(0.1)	1	0.06
Missing	0				0			
Acute respiratory failure								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	3	(0.2)	3	0.23	0			
Missing	0				0			
Nasal septum deviation								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	2	(0.1)	2	0.21	0			
Missing	0				0			
Emphysema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	2	0.17
Missing	0				0			
Pulmonary fibrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.23	0			
Missing	0				0			
Sinus pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.23	1	(0.1)	1	0.11
Missing	0				0			
Asthma								
Hispanic or Latino	4	(1.6)	5	2.96	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Rhinitis allergic								
Hispanic or Latino	0				1	(0.4)	5	2.01
Not Hispanic or Latino	1	(0.1)	1	0.06	4	(0.3)	4	0.44

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Upper respiratory tract inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Nasal obstruction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Respiratory failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.12
Missing	0				0			
Sneezing								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Acquired diaphragmatic eventration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Bronchiectasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Dyspnoea exertional								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Interstitial lung disease								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Laryngeal cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Nasal dryness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Nasal turbinate hypertrophy								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pulmonary embolism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pulmonary mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	4	(0.3)	4	0.34
Missing	0				0			
Throat irritation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Upper-airway cough syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pleurisy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Pulmonary hypertension								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Acute pulmonary oedema								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Allergic bronchitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Allergic cough								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Aphonia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Bronchitis chronic								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Bronchospasm								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			
Dry throat								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Dysphonia								
Hispanic or Latino	0				1	(0.4)	2	1.26
Not Hispanic or Latino	0				0			
Missing	0				0			
Haemoptysis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Increased viscosity of upper respiratory secretion								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Lung disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Paranasal cyst								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Paranasal sinus discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Pleural disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Pleural effusion								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pleuritic pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Respiratory tract inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Skin and subcutaneous tissue disorders								
All								
Hispanic or Latino	7	(2.7)	8	3.46	17	(6.8)	21	10.65
Not Hispanic or Latino	91	(5.6)	98	7.66	86	(5.4)	101	7.70
Missing	1		1		1		1	
Rash								
Hispanic or Latino	0				4	(1.7)	5	2.34
Not Hispanic or Latino	11	(0.7)	11	0.89	7	(0.4)	7	0.48
Missing	0				0			
Eczema								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	9	(0.6)	9	0.69	6	(0.4)	6	0.56
Missing	0				0			
Urticaria								
Hispanic or Latino	0				3	(1.2)	3	1.44
Not Hispanic or Latino	7	(0.4)	7	0.60	6	(0.4)	6	0.37
Missing	0				0			
Pruritus								
Hispanic or Latino	1	(0.4)	1	0.37	3	(1.2)	3	1.84
Not Hispanic or Latino	7	(0.4)	7	0.56	8	(0.5)	8	0.63
Missing	0				0			
Hyperhidrosis								
Hispanic or Latino	1	(0.4)	1	0.37	1	(0.4)	1	0.65
Not Hispanic or Latino	7	(0.4)	7	0.61	4	(0.2)	4	0.29
Missing	0				0			
Dermatitis contact								
Hispanic or Latino	0				3	(1.2)	3	1.43
Not Hispanic or Latino	5	(0.3)	6	0.38	5	(0.3)	5	0.36
Missing	0				0			
Cold sweat								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.34	3	(0.2)	3	0.23
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dry skin								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	4	(0.2)	4	0.29
Missing	0				0			
Alopecia								
Hispanic or Latino	2	(0.8)	2	0.81	1	(0.4)	1	0.40
Not Hispanic or Latino	3	(0.2)	3	0.27	1	(0.1)	1	0.06
Missing	0				1		1	
Night sweats								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	0			
Missing	0				0			
Dermatitis allergic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.11
Missing	0				0			
Ingrowing nail								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	3	(0.2)	3	0.19
Missing	0				0			
Miliaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	4	(0.2)	4	0.25
Missing	0				0			
Psoriasis								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Missing	0				0			
Skin irritation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.19	2	(0.1)	2	0.12
Missing	0				0			
Skin ulcer								
Hispanic or Latino	2	(0.8)	2	1.12	1	(0.4)	1	0.72
Not Hispanic or Latino	2	(0.1)	2	0.17	4	(0.3)	4	0.39
Missing	0				0			
Acne								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Dermatitis								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	6	(0.4)	7	0.58
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diabetic foot								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Erythema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.23
Missing	0				0			
Livedo reticularis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Nail bed inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Blister								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.17
Missing	0				0			
Rash papular								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Angioedema								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Granuloma annulare								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Hyperkeratosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	1		1		0			
Lipodystrophy acquired								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Myxoid cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Skin exfoliation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Skin fissures								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Skin lesion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Urticaria contact								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Intertrigo								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Umbilical haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Decubitus ulcer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Ecchymosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.13
Missing	0				0			
Rash erythematous								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Skin odour abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Actinic keratosis								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Alopecia areata								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Asteatosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cold urticaria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Dermal cyst								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Drug eruption								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Haemorrhage subcutaneous								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hidradenitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Lentigo								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Leukoplakia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Lipohypertrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Macule								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Neurodermatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Pruritus allergic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Purpura								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Rash maculo-papular								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Seborrhoea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Skin discolouration								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Skin reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Urticaria thermal								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Cardiac disorders								
All								
Hispanic or Latino	6	(2.4)	8	4.09	4	(1.6)	10	5.91
Not Hispanic or Latino	79	(4.9)	115	8.09	75	(4.7)	99	7.18
Missing	1		1		0			
Atrial fibrillation								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.40

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	11	(0.7)	12	0.79	5	(0.3)	5	0.36
Missing	0				0			
Coronary artery disease								
Hispanic or Latino	2	(0.8)	2	1.12	1	(0.4)	1	0.40
Not Hispanic or Latino	10	(0.6)	10	0.66	9	(0.6)	9	0.63
Missing	0				0			
Acute myocardial infarction								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.40
Not Hispanic or Latino	8	(0.5)	8	0.57	7	(0.4)	7	0.57
Missing	0				0			
Cardiac failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	8	(0.5)	8	0.53	2	(0.1)	3	0.28
Missing	0				0			
Angina pectoris								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	6	(0.4)	6	0.41	3	(0.2)	3	0.18
Missing	0				0			
Myocardial infarction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	6	(0.4)	6	0.51	4	(0.2)	4	0.24
Missing	0				0			
Ventricular extrasystoles								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.31	2	(0.1)	3	0.18
Missing	0				0			
Palpitations								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	5	(0.3)	5	0.35	5	(0.3)	5	0.36
Missing	0				0			
Acute coronary syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.25	0			
Missing	0				0			
Cardiac failure congestive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.29	2	(0.1)	3	0.32
Missing	0				0			
Tachycardia								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	3	(0.2)	3	0.18	6	(0.4)	6	0.46
Missing	0				0			
Left ventricular hypertrophy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	2	(0.1)	2	0.17
Missing	0				0			
Mitral valve incompetence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.23	2	(0.1)	2	0.12
Missing	0				0			
Arrhythmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	3	(0.2)	3	0.24
Missing	0				0			
Supraventricular tachycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Angina unstable								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Missing	0				0			
Cardiac failure chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	1	(0.1)	1	0.06
Missing	0				0			
Coronary artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	0			
Missing	0				0			
Bundle branch block left								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Left ventricular dysfunction								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.11
Missing	0				0			
Myocardial ischaemia								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	2	0.12
Missing	0				0			
Supraventricular extrasystoles								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	2	0.12
Missing	1		1		0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Arteriosclerosis coronary artery								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cardiac flutter								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Aortic valve incompetence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Atrial flutter								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Atrial thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Bradycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Bundle branch block right								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	6	(0.4)	7	0.52
Missing	0				0			
Cardiac ventricular thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Chronic coronary syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Diastolic dysfunction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Left atrial dilatation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pericardial effusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pericarditis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Sinus tachycardia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.18
Missing	0				0			
Tricuspid valve incompetence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.18
Missing	0				0			
Aortic valve sclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Left atrial enlargement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.17
Missing	0				0			
Atrioventricular block first degree								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Cardio-respiratory arrest								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Mitral valve stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Aortic valve calcification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.17
Missing	0				0			
Atrial enlargement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Atrioventricular block complete								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cardiac arrest								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Cardiac dysfunction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cardiac failure acute								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cardiac perfusion defect								
Hispanic or Latino	0				1	(0.4)	2	1.43
Not Hispanic or Latino	0				0			
Missing	0				0			
Coronary artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Sinus arrhythmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Sinus bradycardia								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Subendocardial ischaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Ventricular arrhythmia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Ventricular tachycardia								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Investigations								
All								
Hispanic or Latino	9	(3.6)	11	5.40	14	(5.7)	14	7.54
Not Hispanic or Latino	71	(4.4)	83	6.64	52	(3.2)	59	4.82
Missing	0				0			
Weight increased								
Hispanic or Latino	3	(1.2)	3	1.82	6	(2.4)	6	3.36
Not Hispanic or Latino	16	(1.0)	16	1.25	12	(0.8)	12	0.94
Missing	0				0			
Blood creatinine increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	8	(0.5)	8	0.75	0			
Missing	0				0			
SARS-CoV-2 test positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.64	0			
Missing	0				0			
Weight decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.25	1	(0.1)	1	0.06
Missing	0				0			
Alanine aminotransferase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.37	0			
Missing	0				0			
Blood immunoglobulin E increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.18	3	(0.2)	3	0.18
Missing	0				0			
Liver function test increased								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	3	(0.2)	3	0.27	0			
Missing	0				0			
Blood pressure increased								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	3	(0.2)	3	0.23	3	(0.2)	3	0.23
Missing	0				0			
Blood alkaline phosphatase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.31	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Prostatic specific antigen increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Blood triglycerides increased								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.41
Not Hispanic or Latino	2	(0.1)	2	0.17	2	(0.1)	2	0.12
Missing	0				0			
Occult blood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Blood urine present								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	3	0.18	0			
Missing	0				0			
Bone density decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Electrocardiogram abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Electrocardiogram ST segment abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Electrocardiogram T wave inversion								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Hepatic enzyme increased								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Low density lipoprotein increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.22
Missing	0				0			
QRS axis abnormal								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Thyroid function test abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Transaminases increased								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Blood creatine increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Blood creatine phosphokinase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Body temperature increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Glycosylated haemoglobin increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	3	0.18
Missing	0				0			
Red blood cell count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Transferrin saturation decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Catheterisation cardiac								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Eosinophil count increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Liver function test abnormal								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	2	0.21
Missing	0				0			
Arthroscopy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Aspartate aminotransferase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Blood potassium increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Monocyte count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Monofilament pressure perception test								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Amylase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Antinuclear antibody positive								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Blood cholesterol increased								
Hispanic or Latino	2	(0.8)	2	0.81	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Blood glucose decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Blood glucose fluctuation								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood glucose increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Blood pressure decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Breath sounds abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Carbohydrate antigen 19-9 increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cardiac murmur								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	0				0			
Missing	0				0			
Cardiac stress test abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Ejection fraction decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Electrocardiogram P wave biphasic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Electrocardiogram repolarisation abnormality								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Electrocardiogram ST segment depression								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Free fatty acids increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Glomerular filtration rate decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Grip strength decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Haematocrit increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Haemoglobin decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Haemoglobin increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
International normalised ratio abnormal								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
International normalised ratio decreased								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
International normalised ratio increased								
Hispanic or Latino	1	(0.4)	2	0.81	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Intraocular pressure increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Lipase increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Lipids increased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Platelet count decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.33
Missing	0				0			
Vitamin D decreased								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Vascular disorders								
All								
Hispanic or Latino	12	(4.8)	12	6.05	4	(1.5)	4	2.60
Not Hispanic or Latino	61	(3.8)	70	5.43	71	(4.4)	89	7.07
Missing	0				1		2	
Hypertension								
Hispanic or Latino	7	(2.8)	7	3.43	3	(1.1)	3	1.88
Not Hispanic or Latino	25	(1.5)	25	2.02	32	(2.0)	37	2.97
Missing	0				0			
Hypotension								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	5	(0.3)	5	0.35	3	(0.2)	3	0.23
Missing	0				0			
Peripheral arterial occlusive disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	5	0.40	2	(0.1)	2	0.13
Missing	0				0			
Superficial vein thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.18	0			
Missing	0				0			
Peripheral coldness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.19	1	(0.1)	1	0.06
Missing	0				0			
Arteriosclerosis								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	2	(0.1)	2	0.12	7	(0.4)	7	0.57
Missing	0				0			
Orthostatic hypotension								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.21	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Haematoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	3	(0.2)	3	0.28
Missing	0				0			
Peripheral artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	5	0.45	0			
Missing	0				0			
Peripheral venous disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	3	(0.2)	3	0.23
Missing	0				0			
Blood pressure inadequately controlled								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Hot flush								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Venous stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Aortic arteriosclerosis								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.28
Missing	0				1		1	
Aortic stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Brachiocephalic arteriosclerosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Missing	0				0			
Flushing								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Hypertensive urgency								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	2	0.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Peripheral artery occlusion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Peripheral vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Varicose vein								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Deep vein thrombosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Diabetic vascular disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	2	0.22
Missing	0				0			
Hypertensive crisis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	2	(0.1)	4	0.39
Missing	0				0			
Arterial insufficiency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Aortic aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Aortic dilatation								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Blood pressure fluctuation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Iliac artery stenosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Intermittent claudication								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Macroangiopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Neovascularisation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Peripheral artery aneurysm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				0			
Missing	0				1		1	
Peripheral ischaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Phlebitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Thrombophlebitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Varicose ulceration								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Renal and urinary disorders								
All								
Hispanic or Latino	3	(1.2)	5	3.23	9	(3.6)	9	4.39
Not Hispanic or Latino	48	(3.0)	57	4.54	41	(2.6)	52	3.70
Missing	0				1		3	
Renal cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	7	(0.4)	7	0.60	4	(0.2)	4	0.29
Missing	0				0			
Nephrolithiasis								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	5	(0.3)	5	0.31	2	(0.1)	3	0.23
Missing	0				1		2	
Pollakiuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	5	(0.3)	5	0.48	2	(0.1)	2	0.13
Missing	0				0			
Renal impairment								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	4	(0.2)	4	0.33	2	(0.1)	2	0.12
Missing	0				0			
Dysuria								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	3	(0.2)	4	0.24	4	(0.2)	4	0.30
Missing	0				0			
Diabetic nephropathy								
Hispanic or Latino	0				2	(0.7)	2	1.26
Not Hispanic or Latino	3	(0.2)	3	0.23	0			
Missing	0				0			
Chronic kidney disease								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.72
Not Hispanic or Latino	3	(0.2)	3	0.28	4	(0.2)	4	0.24
Missing	0				0			
Ureterolithiasis								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	3	(0.2)	3	0.23	2	(0.1)	2	0.12
Missing	0				0			
Acute kidney injury								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	3	(0.2)	3	0.27	4	(0.2)	4	0.24
Missing	0				0			
Nocturia								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	2	(0.1)	2	0.12	2	(0.1)	2	0.13
Missing	0				0			
Urine odour abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.11
Missing	0				0			
Hypertonic bladder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Proteinuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Renal pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Urinary incontinence								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Urinary tract disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Bladder prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Hydronephrosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Nephrotic syndrome								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Polyuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Urethral stenosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Calculus urinary								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Microalbuminuria								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Pyelocaliectasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Renal colic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.28
Missing	0				0			
Chromaturia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Renal failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Bladder mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Cystitis haemorrhagic								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	0				0			
Missing	0				0			
Haematuria								
Hispanic or Latino	1	(0.4)	2	1.42	0			
Not Hispanic or Latino	0				4	(0.2)	4	0.25
Missing	0				1		1	
Hydrocalyx								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Micturition urgency								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Nephropathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Renal mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Strangury								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Stress urinary incontinence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Urinary retention								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Urinary tract inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Urinary tract obstruction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Psychiatric disorders								
All								
Hispanic or Latino	6	(2.4)	6	3.34	5	(2.0)	5	2.89
Not Hispanic or Latino	30	(1.9)	34	2.48	31	(1.9)	32	2.61
Missing	0				1		2	
Insomnia								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	9	(0.6)	9	0.73	5	(0.3)	5	0.36
Missing	0				1		2	
Depression								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	8	(0.5)	8	0.58	8	(0.5)	8	0.63
Missing	0				0			
Sleep disorder								
Hispanic or Latino	0				2	(0.8)	2	1.37
Not Hispanic or Latino	4	(0.2)	4	0.25	2	(0.1)	2	0.22
Missing	0				0			
Anxiety								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.40
Not Hispanic or Latino	4	(0.2)	4	0.25	5	(0.3)	5	0.30
Missing	0				0			
Irritability								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Adjustment disorder with mixed anxiety and depressed mood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Disorientation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Listless								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Post-traumatic stress disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Depressed mood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Mental status changes								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Agitation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Adjustment disorder								
Hispanic or Latino	1	(0.4)	1	0.69	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Adjustment disorder with depressed mood								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Affect lability								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Anxiety disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Bruxism								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				0			
Missing	0				0			
Drug abuse								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Drug dependence								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Emotional distress								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Fear								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.22
Missing	0				0			
Major depression								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Mixed anxiety and depressive disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Mood swings								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Nightmare								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Persistent depressive disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Phobia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Stress								
Hispanic or Latino	1	(0.4)	1	0.37	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Hispanic or Latino	2	(0.8)	2	1.44	0			
Not Hispanic or Latino	29	(1.8)	37	2.75	26	(1.6)	38	2.77
Missing	0				1		2	
Colon adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.27	0			
Missing	0				0			
Metastases to liver								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Seborrhoeic keratosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	3	0.19	0			
Missing	0				0			
Pancreatic neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Colorectal cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	0			
Missing	0				0			
Adenocarcinoma pancreas								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Bladder cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Eye naevus								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	1	(0.1)	2	0.12	0			
Missing	0				0			
Invasive ductal breast carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Invasive lobular breast carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Lipoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pancreatic carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Renal neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Squamous cell carcinoma of skin								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Chronic myeloid leukaemia								
Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Gastric cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Acrochordon								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Basal cell carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.19
Missing	0				0			
Glioblastoma multiforme								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Haemangioma of liver								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Neoplasm skin								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Oral fibroma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Prostate cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Salivary gland neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Osteoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Small cell lung cancer								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Bladder papilloma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Lung cancer metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Missing	0				0			
Skin papilloma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Adenocarcinoma of colon								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Adrenal adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				1		1	
Benign renal neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Bowen's disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Breast cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Breast cancer metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Colon cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Colon cancer stage II								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Dysplastic naevus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Endometrial adenocarcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Gastrointestinal tract adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hepatocellular carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Invasive breast carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Lung adenocarcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				1		1	
Lymphangioma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Malignant melanoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Malignant melanoma in situ								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Malignant peritoneal neoplasm								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Metastases to bone marrow								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Metastases to lymph nodes								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Myxoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Ovarian cancer metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Pancreatic carcinoma metastatic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Prostatic adenoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Renal cell carcinoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Renal hamartoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Small intestine neuroendocrine tumour								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Uterine cancer								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Uterine leiomyoma								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				3	(0.2)	3	0.23

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Blood and lymphatic system disorders								
All								
Hispanic or Latino	5	(2.1)	5	3.01	8	(3.2)	8	4.08
Not Hispanic or Latino	28	(1.7)	30	2.42	22	(1.4)	22	1.68
Missing	0				0			
Anaemia								
Hispanic or Latino	4	(1.7)	4	2.60	6	(2.4)	6	3.27
Not Hispanic or Latino	15	(0.9)	17	1.40	8	(0.5)	8	0.59
Missing	0				0			
Lymphadenopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	1	(0.1)	1	0.06
Missing	0				0			
Eosinophilia								
Hispanic or Latino	1	(0.4)	1	0.41	1	(0.4)	1	0.40
Not Hispanic or Latino	2	(0.1)	2	0.17	1	(0.1)	1	0.11
Missing	0				0			
Iron deficiency anaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	3	(0.2)	3	0.23
Missing	0				0			
Leukocytosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	3	(0.2)	3	0.18
Missing	0				0			
Splenomegaly								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Polycythaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Thrombocytopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Blood loss anaemia								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lymphadenopathy mediastinal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Leukopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Hypochromic anaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Normocytic anaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Pancytopenia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Thrombocytosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Ear and labyrinth disorders								
All								
Hispanic or Latino	1	(0.4)	1	0.73	1	(0.4)	1	0.40
Not Hispanic or Latino	25	(1.5)	28	2.02	21	(1.3)	22	1.82
Missing	0				0			
Vertigo								
Hispanic or Latino	0				0			
Not Hispanic or Latino	10	(0.6)	11	0.85	8	(0.5)	9	0.70
Missing	0				0			
Ear pain								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	4	(0.2)	4	0.29	1	(0.1)	1	0.11
Missing	0				0			
Deafness bilateral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vertigo positional								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Hypoacusis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.16	3	(0.2)	3	0.18
Missing	0				0			
Tinnitus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	2	(0.1)	2	0.17
Missing	0				0			
External ear pain								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Meniere's disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Ear inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Eustachian tube dysfunction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Cerumen impaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Deafness unilateral								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Ear discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Middle ear inflammation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Motion sickness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Presbyacusis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Reproductive system and breast disorders								
All								
Hispanic or Latino	6	(2.5)	6	4.01	4	(1.6)	4	2.38
Not Hispanic or Latino	23	(1.4)	23	1.63	19	(1.2)	23	1.54
Missing	0				0			
Benign prostatic hyperplasia								
Hispanic or Latino	1	(0.4)	1	0.71	1	(0.4)	1	0.72
Not Hispanic or Latino	4	(0.2)	4	0.29	2	(0.1)	2	0.12
Missing	0				0			
Erectile dysfunction								
Hispanic or Latino	1	(0.4)	1	0.37	1	(0.4)	1	0.63
Not Hispanic or Latino	4	(0.2)	4	0.29	0			
Missing	0				0			
Uterine polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.12	0			
Missing	0				0			
Atrophic vulvovaginitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Ejaculation failure								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Menstruation irregular								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pelvic discomfort								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cervical polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Prostatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Breast mass								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Menopausal symptoms								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Ovarian cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Pruritus genital								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.17
Missing	0				0			
Uterine prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Missing	0				0			
Vulvovaginal pruritus								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.12
Missing	0				0			
Prostatic calcification								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Breast pain								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Colpocele								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dysmenorrhoea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Galactorrhoea								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Genital prolapse								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Intermenstrual bleeding								
Hispanic or Latino	2	(0.9)	2	1.46	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Menopausal disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Menstruation delayed								
Hispanic or Latino	1	(0.4)	1	0.73	0			
Not Hispanic or Latino	0				0			
Missing	0				0			
Penile rash								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.13
Missing	0				0			
Testicular cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Uterine enlargement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Vaginal discharge								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Vaginal haemorrhage								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Vulvovaginal dryness								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hepatobiliary disorders								
All								
Hispanic or Latino	2	(0.8)	3	1.22	1	(0.4)	1	0.40
Not Hispanic or Latino	17	(1.1)	22	1.71	20	(1.2)	24	1.94
Missing	0				0			
Hepatic steatosis								
Hispanic or Latino	1	(0.4)	1	0.41	0			
Not Hispanic or Latino	7	(0.4)	7	0.48	9	(0.6)	9	0.69
Missing	0				0			
Cholelithiasis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	3	(0.2)	3	0.18	1	(0.1)	1	0.06
Missing	0				0			
Hepatomegaly								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.17	0			
Missing	0				0			
Hepatic mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Alcoholic liver disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Gallbladder polyp								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Gallbladder cholesterolosis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Liver disorder								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Non-alcoholic steatohepatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Cholecystitis chronic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.11
Missing	0				0			
Hyperplastic cholecystopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Cholecystitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Hepatic function abnormal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	2	(0.1)	2	0.17
Missing	0				0			
Bile duct stone								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.12
Missing	0				0			
Biliary colic								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Biliary dyskinesia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hepatic cirrhosis								
Hispanic or Latino	0				1	(0.4)	1	0.40
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Hepatic cyst								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hypertransaminasaemia								
Hispanic or Latino	1	(0.4)	2	0.81	0			
Not Hispanic or Latino	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Nonalcoholic fatty liver disease								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Steatohepatitis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Hispanic or Latino	2	(0.8)	2	1.40	5	(2.0)	5	2.80
Not Hispanic or Latino	10	(0.6)	11	0.81	10	(0.6)	11	0.96
Missing	0				0			
Seasonal allergy								
Hispanic or Latino	2	(0.8)	2	1.40	3	(1.2)	3	1.77
Not Hispanic or Latino	6	(0.4)	6	0.37	5	(0.3)	5	0.40
Missing	0				0			
Food allergy								
Hispanic or Latino	0				1	(0.4)	1	0.41
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Anaphylactic reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Missing	0				0			
Allergy to arthropod bite								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	2	(0.1)	2	0.22
Missing	0				0			
Drug hypersensitivity								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Hypersensitivity								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Allergy to arthropod sting								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Immunisation reaction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	2	0.13
Missing	0				0			
Endocrine disorders								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Hispanic or Latino	1	(0.4)	1	0.71	2	(0.8)	2	1.35
Not Hispanic or Latino	5	(0.3)	5	0.35	16	(1.0)	16	1.17
Missing	0				0			
Thyroid mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	2	(0.1)	2	0.13	2	(0.1)	2	0.17
Missing	0				0			
Autoimmune thyroiditis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Hypothyroidism								
Hispanic or Latino	1	(0.4)	1	0.71	0			
Not Hispanic or Latino	1	(0.1)	1	0.06	4	(0.2)	4	0.29
Missing	0				0			
Hypogonadism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Missing	0				0			
Adrenal mass								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Adrenocortical insufficiency acute								
Hispanic or Latino	0				1	(0.4)	1	0.72
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Goitre								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.13
Missing	0				0			
Hyperplasia adrenal								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hyperprolactinaemia								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperthyroidism								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				2	(0.1)	2	0.12
Missing	0				0			
Inappropriate antidiuretic hormone secretion								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Secondary hypogonadism								
Hispanic or Latino	0				1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Surgical and medical procedures								
All								
Hispanic or Latino	0				0			
Not Hispanic or Latino	4	(0.2)	4	0.34	6	(0.4)	6	0.46
Missing	0				0			
Cardiac pacemaker replacement								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Missing	0				0			
Knee operation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Shoulder operation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Tooth extraction								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Large intestinal polypectomy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Removal of foreign body								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Skin neoplasm excision								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Spinal operation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Toe amputation								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Hispanic or Latino	3	(1.3)	3	1.87	1	(0.4)	1	0.63
Not Hispanic or Latino	3	(0.2)	3	0.27	4	(0.2)	4	0.24
Missing	0				0			
Hydrocele								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.06	0			
Missing	0				0			
Corneal dystrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.11	0			
Missing	0				0			
Cystic fibrosis lung								
Hispanic or Latino	0				0			
Not Hispanic or Latino	1	(0.1)	1	0.10	0			
Missing	0				0			
Atrial septal defect								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Congenital syphilitic osteochondritis								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Hypertrophic cardiomyopathy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Myotonic dystrophy								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.06
Missing	0				0			
Type V hyperlipidaemia								
Hispanic or Latino	3	(1.3)	3	1.87	1	(0.4)	1	0.63
Not Hispanic or Latino	0				0			
Missing	0				0			


%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Social circumstances								
All								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			
Menopause								
Hispanic or Latino	0				0			
Not Hispanic or Latino	0				1	(0.1)	1	0.11
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.29 Adverse events by ethnicity and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): ETHNIC; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS ETHNIC; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:14 - faedotgrp/faesocgrpethnicitydotontp3asas.png

7.7.30 Adverse events by ethnicity and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool



% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Subjects from France did not report ethnicity. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): ETHNIC; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS ETHNIC; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:19 - faedotgrp/faesocgrpethnicitydotontt2dsas.png